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Summary 
 
Histone post-translational modifications (PTMs), as the histone code assumes, are related with 
regulation of gene transcription, an important mechanism of cells in the differentiation process. Many 
PTMs are simultaneously present in histone proteins, and changes in the PTM stoichiometric ratios can 
have several effects, like changes in the chromatin structure leading to a transcriptionally active or 
repressive state. Significant progresses were made to map variations of histone PTMs by mass 
spectrometry (MS), and although many protocols were developed there are still some drawbacks. 
Incomplete and side reactions were identified, which can directly affect the quantification of histone 
PTMs, because both (incomplete and side reactions) can be misinterpreted as endogenous histone 
post translational modifications. Therefore, a protocol for derivatization of histones with no noticeable 
undesired reactions (<10%) was required. In this thesis a new chemical modification methodology is 
presented, which allows the improvement of sequence coverage by acylation with propionic anhydride 
of lysine residues and N-terminal (free ε- and α- amino groups) and trypsin digestion. more than 95% 
of complete reaction was achieved with the new derivatization methodology. This strategy (chemical 
derivatization of histones), in combination with bottom-up MS approach, allows the quantification of 
lysine methylation (Kme) and acetylation (Kac) in histones from Saccharomyces cerevisiae 
(S.cerevisiae), mouse embryonic stem cells (mESCs) and human cell lines. The results showed histone 
H3 PTM pattern as the most variable profile regarding histone Kme and Kac across the three different 
organisms and experimental conditions. Therefore, it was concluded that quantification of H3 PTM 
pattern can be used to examine changes in chromatin states when cells are subjected to any kind of 
perturbation. 
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Aims 
 
Histones and their PTMs play crucial roles in chromatin regulation and gene transcription. Therefore, 
the aims for this doctoral thesis are: 
 
1. To develop a methodology for chemical derivatization of free α and Ɛ-amino groups with no-
noticeable side reactions. To establish a robust, sensitive and selective method for qualitative 
and quantitative analysis of histone lysine methylation (Kme) and acetylation (Kac), using bottom-
up MS-based approach.  
 
2. To examine histone lysine methylation and acetylation profiles in different organisms like yeast 
(Saccharomyces cerevisiae), mouse (Embryonic mouse stem cells) and human cell lines. 
 
3. To determine changes of histone H3 Kme and Kac patterns in Saccharomyces cerevisiae when 
a COMPASS member is mutated or deleted. 
 
4. To determine changes of Kme and Kac patterns in histone H3, H4, H2A and H2B of Embryonic 
mouse stem cells when growth conditions are changed to maintain pluripotency.  
 
5. To determine changes of Kme and Kac patterns in histone H3, H4, H2A and H2B of MCF-7, 
HeLa, HeK-293T and MDA-MB231 during proliferation and when cells are arrested to 100% 
confluency. 
 
6. To identify novel isoforms of histone lysine modifications that may be valuable to understand 
transcriptional activity.  
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Chapter 1. Introduction 
 
1.1 Nucleosome structure  
In eukaryotic cells, the repeating unit of chromatin is the nucleosome. It is a complex of DNA and histone 
and non-histone proteins. All components together maintain and regulate this organized and dynamic 
structure. Chromatin contains about twice as much protein as DNA within the nucleus (Luger, et al., 
1997). The compaction of the nucleosome starts with its organization in ~147bp of DNA wrapped in an 
octamer consisting of two heterodimers of core histones H2A and H2B, and heterotetramer of core 
histones H3 and H4. More compaction is also achieved by the linker histone H1 that binds DNA between 
nucleosomes. Further, this structure is again compacted in solenoids (30 nm chromatin fiber), and finally 
chromosomes are formed (the highest order of organization) (Richmond et al. 1997; Davey et al. 2002; 
Maeshima et al. 2014) (Figure 1.1). 
 
Figure 1.1. Schematic chromatin representation of its compaction. First, DNA is wrapped in an octamer of H3, 
H4, H2A and H2B to form the nucleosome. After chromatin is compacted again by bounding the outside DNA to 
the histone core throughout the linker histone H1 stabilizing the new condensed chromatin. Finally, chromatin fiber 
and chromosome are the highest order of organization of chromatin structures. 
 
 
Histones are highly conserved between species, and its function is to provide structural support in the 
nucleosome, among others. Furthermore, these proteins are characterized to have an unstructured N-
terminal tail that sticks-out from the nucleosome. These N-terminal tails are positively charged due to 
the enrichment of basic amino acids like arginine (R) and lysine (K). Also, histones have a globular 
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domain C-terminus that is the biggest part of the histone protein. Moreover, several reports indicated 
that chromatin can be separated in heterochromatin and euchromatin. Heterochromatin, is a 
transcriptionally inactive form because chromatin is condensed throughout the cell cycle. Euchromatin 
is a transcriptional active form, chromatin structure is open which makes possible that genes can be 
transcribed. In order to regulate the chromatin forms (euchromatin or heterochromatin) and their 
functions, cells utilize mechanisms like integration of histone variants, histone posttranslational 
modifications (PTMs), among others. For instance, alteration or changes in histone PTMs can result in 
alteration of some DNA-based biological processes, like transcription of RNA, DNA replication and DNA 
repair (Millar and Grunstein 2006; Arrowsmith et al. 2012; Huang et al. 2015). 
 
1.2 Role of Histone posttranslational modifications and the histone code 
As described before, most of the histone PTMs occur on the N-terminal tail, because it protrudes from 
the nucleosome. However, some modifications from the C-terminus were also reported. There are many 
sites that can be modified, but the major histone modifications and the best studied are methylation or 
acetylation of lysine (Kme or Kac), methylation of arginine (Rme), phosphorylation of serine or threonine 
residues (Sp or Tp) (Figure 1.2 and 1.3). These different PTMs, acetylation, methylation and 
phosphorylation, are related to chromatin states and regulate the DNA access to transcription factors 
(Workman and Abmayr 2014). Such histone PTMs, in addition with some others reported by several 
authors like sumoylation or ubiquitination of lysine (Ksu or Kub), or isomerization of proline (P-cis P-trans), 
among others (Figure 1.2), were detected by specific antibodies or by mass spectrometry (Kouzarides 
2007; Bhaumik et al. 2007).  
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Figure 1.2 List of post-translational modifications identified on histones. Table with post-translational 
modifications identified on histones and the function(s) that have been associated. In the first column are listed the 
post-translational modifications identified; the second column shows the residue that is modified; and the third 
column shows the associated function(s) for each histone PTM. ac, me, ph, ub, su, ar and Cit refer to acetylation, 
methylation, phosphorylation, ubiquitination, sumoylation, ADP ribosylation and deamination, respectively. Table 
taken from (Kouzarides 2007). 
 
Figure 1.3 Molecular structures of some post-translational modifications on histone proteins. Molecular 
structures of the best studied histone PTMs and the different methylated forms of arginine (symmetric Rme2 is in 
the upper part, and asymmetric Rme2 is in the lower and left part of the figure) and lysine residues (to see more 
histone PTMs check (Kouzarides 2007; Bhaumik et al. 2007). 
S-p  T-p 
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Chromatin structure and function are regulated by histone PTMs via structural modifications or by 
recruiting chromatin-associated factors. The first mechanism is a “direct structural perturbation”, as 
Bannister and Kouzarides reported. This structural perturbation is produced by histone PTMs that alter 
the charged state of histone proteins, like acetylation and phosphorylation. The alteration of the charge 
results in the modification of chromatin packaging, because the positive charges of histones are 
neutralized, disrupting electrostatic interactions between histones and DNA. The modification of 
chromatin packaging can result in an open or condensed chromatin structure, which can lead to gene 
activation or repression, respectively (Figure 1.4) (Bannister and Kouzarides 2011).  
 
 
Figure 1.4. Representation of direct structural perturbation of chromatin by histone PTMs. On the right side 
of the figure a relaxed or open chromatin structure is shown due to reduction of histone positive charges by 
acetylation. On the left side of the figure a close or condensed chromatin structure is shown due to absence of any 
PTM that can alter the charged state of the structure, like acetylation. Image taken and modified from (Rodd et al. 
2012). 
 
 
The second mechanism is the “regulation of chromatin factor binding” as Bannister and Kouzarides 
mentioned. In this mechanism histone PTMs, like lysine methylation, acetylation and phosphorylation, 
are binding site for several chromatin-associated factors (readers) by interaction of histone PTMs with 
different factor domains (Figure 1.5). However, histone PTMs not only offer a dynamic binding site for 
various factors, histone PTMs can also disrupt the interaction with chromatin-associated factors by 
recruiting specific enzymes that “erase” specific modifications of histone. Few examples of “erasers” 
are histone deacetylases (HDAC) or lysine demethylases (KDM), which remove acetyl groups or methyl 
groups from lysine residues, respectively (Figure 1.6). (Berger 2002; Kouzarides 2007; Bannister and 
Kouzarides 2011; Arrowsmith et al. 2012). 
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Figure 1.5. Representation of histone PTMs that regulate chromatin-factor binding. The figure shows several 
reported histone PTMs which work as binding site for chromatin factors. Figure taken from (Bannister and 
Kouzarides 2011). 
 
 
 
Figure 1.6. Representation of enzymes that “erase” histone PTMs resulting in a condensed chromatin 
structure. In the figure histone deacetylases (HDAC) and lysine demethylases (KDM) are shown as examples of 
“erasers” of acetylation and methylation, respectively. As a consequence, chromatin adopts a close structure and 
therefore genes are transcriptionally repressed. Figure taken and modified from (Layman and Zuo 2014). 
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Such histone PTMs, depending on the types and locations, can correlate with gene transcriptional 
activation or repression. The best studied histone PTMs are lysine acetylation (Kac) and methylation 
(Kme). Kac correlates with transcriptional activation, while lysine deacetylation correlates with 
transcriptional repression. Kme is implicated in both gene activation (H3K4, H3K36, and H3K79) and 
transcriptional repression (H3K9, H3K27, and H4K20). For example, H3K9me1 and H3K27me1 are 
involved in transcriptional activation, while trimethylation at the same sites (H3K9me3 and H3K27me3) is 
linked to repression (Kouzarides 2007). 
 
1.2.1 Histone acetylation 
Ɛ-N acetylation of lysine residues in histones was first reported in 1964 (Allfrey, et al., 1964). Acetylation 
is one of the most studied and well characterized histone modification, and it is mainly involved in gene 
activation. Due to the property of this histone modification to neutralize the positive charge of lysine 
residues, the electrostatic interactions between histones and DNA are disrupted, which allow to 
chromatin adopts an open structure and permitting that genes can be transcribed (Sidoli, et al., 2012).  
Attachment of acetyl groups to the Ɛ- amino group of lysine residues is mediated by histone 
acetyltransferases (HATs), these enzymes catalyze the transfer of acetyl groups from Acetyl-CoA. 
Furthermore, acetylation is a reversible modification that can be removed by histone deacetylases 
(HDACs) (Figure 1.7) (Workman and Abmayr 2014). 
 
 
Figure 1.7 Schematic representation of acetylation and deacetylation reactions of lysine residues. Histone 
acetyltransferase (HAT) and histone deacetylase (HDAC) catalyze the acetylation and deacetylation reactions of 
lysine. During acetylation Acetyl-CoA is the substrate that is converted to coenzyme A, and during deacetylation 
acetate is released. Image taken from (Workman and Abmayr 2014). 
 
 
Both HATs and HDACs are commonly known as writers and erasers of acetylation in chromatin, 
respectively. However, there are readers also that can recognize this modification as a histone mark 
(Figure 1.8). Acetylation can be recognized by specific domains of proteins, like bromodomain- and 
PHD-containing proteins. These domains are found in several proteins such as chromatin remodeling 
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enzymes, co-activators, general transcription factors and histone acetyltransferases (Arrowsmith et al. 
2012; Carlberg and Molnár 2014; Workman and Abmayr 2014).  
 
 
Figure 1.8. General representation of writers, readers and erasers of histone acetylation. HAT or histone 
acetyltransferases are known as writers because catalyze the addition of an acetyl group to ε-amino group of lysine. 
HDAC or histone deacetylases are known as erasers because release the attached acetyl group of lysine. Finally, 
the readers are non-histone proteins that possess specific domains that recognize acetyl groups as a histone mark, 
like bromodomain- and PHD-containing proteins. Then readers can mediate several biological processes 
(Workman and Abmayr 2014). 
 
 
a. Histone acetyltransferases or HATs: 
HATs are the enzymes that catalyze acetylation of lysine residues. The HATs can be classified in two 
predominant groups according to its structural similarities:  
- GNATs or Gcn5-related acetyltransferases: these groups of enzymes present similar 
sequences and structure with the yeast protein Gcn5. These enzymes also share an important and 
conserved motif, known as “motif A”. Motif A recognizes acetyl-coA binding to this substrate. Moreover, 
GNAT members possess the conserved bromodomain, which recognizes acetylation as a histone mark 
(Workman and Abmayr 2014). 
- MYST HATs or MOZ, Ybf2/Sas3, Sas2 and Tip60 histone acetyltransferases: these groups of 
proteins share also similar sequences, but they possess a domain known as MYST. This domain, 
similar to motif A, recognizes and binds to acetyl-coA. Some members of this MYST group, contain also 
other domains like, chromodomain (which recognizes methylated residues), plant homeodomain (PHD) 
fingers (which recognizes methylated lysine), among others (Workman and Abmayr 2014).  
 
Moreover, HATs can be also classified according to their localization in the cell. HAT-A are the histone 
acetyltransferases located in the nucleus, and therefore these proteins acetylate nucleosomal histones. 
And HAT-B are the histone acetyltransferases mainly located in the cytoplasm, and therefore these 
proteins acetylate no-nucleosomal histones or newly synthesized histones (Workman and Abmayr 
2014).  
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The histone acetyltransferases usually are members of complex proteins, which contain several 
subunits that are essential for HAT activity. For example:  
- for GNAT family, three main complexes have been reported, which contain the nucleosomal 
HAT. The complexes are SAGA, ATAC, and HATA2. These complexes contain, besides multiple 
subunits (non-histone protein), the histone acetyltransferase Gcn5.  
- For MYST family, four main complexes have been reported, which contain the nucleosomal 
HAT. The complexes are NuA4, MOF, NuA3 and other MYST complex. Similar to previous GNAT 
family, these complexes contain multiple subunits (non-histone protein) and the human HAT TIP60, 
MOF, MOZ and HBO1, respectively (Workman and Abmayr 2014) . 
 
In addition to these two HAT families, there is a small family known as CBP/p300. This small family 
contains the human HATs CBP and p300. The histone acetyltransferases of all three families modify 
more than one lysine, but some limitations have been reported which are summarized in Figure 1.9 
(Kouzarides 2007). 
 
 
Figure 1.9. Specificity of histone acetyltransferases. HAT or histone acetyltransferases are listed and the lysine 
residue that is modified.  
 
 
Moreover, the multiple subunits (non-histone proteins) of the HAT complexes have several functions. 
Besides to be essential for HAT activity, these non-histone proteins can also have cellular functions, 
like binding the HAT complex to specific site of DNA. The subunits are recruited by specific histone 
PTMs. Specifically, the different domains interact with specific histone PTMs, like bromodomain, which 
binds to acetylated K, chromodomain, which binds to methylated lysine, and tudor domain, which binds 
to methylated K and R. For example: the PHD finger domain of Yng1 (subunit of NuA3 HAT complex) 
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binds to methylated H3K4 and subsequently H3K14 is acetylated by the histone acetyltransferase NuA3 
(Workman and Abmayr 2014). 
 
b. Histone deacetylases or HDACs 
Histone acetylation is a reversible process carried out by histone deacetylases. In normal conditions or 
wild type, there is a balance between acetylation and deacetylation of histones. It is important to have 
an equilibrium of hyper- and hypo-acetylation, because this histone modification produces a direct 
impact in chromatin opening and compaction, respectively. Therefore, this structural changes can lead 
to facilitate gene transcription or repression (Workman and Abmayr 2014). 
 
1.2.2 Histone methylation 
This modification is widely studied due to its potential for signaling and its effect in regulation of 
biological processes (Workman and Abmayr 2014). Lysine and arginine residues can be methylated, 
lysine can be mono- (me1), di- (me2), and trimethylated (me3) by lysine methyltransferases (KMTs). 
While arginine can be monomethylated (me1) by the protein arginine methylatransferases type I (PRMT 
type I), and symmetrically (me2s) or asymmetrically (me2a) dimethylated by the protein arginine 
methylatransferases type II (PRMT type II) (Figure 1.10) (Zhang 2001). In contrast to acetyl groups, 
methylation does not change charges of lysine residues. Methylation provides a binding site for non-
histone proteins (or readers), which can produce two effects: the nucleosomes can be compacted by 
effect of these readers, or these non-histone proteins can also recruit some others non-histone proteins, 
like regulatory proteins (Figure 1.11) (Bannister and Kouzarides 2011; Arrowsmith et al. 2012; Workman 
and Abmayr 2014). Moreover, the degree of methylation defines different biological functions. Then, 
the regulation of transcription by methylation depends on the site of modification and on the level of 
methylation of lysine (me1, me2, me3) or of arginine (me1, me2s, me2a) (Sidoli et al. 2012).  
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Figure 1.10. Methylation of arginine and lysine residues. Figure A shows monomethylation and symmetric and 
asymmetric dimethylation of arginine catalyzed by PRMT (protein arginine methyltransferase) type I and II. Figure 
B shows mono-, di- and trimethylation of lysine catalysed by HMT (histone methyltransferase). The methyl group 
is transferred from AdoMet (S-adenosyl-L-methionine) to guanidine nitrogen of arginine or to ε-amino group of 
lysine generating as product AdoHcy (S-adenosylhomocysteine). Image taken from (Zhang 2001). 
 
 
a. Histone methyltransferases or HMTs 
The histone methyltransferases (HMTs), known also as writers, catalyze the methylation of arginine 
and lysine (Figure 1.10). Lysine methyltransferases (KMTs) catalyze the transference of methyl group 
(one, two or three) to lysine ε-amino group from S-adenosyl-L-methionine (AdoMet) (Figure 1.11). 
Whereas methylation of arginine is catalyzed by two types of protein arginine methyltransferases 
(PRMTs) that transfer methyl groups from S-adenosyl-L-methionine to guanidine nitrogen of arginine: 
PRMT type I and type II catalyze R monomethylation, while PRMT type I catalyzes asymmetric 
dimethylation of arginine, and PRMT type II catalyzes symmetric dimethylation of arginine (Figure 1.10) 
(Zhang 2001).  
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Figure 1.11. Lysine methylation reaction. The figure shows several levels of lysine methylation catalyzed by 
HMTs by transference of methyl group from AdoMet or S-adenosyl-L-methionine. Moreover, lysine methylation is 
a reversible process, and demethylation is mediated by histone lysine demethylases. Image taken from (Yang 
2013) 
 
 
Lysine methyltransferases (KMTs) contain a conserved SET domain (Su(var)3-9, Enhancer of Zeste, 
Trithorax domain) except one, known as DOT1L or KMT4. This conserved domain is the responsible 
for the enzymatic activity of KMTs. Moreover, KMTs have been classified according to their similarities 
in several groups or families, (sequence or domain similarities) (Zhang et al. 2012) as summarized in 
Table 1.1: 
 
Table 1.1. Summary of lysine methyltransferases classification into several families. Table modified from 
(Zhang et al. 2012) 
Family name Enzymes  Residues Methylation state 
KMT1 or SUV39 
SUV39H1, SUV39H2, G9a, EHMT1/GLP, 
SETDB1, SETDB2 
H3K9 
me1, me2, me3 
me2 (G9a methylates 
H3K27) 
KMT2 or MLL  MLL1 to MLL5, SET1A, SET1B, ASH2 H3K4 me1, me2, me3 
KMT3 or SET2  SET2, NSD1, SMYD1 to SMYD3 H3K36.  me1, me2, me3 
KMT4 or DOT1L DOT1L H3K79 me2, me3 
KMT5 SET8, SUV420H1, SUV420H2 H4K20 me1, me2, me3 
KMT6 EZH2, EZH1 H3K27 me3 
KMT7 SET7/9 H3K4 me1 
KMT8 PRDM2/RIZ1 H3K9 me3 
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b. Histone demethylases or HDMs 
Histone methylation is a reversible process as shown in Figure 1.11. The histone demethylases 
(HDMs), known also as erasers, release methyl group from methylated lysine residue. Some reported 
HDMs are lysine demethylase 1 (LSD1) and Jumonji domain-containing (JmjC) histone demethylases. 
These enzymes are highly conserved from yeast to human, but demethylation of arginine remains 
elusive (Workman and Abmayr 2014). 
Like KMTs, lysine demethylases (KDMs) are classified per their substrate specificity and domain 
similarity (as shown in Table 1.2) 
 
Table1.2. Summary of lysine demethylases classification into several families. Table modified from (Zhang 
et al. 2012) 
Family name Enzymes  Residues Methylation state 
KMD1 LSD1, LSD2 
H3K4, 
H3K9 
me1, me2 
KMD2 JHDM1A, JHDM1B H3K36 me1, me2 
KMD3 JHDM2A, JHDM2B H3K9 me1, me2 
KMD4 JMJD2A, JMJD2B, JMJD2C, JMJD2D 
H3K9, 
H3K36 
me2, me3 
KMD5 JARID1A, JARID1B, JARID1C, JARID1D H3K4 me2, me3 
KMD6 UTX, JMJD3 H3K27 me2, me3 
KMD7 JHDM1D, PHF2, PHF8 
H3K9, 
H3K27 
me1, me2, and me1 of 
H4K20 
 
 
1.2.3 Histone methylation and acetylation in chromatin modulation 
Euchromatin is the open conformation of chromatin and heterochromatin is the condensed form of 
chromatin. In Euchromatin mainly histone marks as methylation of H3 K4, K36 and K79 can be found, 
while in heterochromatin mainly the histone marks methylation of H3 K9, K27 and H4K20 can be found. 
Moreover, euchromatin and heterochromatin are characterized to be hyper- and hypo-acetylated, 
respectively (Kouzarides 2002; Kouzarides 2007; Carlberg and Molnár 2014; Zhang et al. 2015).  
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a. Histone methylation associated with euchromatin:  
H3K4 and H3K36 methylation (H3K4me and H3K36me) have been associated with transcriptionally active 
chromatin. The localization on the genome of H3K4me differs from H3K36me. H3K4me is found at the 
promoters reaching the transcription start site (TSS) or 5’ end, while H3K36me is found distributed at the 
gene body or 3’ end of active genes (as shown in Figure 1.12) (Kouzarides 2002; Kouzarides 2007; 
Zhang et al. 2015). Therefore, H3K4 trimethylation is associated with the initiated form of RNA pol II, 
specifically with the phosphorylated serine 5 of its C-terminal domain. While H3K36 trimethylation is 
associated with the elongating form of RNA pol II, specifically H3K36me3 is associated with the 
phosphorylated serine 2 of RNA pol II. For that reason, H3K4me3 and H3K36me3 have been described 
as histone marks of transcription initiation and elongation, respectively (Kouzarides 2007). Moreover, 
these histone marks are recognized by several non-histone proteins or readers via specific domains, 
like chromodomain or PHD finger (Workman and Abmayr 2014). In addition, H3K79 methylation is also 
associated with euchromatin. This histone mark has been reported to be localized around TSS and 
gene body, as shown in Figure 1.12, because H3K79me was found to interact with Ser5- and Ser2-
phosphorylated forms of the RNA pol II (Zhang et al. 2015). 
 
 
Figure 1.12. Histone marks associated with active genes. The figure shows the genomic distribution of several 
lysine methylation histone marks associated with euchromatin. Image taken and modified from (Zhang et al. 2015).  
 
 
b. Histone methylation associated with heterochromatin:  
Histone H3 lysine 9, 27 and H4K20 have been associated with transcriptionally repressed chromatin 
(Figure 1.13). Methylated H3K9 is associated with repression of genes and heterochromatin formation 
by recruiting methylating enzymes and chromodomain-containing protein HP1 to the promoter of genes, 
respectiively. HP1 is a transcriptional repressor that can bind to H3K9me3 recruiting also DNA 
methyltransferases. Then, DNA methylation is recognized by a protein containing a methyl binding 
domain (MBD), and this domain binds to SUV3-9 enzymes. As mentioned before, these enzymes 
(SUV3-9) mediate methylation of H3K9. Moreover, it is still unknown how HP1 generates a highly 
compact chromatin. Some authors suggested that either this protein HP1 may connect the nucleosomes 
to form the condensed structure, or it may recruit additional proteins for compaction. A summary of 
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H3K9 trimethylation as a repressed histone mark is shown in Figure 1.14 (Kouzarides 2002; Lee et al. 
2005; Zhang et al. 2015). H3K27 methylation is another histone mark associated with gene repression. 
The histone methyltransferase EZH2 mediates methylation of H3K27. EZH2 is member of PRC2 
complex, and PCR2 is one of the three members of Polycomb group complexes (PcG). The other two 
members of PcG are PCR1 and PhoRC complexes. PcG is assembled to chromatin mediating 
monoubiquitination of H2AK119 and H3K27 methylation. Specifically, a subunit of PCR1 (a PcG 
member) complex is the enzyme that catalyses H2AK119ub, while the HMT EZH2 is a subunit of PCR2 
(another PcG member) complex. Besides, PCR2 contains another subunit known as EED, which 
stimulates enzymatic activity of EZH2. Finally, the third PcG member PhoRC binds to DNA. The 
mechanism of PcG assembly to chromatin is summarized as follow: 
-  First the PhoRC complex binds to DNA,  
- Second, the PhoRC binding recruits PCR2,  
- PCR2 mediates methylation of H3K27 
- The binding site produced by H3K27 methylation recruits PCR1, 
- PCR1 mediates ubiquitination of H2AK119 
Therefore, PcG assembly to chromatin, establishes two repressive histone marks (Suganuma and 
Workman 2008; Smith and Shilatifard 2010; Ma et al. 2015).  
Finally, H4K20 methylation is another repressive histone mark. This histone PTM has a role in the 
heterochromatin formation. Because several reports indicated that Set8 knockout showed defects 
during chromatin compaction. Moreover, H4K20 is monomethylated by Set8 only during M phase, while 
di- and tri-methylated H4K20 levels do not change largely during cell cycle. Additionally, the methylation 
state of H4K20 correlates with its location in heterochromatin. For example, H4K20me1 and H3K9me1 are 
located in facultative heterochromatin. Trimethylated H4K20 and H3K9 are found in constitutive 
pericentric heterochromatin. The exact effect that these histone PTMs (monomethylated H4K20 and 
H3K9, in addition to trimethylated H4K30 and H3K9) produced on heterochromatin is unknown, but it 
has been suggested that might be cross-correlation between H3 and H4 (Sautel et al. 2007; Latham 
and Dent 2007; Evertts et al. 2013). 
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Figure 1.13. Histone marks associated with repressed genes. The figure shows the genomic distribution of 
several lysine methylation histone marks associated with heterochromatin. Image taken and modified from (Zhang 
et al. 2015).  
 
 
 
Figure 1.14. Effect of H3K9 trimethylation in gene repression. In stage 1 H3K9me3 recognized by HP1 is shown, 
which recruits DNA methylases (DNMT3). As a consequence, DNA is methylated. Stage 2 shows that methylated 
DNA is recognized by MBP (methyl binding proteins, which contain methyl binding domain or MBD). MBP recruit 
histone deacetylases and these enzymes recruit methylating enzymes to maintain methylated DNA and the 
repressive state. Additionally, ESET or other MBD-SET protein that contain a methyl binding domain have doubly 
role: bind to methylated DNA thanks to MBD and methylate histone lysine residues. Image taken from (Kouzarides 
2002). 
 
 
c. Histone acetylation in euchromatin 
This histone PTM is associated with euchromatin because acetylation produces a structural change in 
chromatin structure. Most of acetylated lysine residues that have been reported are located in the N-
terminal tail of histones. But recently, lysine residue located at the C-terminal of histones (H3K56) has 
been also reported. The particular position of this histone PTM is ideal to disrupt the interaction between 
DNA and nucleosome, because H3K56 is opposite to the major channel between DNA and nucleosome 
(Kouzarides 2007).  
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1.3 Model organisms 
 
1.3.1 Saccharomyces cerevisiae (S.cerevisiae) 
S.cerevisiae is a simple model organism that has been used for many years to study cellular processes. 
The chromatin of S.cerevisiae is regulated by less histone PTMs and is less compacted compared to 
human chromatin (Fuchs and Quasem 2014). Moreover, histone proteins are conserved from yeast 
to humans, which makes possible to use a simple model like yeast and get a close approximation to 
human cells (Sautel et al. 2007). Several histone PTMs from S.cerevisiae have been reported, like 
lysine acetylation, ubiquitylation, sumoylation and methylation, arginine methylation, and serine, 
threonine, and tyrosine phosphorylation, and most of their biological functions are conserved from yeast 
to human (Shilatifard 2006; Kouzarides 2007; Shahbazian and Grunstein 2007; Fuchs et al. 2009).  
Among the histone PTMs above mentioned, methylation of H3 K4, K36 and K79 have been associated 
with gene transcription. These histone marks are catalyzed by Set1, Set2 and Dot1, respectively. In 
yeast, these enzymes catalyze the three methylation states, for example Set1 catalyzes H3K4me1/me2/me3 
(Miller et al. 2001; Roguev 2001; van Leeuwen et al. 2002; Ng 2002). Moreover, it was reported that 
some HMTs are members of macromolecular complexes. For example, considering again Set1. This 
HMT is member of the Set1C complex or COMPASS complex (COMplex Protein ASsociated with Set1). 
COMPASS contains several subunits (Figure 1.15), which have as function to stimulate enzymatic 
activity of Set1 (Workman and Abmayr 2014). Deletion of Set1 or any other Set1C subunit, led to 
complete deletion or to reduce levels of H3K4 methylation (Shilatifard 2012). For example, deletion of 
Spp1 does not disrupt COMPASS integrity but H3K4me3 levels are reduced, which indicates that 
COMPASS is ineffective to trimethylate H3K4 (Takahashi and Shilatifard 2010). The other COMPASS 
members are Swd1 and Swd3, which were reported to be essential for complex integrity. Swd2, which 
was reported to be also part of CPF complex (cleavage and polyadenylation factor). This subunit forms 
a link between CPF and COMPASS complex that is essential for yeast. Then Swd2 is part of both 
complexes, COMPASS and CPF. Sdc1 and Bre2 subunits were observed to form a heteromer, which 
is required for trimethylation of H3K4. Finally, Shg1 interacts with RNA affecting SET1 complex 
assembly (Roguev 2003; Dehé et al. 2005; Halbach et al. 2009; Wang et al. 2009; South et al. 2010; 
Tuukkanen et al. 2010).  
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Figure 1.15 Schematic representation of Set1C complex subunits of yeast. In the center of the figure the Set1 
protein is shown, which is surrounded by nine subunits: Swd1-Swd3 core, shg1, Swd2-Swd2 dimer, bre2-bre2 
dimer, spp1 and sdc1. The black lines represent the interaction between such subunits. Figure modified from 
(Tuukkanen et al. 2010). 
 
 
1.3.2 Mouse Embryonic Stem Cells (mESCs) 
mESCs are model systems used in biomedical research and in the study of developmental biology due 
to their ability for pluripotency. Pluripotency is the capacity of a single cell to generate any type of the 
three germ layers (ectoderm, mesoderm and endoderm). Additionally, mESCs have the ability of self-
renewal; which means that cells can proliferate in the same state. These cells become isolated from 
the inner cell mass (ICM) of blastocysts 4 days post fertilization, approximately. Previous reports 
indicated that mESCs were maintained in a media supplemented with leukemia inhibitory factor (LIF) 
and fetal calf serum. This media was reported to maintain cells undifferentiated and with continue 
proliferation (Martin 1981). Additionally, several reports indicated that mESCs grown in supplemented 
media with fetal calf serum were subjected to uncontrolled multifactorial perturbations, like fluctuation 
in pluripotency factor levels and spontaneous differentiation (Ying et al. 2008). Therefore, currently 
pluripotency of mESCs is maintained without serum factors by using two small molecule kinase 
inhibitors (2i). These inhibitors are mitogen-activated protein kinase (MeK) and glycogen synthase 
kinase 3 (Gsk3). These inhibitors together with leukemia inhibitory factor (LIF) protect cells from 
differentiation triggers (Shimizu et al. 2012; Marks and Stunnenberg 2014; Dowell et al. 2014). 
Currently, only transcriptomic and epigenomic studies about mESC grown in 2i- and serum-containing 
media have been reported (Marks et al. 2012; Marks and Stunnenberg 2014). In these studies, some 
hallmarks of pluripotency were reported. These hallmarks include DNA hyphomethylation, absence of 
bivalent chromatin, differentiation genes were silenced and pluripotency genes were expressed (Marks 
et al. 2012). 
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1.3.3 Human cell lines 
The human cell lines HeK-293T (Human Embryonic Kidney 293T), HeLa (cervical cancer), MDA-MB231 
and MCF-7 (Human breast cancer) are useful model systems to understand more complex biological 
systems. Additionally, these cell lines are often used by researchers because all physicochemical 
properties during cell cultures can be regulated having a precise control over their growth. Besides, 
human cell lines are homogeneous, have a short generation time and have the ability to produce 
proteins and PTMs similar to those synthesized naturally by humans (Ghaderi et al. 2010; Jain et al. 
2012). During this thesis, these four cell lines will be used to study differences in the histone PTM 
pattern during two specific cellular states: proliferation and confluency. Currently, most of reports are 
related to human cell lines subjected to induced perturbations, like specific mutations or addition of 
drugs (Robin et al. 2007; Gelman et al. 2011; Tang et al. 2013), and only few studies are related to 
study changes in the histone PTM pattern of human cell lines with non-induced perturbations. Recently, 
changes in the histone PTM pattern during cell cycle (S phase, G2/M phase and G1 phase) in H3 were 
reported (Zee et al. 2012). Additionally, some authors sought to compare the histone H3 and H4 PTM 
profiles of several organisms. And finally, others reports intended to compare the histone H3 and H4 
PTM profiles of human cell lines and healthy or normal tissues (Cuomo et al. 2011). 
 
1.4 Identification of histone modifications by mass spectrometry 
It is well known that histone post-translational modifications play important roles in chromatin structure 
and function. Therefore, there is a need to accurately identify and quantify histone PTMs and to 
correlate them with biological processes. So far, several reports were published using different 
approaches for PTM identifications, like ChIP-seq  or chromatin immunoprecipitation combined with 
mass spectrometry (Zee et al. 2012; Voigt et al. 2012; LeRoy et al. 2013). These approaches allowed 
the identification of known modifications only. For that reason, mass spectrometry became a powerful 
tool to detect modifications on histones without a priori knowledge of the modified sites (PTM discovery). 
Moreover, using MS many diverse modifications can be identified and quantified at the same time in a 
single experiment under diverse experimental conditions (e.g. diverse cellular physiology or cells in 
healthy and disease conditions) (Huang et al. 2015)(Huang, et al., 2015). Different MS approaches are 
available to identify and quantify histone PTMs, like top-down, middle-down and bottom-up, as 
summarized in Figure 1.16. 
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Figure 1.16 Summary of available MS approaches to identify proteins and histone PTMs. Image taken from 
(Moradian et al. 2014). 
 
 
1.4.1 Top-down MS approach 
In this approach the intact protein is selected and analyzed directly by MS/MS. Therefore, no enzymatic 
digestion is required. In Top-down proteomics, proteins are usually ionized by electrospray ionization. 
The protein ions are stored in the ion trap (in a Fourier transform ion cyclotron resonance or in a 
quadrupole ion trap) to be delivered for fragmentation (Kelleher 2004). Fragmentation of proteins is 
achieved by electron capture dissociation (ECD) or electron-transfer dissociation (ETD). In ECD, the 
protein ions (that are in gas-phase) are fragmented by low-energy electrons (<1 eV) as shown in Figure 
1.17. During this fragmentation, the ions are randomly cleaved at N-Cα bonds of the peptide backbone 
without the loss of labile modifications (like phosphorylation), producing c- and z- ions (Figure 1.18) 
(Zubarev et al. 1998). Like ECD, ETD fragmentation also produces c- and z- ions (Figure 1.18). This 
type of fragmentation is usually used in different mass spectrometers. While ECD is used in Fourier 
transform ion cyclotron resonance mass spectrometers, ETD is used in quadrupole time-of-flight (Q-
TOF), quadrupole ion trap (QIT) and linear quadrupole ion trap (QLT) instruments (Syka et al. 2004). 
In ETD fragmentation, electrons are transferred to multiple protonated precursor molecules. First, to 
transfer an electron to protein ions, molecular radical anions are generated using anthracene. 
Anthracene generates reactive radical anions by negative chemical ionization. Fluoranthene can be 
also used to generate reactive radical anions. Then, the precursor molecules and radical anions are 
combined in the ion trap, and an electron is transferred to the charged protein. Finally, fragments are 
analyzed by MS/MS (Figure 1.17) (Kim and Pandey 2012).   
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Figure 1.17 Schematic representation of ECD and ETD fragmentation. Fragmentation is achieved by 
introduction of low-energy electrons to protein ions (ECD), or by transferring an electron from a reagent ion (ETD). 
Then the ions are dissociated producing c- and z- ions. Image taken from (Hirabayashi et al. 2008) 
 
 
Figure 1.18 Schematic representation of ETD/ECD fragmentation, generating c- and z- ions. Image taken 
and modified from (Zenaidee and Donald 2015).  
 
 
1.4.2 Middle-down MS approach 
In middle-down proteomics, enzymatic digestion is required. Proteins are commonly digested with Glu-
C or Asp-N enzymes, generating peptides between 3 to 9 kDa (Moradian et al. 2014). This approach 
largely preserves the combinatorial modification of the histone tail, making possible to determine the 
stoichiometry of histone PTMs (Cannon et al. 2010; Siuti and Kelleher 2010; Karch et al. 2013). Similar 
to top-down, middle-down also uses ECD or ETD for ion fragmentation, producing c- and z- ions, as 
shown in Figure 1.17. Fragmentation spectra generated from highly modified large polypeptides (like 
N-tail of histone H3) are extremely complex, but some authors suggested that ECD produces a super 
sequence coverage because of the high resolution of Fourier transformation ion cyclotron resonance 
mass analyzer (Moradian et al. 2014). 
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1.4.3 Bottom-up MS approach 
This approach is often used, because it is more sensitive than middle-down and top-down. Due to its 
sensitivity, bottom-up has been successfully used for PTM discovery (Sidoli et al. 2012). In contrast to 
middle-down, this approach is not well suitable for characterization of combinatorial modification 
patterns, because simultaneously occurring distant PTMs would be in different peptides (Figure 1.19) 
(Moradian et al. 2014). The general workflow of this approach includes: protein digestion into short 
peptides (<20 amino acids), peptide separation by liquid chromatography, and peptide analysis by 
tandem mass spectrometry. Usually, trypsin is the enzyme of choice because it is highly specific and 
efficient, cleaving at the C-terminal of arginine and lysine residues. Trypsin digestion generates a 
problem for histones in particular, because these proteins are highly enriched in lysine and arginine 
residues. Thus, tryptic digestion leads to many short (about 3 amino acids) and hydrophilic peptides 
that cannot be retained in reversed-phase HPLC columns (RP-HPLC) (Garcia et al. 2007). Arg-C 
protease could circumvent this problem, because it cleaves only at the C-terminal of arginine residues. 
However, this protease has low specificity and efficiency, which is not recommendable for quantification 
(Zee and Garcia 2012). Chemical derivatization by acylation of α- and ε- amine group is the best choice 
to improve sequence coverage and detect the most histone PTMs. Acylation of free and 
monomethylated amine groups can be achieved using either propionic or acetic anhydride (PAA or 
AAA) (Bonaldi et al. 2004; Garcia et al. 2007). This chemical derivatization generates more hydrophobic 
peptides improving retention of tryptic peptides on RP-HPLC. Additionally, acylation neutralizes charges 
of α- and ε- amino groups, causing less hydrophilic peptides. (Peters et al. 2003; Bonaldi et al. 2004; 
Garcia et al. 2007; Huang et al. 2015)(Peters, et al., 2003; Bonaldi, et al., 2004; Garcia, et al., 2007; 
Huang, et al., 2015).  
 
Figure 1.19 Schematic representation of differences between middle-down and bottom-up for 
characterization of combinatorial modification patterns. The figure exemplified how in bottom-up MS approach 
is not possible to characterize combinatorial modification pattern that occur simultaneously in distant lysine 
residues, like K9 and K36 due to trypsin digestion (up Figure). While in middle-down it is possible to characterize 
combinatorial PTM patterns, for example in 50 amino acid polypeptides in H3 by Glu-C digestion. Image taken and 
modified from (Sidoli et al. 2015). 
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In the bottom-up MS approach, the fragmentation of precursor molecules is achieved by CID and/or 
HCD. CID or collision-induced dissociation is the most used fragmentation technique to identify and 
quantify protein and PTMs. In CID, the precursor ions collide with neutral gas molecules (like He) in the 
ion trap, these interactions cause ion dissociation at amide bonds of the peptide backbone, generating 
b- and y- ions and loss of small neutral molecules (like water and ammonia), as shown in Figure 1.20 
(Huang and McLuckey 2010). HCD or higher-energy collision dissociation is characterized with higher 
activation energy and shorter activation time compared to CID. HCD was incorporated into the hybrid 
ion trap-orbitrap mass spectrometers. This fragmentation type is performed outside the ion trap (HCD-
collision cell) and the fragments are analyzed in the orbitrap (Olsen et al. 2007). Like CID, HCD also 
generates b- and y- type ions (Figure 1.20). The high energy of HCD generates predominantly y- ions, 
and a-ions can be also generated by further fragmentation of b- ions. HCD is useful for PTMs 
identification because diagnostic ions of PTMs can be identified (Olsen et al. 2007; Lingdong Quan 
2013). For example, diagnostic ion of acetylated or propionylated K are found at m/z 126 and 140, 
respectively.  
 
 
Figure 1.20 Schematic representation of CID/HCD fragmentation, generating y- and b- ions. Image taken 
from (Jones and Cooper 2011).  
 
1.5 Data analysis 
Several software packages have been developed to process fragment spectra and align them against 
theoretical fragmentation patterns (Figure 1.21). For bottom-up, all possible tryptic peptides derived 
from the protein sequence database are used for alignment, and to find the best match. The most 
commonly software used by researchers are Sequest, Mascot, X!Tandem, pfind, Skyline, among 
others. Additionally, the most commonly used protein sequence databases are Uniprot and NCBI. 
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Figure 1.21. MS procedure to identify histone PTMs using database. Tryptic peptides elute from nanoLC, they 
are ionized, analysed by mass spectrometry and acquired. MS/MS spectra are submitted to database searching 
against a database of predicted MS/MS spectra calculated from translated genomic sequences. The entries in the 
protein sequence collection are ranked according to how well they match the experimental data. 
Although all software used for PTM identification are useful, manual inspection of MS/MS spectra is 
required. For example: when Mascot is used to search PTMs, the software allows up to 9 variable 
modifications, like lysine acetylation, methylation, among others. Then, many combinations of 
modifications (permutations) and/or residues can match with particular fragmentation spectra. 
Therefore, these permutations often produce miss-assignment of PTMs. Considering now histone 
PTMs, like lysine acetylation (Kac), propionylation (Kpr) and methylation (Kme), the miss-assignment of 
PTMs is very likely, because there is a mass shift between Kac, Kpr and Kme multiple of +14Da. Similar 
misinterpretation can happen, if the software confuses a modified sequence with a non-modified 
peptide, which possesses a small difference in the amino acid sequence having also +14Da mass shift. 
For example: the peptide sequence Kpr/me1QLATKprAAR (H3) and the KprQLATKprVAR (H3.1T), both 
share the same mass and its MS/MS are very similar. But the difference is indeed in the sequence (in 
red) and histone modification (in blue). 
 
1.6. Quantitative mass spectrometry  
Mass spectrometry is the technique of choice for the quantification of histone PTMs due to its sensitivity 
and specificity. Quantification by MS can be absolute or relative depending on the method used. 
Absolute quantification measures the exact amount of an analyte in the sample, like fmol per µg of total 
protein. This is achieved by adding a labelled standard (Kettenbach et al. 2011). In contrast, relative 
quantification measures the differences in abundance of a peptide between two or more samples. The 
result is expressed as fold changes or percentage (Sidoli et al. 2012).  
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Several methods for quantification by mass spectrometry are available, and Figure 1.22 summarizes 
them:  
 
 
Figure 1.22. Summary of MS-based quantification methods. Quantification can be grouped in four groups, 
labelled- or non-labelled based. Quantification can be obtained by precursor ion or product ions depending on the 
method 
 
 
- Chemical labelling: in this method, biological samples are in vitro labelled by chemical 
reactions. An isotopic mass tag is added after protein samples are digested by a protease (Sidoli et al. 
2012). For example, in the ICAT labelling method, proteins are denatured, digested and reduced. After 
reduction, the SH groups of cysteine are acylated with iodoacetamide. The iodoacetamide contains the 
reagent to target proteins. The labelled peptides are known as heavy and unlabelled peptides are the 
light. Finally, heavy and light peptides are combined, subjected to cation exchange chromatography (to 
remove excess of unreacted reagent) and then analyzed by MS. The mass difference between heavy 
and light peptides is compared and the abundance of the protein is determined. Therefore, the heavy 
peptide has the role of internal standard (Chaerkady and Pandey 2007).  
 
- Metabolic labelling: in this method labelled amino acids are incorporated to the growth medium 
of cells. Then, cells incorporate the labelled amino acids into cellular proteins (Sidoli et al. 2012). Usually 
labelled lysine and arginine are introduced to the cell cultures, because at least one of these amino 
acids will be included in tryptic peptides. Additionally, the culture media are depleted of arginine and 
lysine and replaced by the labelled homologs. Finally, samples containing the labelled amino acids 
(heavy) are combined with samples containing unlabeled R and K (light). The abundances of tryptic 
peptides of heavy and light are compared, and relative quantification is achieved (Chaerkady and 
Pandey 2007). 
 
- Labelled internal standards: in this method, synthetic peptides or proteins that are 
indistinguishable from the endogenous counterparts are introduced into the sample before or after 
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digestion. becoming an internal standard (Kirkpatrick et al. 2005). Then, samples containing the internal 
standard are quantified by mass spectrometry. Addition of the internal standard allows to determine the 
absolute amount (like fmol per µg of total protein) in a given sample. This is determined by plotting the 
intensity of the endogenous peptide against a standard curve, which was previously generated with 
different concentrations of internal standard (Chaerkady and Pandey 2007). 
 
- Label-free: in this method relative quantification of changes in the abundances among many 
samples can be determined. MS-based label free quantification is based on precursor ions intensities. 
MS-based quantification is achieved by creating extracted ion chromatograms (XIC) and determining 
the areas under the peak. These values are then compared among samples, and the abundance is 
determined. MS/MS-based label free quantification is based on product ions intensities. MS/MS-based 
quantification is often applied for determining relative ratios of isomeric peptides. Isomeric peptides are 
not chromatographically separated, and their molecular weights are identical. Therefore, isomeric 
peptides co-elute. Then, diagnostics ions from MS/MS are used for quantification of isomers (Pesavento 
et al. 2006; Garcia et al. 2007). 
 
1.7. Quantification of histone lysine methylation and acetylation by mass spectrometry 
As described before, histone PTMs are involved in several biological processes, like transcription, DNA 
repair, pluripotency maintenance of ESCs, among others. Lysine acetylation produces a direct effect 
over chromatin structure. This histone PTM neutralizes the charges of lysine residues disrupting the 
interactions between nucleosome and DNA, generating an open chromatin structure or euchromatin. 
In contrast, methylation does not affect charges of lysine residue. Lysine methylation is a binding site 
for several non-histone proteins. These histone proteins are usually members of macromolecular 
complexes; these complexes can then modulate chromatin state.  
Regarding the importance of these two histone PTMs in chromatin state modulation, several studies 
have been focused on the quantification of lysine methylation and acetylation. Besides, several 
approaches are available to facilitate the quantification of these histone PTMs. Currently, most 
researchers use bottom-up MS approach to study histone PTMs, because it allows discovery of new 
histone PTMs. This MS approach also provides sensitivity to identify and quantify levels of the reported 
histone modifications. However, most reports are based on the same protocol to determine histone 
PTM quantification, a protocol that shows incomplete and side reactions. Along this thesis, a new 
protocol for accurate quantification of lysine methylation and acetylation is provided. Moreover, this new 
protocol was applied to several organisms, yeast, mESCs, and human cell lines. The main goal is to 
identify the histone lysine methylation and acetylation patterns of these three model systems, and to 
determine whether histone PTM patterns are conserved under different experimental conditions. 
Finally, considering that bottom-up approach allows the discovery of new histone PTMs, it is expected 
to identify novel isoforms that may help to better understand chromatin dynamic changes under different 
experimental conditions.
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Chapter 2: Material and Methods 
 
2.1 Reagents 
Solvents; common chemicals and buffers were purchased from Sigma-Aldrich (Munich, Germany) and 
Merck (Darmstadt, Germany). Porcine trypsin (sequencing grade modified trypsin) was purchased from 
Promega (Mannheim, Germany). LC solvent from Fisher Scientific (Schwerte, Germany), and Formic 
acid was purchased from Merck (Darmstadt, Germany). Deuterated propionic anhydride (D10-PAA) 
was purchased from Sigma-Aldrich (Munich, Germany). 
 
2.2 Peptide standards 
Histone H3K4 peptide standards were purchased from Peptide specialty laboratories, PSL (Heidelberg, 
Germany) (Table 2.1). 
 
Table 2.1. Standard peptides purchased from PSL 
Histone H3K4 non-methylated  H3K4me0 TKQTAR 
Histone H3K4 mono-methylated  H3K4me1 TKme1QTAR 
Histone H3K4 di-methylated  H3K4me2 TKme2QTAR 
Histone H3K4 tri-methylated  H3K4me3 TKme3QTAR 
 
 
2.3 Histone extraction 
2.3.1 S.cerevisiae  
Histone H3 from yeast was kindly prepared by Rupam Choundhary, PhD student of Prof. Dr. Francis 
Stewart from Biotechnology Center (BIOTEC) of the TU Dresden. Histones were extracted under 
denaturing conditions based on Waterborg protocol (Waterborg 2001). Briefly, harvested yeast pellets 
from 2L cultures were washed once in a modified nuclear isolation buffer (NIB: 0.25M sucrose, 60mM 
KCl, 15mM NaCl, 5mM MgCl2, 1mM CaCl2, 20 mM HEPES pH8, 0,5mM spermine, 2.5 mM spermidine, 
0.8% Triton X-100, 100 mM Na-butyrate and protease inhibitors 1mM PMSF, 1 ug/mL Apotinin, 2 ug/mL 
Leupeptin, 1 ug/uL Pepstatin). Homogenization was carried out in 50 mL NIB at 4°C using 0.5mm glass 
beads in a beadbeater (BioSpec, USA). The homogenate was centrifuged at 32,000g for 15 min, the 
crude chromatin pellet was then resuspended in 0.25 N HCl and sonicated for 90 seconds at 55% 
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amplitude (Branson micro-tip, W-450 D) and rotated at 4°C for one hour. Acid insoluble material was 
cleared by centrifugation at 10,000g for 10 min and discarded. Acid soluble material was diluted in 5% 
G buffer (5% guanidine hydrochloride, 100 mM potassium-phosphate, pH 6.8). The eluate was dialysed 
against 5% acetonitrile, 0.1% TFA before reverse phase HPLC. Histone samples were loaded directly 
to a C4 reverse phase HPLC columns. Histones were eluted by a linear acetonitrile gradient (30-65% 
v/v of buffer B) delivered at a flow rate of 1 mL/min for 50 min (buffer A: 0.1% TFA; buffer B: 0.09%TFA 
in ACN). 1 mL fractions were collected and those containing histones were identified by SDS-PAGE 
and 10% of the volume was used for identification by dot-blotting (performed by Rupam Choundhary, 
Biotechnology Center (BIOTEC) of the TU Dresden) 
 
2.3.2 Mouse Embryonic ES:  
mESCs were kindly prepared in collaboration with Kristin Dürschke, from Biotechnology Center 
(BIOTEC) of the TU Dresden. Media for cell cultures were prepared as described in Table 2.2.  
 
Table 2.2. mESC-medium in serum based and in 2i conditions  
Reagent for mESC-medium  
(serum-containig) 
Final 
concentration 
Reagent for N2B27-medium  
(2i-based) 
Final 
concentration 
Fetal calf serum (FCS) 15% DMEM/F-12 medium 0.5x 
Beta-mercaptoethanol 100uM Neurobasalmedium 0.5x 
L-glutamine 2mM B-27 supplement 0.5x 
Sodium pyruvate 1mM N2 supplement 0.5x 
100xNon-essential amino acids 1x 100xNon-essential amino acids 1x 
Penicillin 100U/ml L-glutamine 2mM 
Streptavidin 100ug/ml Beta-mercaptoethanol 100uM 
LIF 1000U/ml LIF 1000U/ml 
  PD0325901 1uM 
  CT-99021 3uM 
 
 
Cells were grown for 1 week at 37 °C. Further, these were splitted every second day with trypsin and 
harvested after 1 week. Cells were trypsinated, resuspended in growth medium and pelleted by 
centrifugation (5 min at 600 rpm at room temperature). After mESCs were resuspended in 5 mL cold 
1x PBS. mESCs and were again pelleted by centrifugation (5min at 600 rpm at room temperature), and 
washed twice with PBS. After cells were resuspended in TEB buffer (1xPBS, 0.5% Triton x-100, 
complete protease inhibitor) at 1x107 cells/mL, incubated on ice for 10 min with occasional gentle flicking 
and centrifugated 10 min at 2000 rpm at 4°C. Cell pellet was washed once with half of the initial volume 
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of TEB buffer and centrifugates as before. The pellet was resuspended in 0.2 N HCl and extracted over 
night at 4°C with gently shaking. Afterword, the extract was centrifugated for 10 min at 1000g at 4°C. 
Supernatants were neutralized with 1M NH4HCO3 (50% of extract volume) and stored at -20°C. 
 
2.3.3 Human cell lines:  
Human samples were provided by Dr. Alexandra Shambony from Friedrich-Alexander Universität 
Erlangen, Nürnberg. Cells were seeded in 25 cm2 flasks and grown to approx. 30-80% confluency 
(proliferative phase) or to 100% confluency (contact inhibition). Cells were trypsinated and washed twice 
with PBS and complete protease Inhibitor.  An aliquot was removed and cell number determined by 
manual counting (Neubauer chamber). Cell pellets were resuspended in 200 µl Buffer B10 (15 mM 
HEPES pH 7.6, 10 mM KCl, 5 mM MgCl2, 0.1 mM EDTA, 0.5 mM EGTA, 0.5 mM DTT, complete 
protease Inhibitor cocktail) and incubated on ice for 10 min. After, cells were lysed by 40 strokes on ice 
in a Dounce Homogenizer using the B type pestle and the lysate transferred to Eppendorf cups. Nuclei 
were pelleted by centrifugation for 10 min at 2400xg/4°C, washed once in Buffer B10 and pelleted as 
before. Nuclei pellets were stored at -80°C.  
Cells were trypsinated and resuspended in growth medium. Cells were pelleted by centrifugation (5min 
at 600 rpm at room temperature) and resuspended in 5 mL cold 1x PBS. Cells were again pelleted by 
centrifugation (5min at 600 rpm at room temperature) and washed twice with PBS. After were 
resuspended in TEB buffer (1xPBS, 0.5% Triton x-100, complete protease inhibitor) at 1x107 cells/mL, 
incubated on ice for 10 min with occasional gentle flicking and centrifugated 10 min at 2000 rpm at 4°C. 
The cell pellet was washed once with half of the initial volume of TEB buffer and centrifugates as before. 
The pellet was resuspended in 0.2 N HCl and extracted over night at 4°C with gently shaking. Afterword, 
the extract was centrifugated for 10 min at 1000g at 4°C. Supernatants were neutralized with 1M 
NH4HCO3 (50% of extract volume) and stored at -20°C 
 
2.4 Chemical derivatization of synthetic peptides 
Based on several reports (Peters et al. 2003; Bonaldi et al. 2004; Garcia et al. 2007), a simple and 
reliable protocol to derivatize ε-amino groups at lysine and N-terminal in histone proteins was 
developed. Histone peptide standards were propionylated as in Table 2.3 is described. Each experiment 
was performed taking 1nmol of peptide standard (Table 2.1), and incubated for 2h at 37°C with buffer, 
alcohol (mixture details are described in Table 2.3) and 20µL propionic anhydride (PAA). After 
incubation, propionylated peptides were thoroughly evaporated by a SpeedVac to remove any volatile 
remnants and ready for MS analysis. Each experiment was performed with 5 replicates and histone 
peptides were also derivatized using propionic anhydride-D10 only in experiment number 8. 
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Table 2.3. Buffer and alcohol mixtures used to propionylate ε-amino groups at lysine and N-terminal in 
histones 
Experiment Buffer Alcohol 
1 80µL 50mM Ammonium bicarbonate (Ambic) 160µL Methanol (MeOH) 
2 80µL 50mM Ammonium bicarbonate (Ambic) 160µL Ethanol (EtOH) 
3 80µL 50mM Ammonium bicarbonate (Ambic) 160µL 1-Propanol (1-PrOH) 
4 80µL 50mM Ammonium bicarbonate (Ambic) 160µL 2-Propanol (2-PrOH) 
5 80µL 30mM Triethylamine (TEA) 160µL Methanol (MeOH) 
6 80µL 30mM Triethylamine (TEA) 160µL Ethanol (EtOH) 
7 80µL 30mM Triethylamine (TEA) 160µL 1-Propanol (1-PrOH) 
8 80µL 30mM Triethylamine (TEA) 160µL 2-Propanol (2-PrOH) 
 
 
2.5 Histone digestion and derivatization 
Histones from yeast, mESCs and human were loaded into 1mm thick mini-ready-gel. Proteins were 
separated by 15% (yeast) and 4-16% (mESCs and human) SDS-PAGE, following by coomassie 
staining. Histone bands were cut-off and destained with acetonitrile and 100 mM NH4HCO3. After the 
clean-up steps the ε-amino groups at lysine and N-terminal were chemically modified using TEA, PAA 
and 2-PrOH. They were incubated overnight at room temperature. The gel pieces containing histones 
were digested with trypsin overnight and then extracted according to (Shevchenko et al. 2007). A 
second round of chemical modification was performed to propionylate the new N-terminal generated 
after the digestion, and thoroughly evaporated by a SpeedVac. Propionylated peptides were stored at 
-20°C for MS analysis. 
 
 
2.6 Mass spectrometry analyses 
2.6.1 Direct infusion:  
The MS analyses of synthetic peptides were performed by nano-electrospray based methodology. 
1pmol of synthetic peptides were ionized using a Nanomate Triversa ion source (Advion, Biosciences), 
and MS analysis was carried-out on LTQ Orbitrap XL (Thermo Fisher Scientific, Bremen, Germany) 
manually. MS and MS/MS settings are described in Table 2.4. 
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Table 2.4. MS and MS/MS setting used in LTQ Orbitrap XL 
Parameter Value 
Scan range 200-1200 m/z 
Nominal resolution (at 400 m/z) 60000 
Lock mass 445.120005 (siloxane)  
Data mode Centroid  
Target ion count 1x105 (FT) 
Max fill time 500 ms (FT) 100 ms (IT) 
Automatic gain control (AGC) On 
Activation type (MS/MS) CID 
Intensity threshold for DDA 4000 
Isolation width 2 m/z 
Normalized collision energy 35% 
Exclusion mass width 3 ppm 
 
 
2.6.2 LC-MS/MS:  
Propionylated peptides from yeast, mESC and human were reconstituted in 20 μL 30% formic acid, 
dilution of samples was perfomed: 2 μL of sample, 2 μL deuterated H3K4 synthetic peptides, 2 μL 
retention time standard and 40 μL H2O.  
LC-MS/MS consisted of a nanoLC system (Eksigent, USA) interfaced on-line to a hybrid LTQ Orbitrap 
Velos (Thermo Fisher Scientific, Bremen, Germany). The mobile phase was 0.1% formic acid (Solvent 
A) and 0.1% formic acid in 60% ACN (solvent B) peptides were loaded on a nanocolumn C18 in-house 
packed triart (YMC) endcapped for yeast analysis (10 cm x 75μm ID, 3 μm) and for human and mESCs 
on a nanocolumn C18 in-house packed triart (Dr. Maisch) endcapped (10 cm x 75μm ID, 3 μm) at a 
flow rate of 200 nL/min and separated over 90 min elution gradient from 0-60% B.  
MS and MS/MS spectrum were acquired in a data dependent analysis. MS and MS/MS settings are 
described in Table 2.5. 
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Table 2.5. MS and MS/MS setting used in LTQ Orbitrap Velos 
Parameter Value 
Scan range 300-1500 m/z 
Nominal resolution (at 400 m/z) 60000 
Lock mass 445.120005 (siloxane)  
Data mode Centroid 
Target ion count 2x106 (FT) 2x104 (IT) 
Max fill time 500 ms (FT) 100 ms (IT) 
Automatic gain control (AGC) On  
Activation type (MS/MS) CID 
Intensity threshold for DDA 5000 
Isolation width 3 m/z 
Normalized collision energy 35% 
Exclusion mass width 3 ppm 
 
 
2.7 Data processing  
To identify peptides and their fragments, Mascot v.2.2 (Matrix science, London, UK) was used by 
searching against a database compiled from histones H3, H4, H2A and H2B proteins for yeast, mESCs 
and human. Sequences were extracted from UniProt database and complemented with all entries for 
human keratins and porcine trypsin (a separated database was prepared for each organism). Mascot 
settings are shown in Table 2.6. Moreover, all MS/MS spectra from peptide standards and samples 
were manually checked using Qual Browser (Thermo Fisher Scientific) software, with a mass tolerance 
of 5 ppm and precision up to four decimal places. 
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Table 2.6. Mascot parameter  
Name Value 
Fixed modification none 
Variable modification Acetyl (K), Dimethyl (K), Methyl (K), Oxidation (M), Propionyl (KSTY)(N-term), 
Propionyl-methyl (K), Trimethyl (K) 
Report (hits) Auto 
Max missed cleavages 4 
Decoy database yes 
Peptide charge 2+ and 3+ 
Peptide tolerance ± 5 ppm 
Enzyme Trypsin 
Taxonomy All entries 
Database Sc_Histone-mESCs-human 
Precursor mass calculation Monoisotopic 
Data format Mascot generic 
MS/MS ion search yes 
MS/MS tolerance  ± 0.6 Da 
Quantitation none 
Instrument ESI-TRAP 
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Chapter 3: Results and Discussion 
 
3.1 Development and optimization of LC-MS/MS method for PTM quantification  
3.1.1 Efficient chemical derivatization 
There is considerable interest in using mass spectrometry approaches to assess histone post-
translational modifications, particularly acetylation and methylation, because they appear to play 
significant roles in many cellular processes and species (Liao et al. 2013). Analysis of histone 
posttranslational modifications (PTMs) by mass spectrometry (MS) is challenging due to histone protein 
sequence. Histone proteins are enriched in lysine and arginine residues, especially on the N-termini 
where most PTMs are positioned (Garcia et al. 2007). This characteristic (enrichment of K and R) 
causes problem when the protein is enzymatically digested with trypsin, because tryptic peptides are 
too small and hydrophilic and therefore hardly retained on reversed-phase high performance liquid 
chromatography (RP-HPLC) columns. Arg-C (enzyme that cleaves after carboxyl groups of arginine) 
and/or Glu-C (enzyme that cleaves after carboxyl groups of glutamic acid) could be used to generate 
suitable peptides for RP-HPLC columns. However, both have the disadvantages of low efficiency and 
low specificity (Zee and Garcia 2012). Then, to get optimal peptides for RP-HPLC using robust enzyme 
like trypsin, researchers have derivatized lysine residues (Ɛ- and α- amino groups of free and 
monomethylated K) with propionic or acetic anhydrides, blocking this residue from trypsin digestion and 
generating Arg-C-like peptides (Bonaldi et al. 2004; Garcia et al. 2007). Besides the obtaining of less 
hydrophilic histone peptides due to derivatization with propionic or acetic anhydrides, the charges at 
the N-terminus and unmodified and monomethylated lysine residues are also neutralized. It makes 
propionylated peptides more ideal for mass spectrometric detection, because only doubly and triply 
charged ions are produced by electrospray ionization generating MS/MS fragmentation spectra easier 
to interpret (Garcia et al. 2007). 
Several and similar protocols for chemical derivatization of lysine residues have been reported (Smith 
et al. 2002; Peters et al. 2003; Bonaldi et al. 2004; Garcia et al. 2007), and Drogaris and co-workers 
recommended to have no double rounds of histone propionylation because the ion abundance is 
decreased for mass spectrometry detection (Drogaris, et al., 2008). However, the low abundance of 
propionylated ions (complete reaction) is related to the presence of incomplete and side reactions (like 
esterification at C-terminal arginine). For instance, Garcia and co-workers derivatized lysine residues 
with propionic anhydride (PAA) and methanol (MeOH) in ammonium bicarbonate (Ambic) buffer. This 
reaction gives as products propionic acid and methyl propionate (propionylation reagent) as shown in 
Figure 3.1. The pH of the reaction decreases (due to formation of propionic acid) and it is adjusted to 
pH 8 with ammonium hydroxide (Garcia et al. 2007). One of the consequences of this derivatization 
method, in addition to some older protocols (Peters et al. 2003; Bonaldi et al. 2004), is that quantification 
is not reliable and misinterpretation can occur due to side reactions. Therefore, in this study it is desired 
to develop a quantitative derivatization methodology of histones with absence or reduced levels of 
incomplete and side reactions.  
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Propionic anhydride      methanol    propionic acid  methyl propionate 
 
Figure 3.1. Chemical reaction of propionic anhydride and methanol. Reaction of propionic anhydride and 
methanol to derivatize histones. Reactants are propionic anhydride and methanol and propionic acid and methyl 
propanoate are the products. 
 
 
It is expected that the new methodology consisting in PAA with a less reactive alcohol (solvent) like 
isopropanol (2-PrOH) in a more basic buffer like triethylamine (TEA), would reduce notably esterification 
at the C-terminal of arginine, and more than 95% of complete reaction would be obtained. Recently, 
another kind of side reaction was reported, which implicate O-propionylation of S, T and Y (Liao et al. 
2013; Paternoster et al. 2016). Therefore, and considering both reports (just mentioned), it is expected 
to obtain low abundances of O-propionylated S, T and/or Y. Besides, if this new side reaction cannot 
be reduced completely, it is expected that O-propionylated S, T and/or Y abundances will not interfere 
quantification because their levels will be included in the final results. 
Initially, different methylation states of synthetic H3 peptide standards TKQTAR (H3K4), TKme1QTAR 
(H3K4me1), TKme2QTAR (H3K4me2) and TKme3QTAR (H3K4me3) were derivatized using MeOH, 
ammonium bicarbonate (Ambic) and PAA according to (Garcia et al. 2007), and 2-PrOH, triethylamine 
(TEA) and PAA (the new protocol). Samples were analyzed by direct infusion, TriVersa robotic 
nanomate ion source (Advion BioSystems, USA), into LTQ Orbitrap XL mass spectrometer. Spectra 
were manually acquired in high resolution (Rm/z 400=60000) MS mode. 
By analyzing MS spectra of standards derivatized with MeOH, Ambic and PAA, two additional different 
precursor ions were identified: 
1. The first precursor ion corresponds to the incomplete reaction in the case of H3K4 and H3K4me1 
(Figure 3.3a & 3.3b). According to MS/MS fragmentation spectra, propionylation was achieved mainly 
at the N-terminal in both peptides (Figures 3.4a and 3.4b). If the pKa values of the α-amino group of T 
(pKa=9.10) and the ε-amino group of K (pKa=10.53) are considered, it would be expected that ε-amino 
group of K would react faster with methyl propionate (propionylation reagent) than α-amino group of T, 
because the higher pKa the better nucleophile, however α-amino group of T is more accessible. 
2. The second additional precursor ion identified in MS spectra corresponds to side reaction 
(Figure 3.5a - d) that relates to esterification of C-terminal carboxyl in all four peptides (H3K4, H3K4me1, 
H3K4me2 and H3K4me3) as shown in Figures 3.6a - d. 
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The following mechanisms of reactions describe chemical derivatization of: α-amino group of K (Figure 
3.2a) and α-amino group of T (Figure 3.2b). 
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Figure 3.2. Mechanisms of reaction during chemical derivatization of histones using propionic anhydride 
in methanol with ammonium bicarbonate as buffer. Mechanism of reaction of methyl propanoate with ε-amino 
group of K (Figure a) and α-amino group of T (Figure b) 
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Figure 3.3. Incomplete and complete reaction mass spectrum of propionylated H3K4 and H3K4me1 peptides 
acquired by direct infusion-MS. Mass spectrum (MS1) of (A) unmodified H3K4 peptide and (B) monomethylated 
H3K4 peptide. Both MS1 correspond to synthetic peptides after propionylation of free and monomethylated amino 
group and N-terminal (In the case of complete reaction). The arrows indicate the precursor ion of: incomplete 
reaction (red arrow) and complete reaction (blue arrow). m/z 785.8420 of Glu-1-Fibrinopeptide B, standard used 
for injection control. 
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Figure 3.4. Tandem MS/MS spectra of incomplete reaction acquired from H3K4 and H3K4me1 synthetic 
peptides. MS/MS spectrum of the [M+2H]2+ 3-8 peptide containing: (A) IT MS/MS of H3K4 peptide, only the N-
terminal is propionylated and its precursor ion is m/z 380.7194 ([M+2H]2+), and (B) HCD MS/MS of H3K4me1 
peptide, only the N-terminal is propionylated and its precursor ion is m/z 387.7272 ([M+2H]2+). “y“ and “b” type ions 
are designated for each fragment. pr: propionyl group, me1: monomethyl group. 
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Figure 3.5. Side and complete reaction mass spectrum of propionylated H3K4, H3K4me1, H3K4me2 and 
H3K4me3 peptides acquired by direct infusion-MS. Mass spectrum (MS1) of: A) unmodified H3K4 peptide after 
propionylation of free N-group and N-terminal, B) monomethylated H3K4 peptide after propionylation of 
monomethylated N-group and N-terminal, C) dimethylated H3K4 peptide after propionylation of N-terminal, and D) 
trimethylated H3K4 peptide after propionylation of N-terminal. The arrows indicate the precursor ion of: complete 
reaction (blue arrow) and side reaction (green arrow). m/z 785.8420 of Glu-1-Fibrinopeptide B, standard used for 
injection control.  
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Figure 3.6. Tandem MS/MS spectra of side reactions acquired from H3K4, H3K4me1, H3K4me2 and H3K4me3 
synthetic peptides. MS/MS spectrum of the [M+2H]2+ 3-8 peptide containing: A) propionylated H3K4 and 
esterified C-terminal of arginine observed precursor ion m/z 415.7459. B) Propionylated H3K4me1 and esterified C-
terminal of arginine, observed precursor ion m/z 422.7428. C) Propionylated H3K4me2 and esterified C-terminal of 
arginine observed precursor ion m/z 401.7428. D) Propionylated H3K4me3 and esterified C-terminal of arginine 
observed precursor ion m/z 408.7528. “y” and “b” type ions are designated. pr: propionyl, me1: monomethyl, me2: 
dimethyl and me3: trimethyl. 
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In order to quantify the abundances of C-terminal esterification, incomplete and complete reactions, the 
intensities of their corresponding precursor ions were obtained. For instance, for the same peptide 
H3K4 (TKQTAR) three forms were detected as shown in Figures 3.2a and 3.4a. These three detected 
forms were esterified H3K4 (pr-TKprQTAR-CH3), incomplete reaction of propionylation on H3K4 (pr-
TKQTAR) and complete reaction of propionylation on H3K4 (pr-TKprQTAR). Then, intensities of each 
ion were summed-up, this value represented 100% and abundances for each form (esterification, 
incomplete and complete reaction) were calculated. The same was done for all peptides (H3K4, 
H3K4me1, H3K4me2, H3K4me3), and the results are shown in Figure 3.7. 
 
 
Figure 3.7. Efficiency of propionylation of H3K4 synthetic peptides using PAA, MeOH in Ambic buffer. 
Relative abundances of complete, incomplete and side reactions of propionylated Ɛ- and α amine groups of H3K4 
peptides (3-8 residues) in their different methylation states. Error bars indicate standard deviation of 5 replicates 
analyzed. 
 
 
As shown in Figure 3.7, methyl-esterification was identified in all peptides with abundances of 10% 
approximately. It is important to reduce this side reaction because it can be misinterpreted as natural 
methylation (endogenous) interfering with quantification. Moreover, incomplete reaction in non- and 
mono-methylated H3K4 reached 7 and 31%, respectively. Then, propionylation efficiency resulted in 
poor conversion (Figure 3.7). Therefore, the aim in in this section is to develop an accurate and efficient 
method for chemical modification of lysine Ɛ- and α amine groups of H3K4 peptides, that can be applied 
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later to histone proteins. Besides propionic anhydride (PAA), several alcohols (ethanol, 1-propanol and 
isopropanol) and an alternative buffer (triethylamine) were used to derivatize H3K4 peptides (all 
mixtures used during this experiment are summarized in Table 3.1).  
 
Table 3.1: Summary of buffer and alcohol mixtures used for chemical derivatization. Components for 
chemical derivatization were PAA:Alcohol:Buffer in a ratio of 1:8:4 and incubated 2.5h at 37°C. Ambic, ammonium 
bicarbonate; TEA, triethylamine; MeOH, methanol; EtOH, ethanol; 1-PrOH, 1-propanol; 2-PrOH, 2-propanol or 
isopropanol; PAA, propionic anhydride. 
Mixture Buffer Alcohol  Mixture Buffer Alcohol 
1 50mM Ambic MeOH  5 30mM TEA MeOH 
2 50mM Ambic EtOH  6 30mM TEA EtOH 
3 50mM Ambic 1-PrOH  7 30mM TEA 1-PrOH 
4 50mM Ambic 2-PrOH  8 30mM TEA 2-PrOH 
 
 
The eight mixtures shown in Table 3.1 were used to derivatize all H3K4 synthetic peptides (H3K4, 
H3K4me1, H3K4me2, H3K4me3). Figure 3.8 summarizes relative abundances of side, incomplete and 
complete reactions identified in monomethylated H3K4 when MeOH/Ambic/PAA and 2PrOH/TEA/PAA 
were used for derivatization, in Suppl. Figure 5.1.1 all peptides in all mixtures are shown. The results 
showed an impact of solvent on C-terminal esterification degree (side reaction). Methanol (MeOH) is 
more reactive than isopropanol, and 2-PrOH would impede a nucleophilic attack (due to steric effect) 
by the hydroxyl group from alcohol to carboxyl terminal of arginine. This results are supported by 
Paternoster and co-workers (Paternoster et al. 2016). They reported that either isopropanol or 
acetonitrile would be a suitable solvent to avoid side reactions as esterified C-terminal during chemical 
derivatization (Paternoster et al. 2016). Additionally, buffers showed an impact on completeness of the 
reaction and thus far there are no reports about this (Suppl. Figure 5.1.1). It is assumed that TEA is a 
more basic buffer and therefore there is no need to adjust the pH with ammonium hydroxide (Garcia et 
al. 2007; Paternoster et al. 2016), preventing that ammonia competes with α- or ε- amino groups during 
derivatization. Finally, substituting methanol by isopropanol and Ambic by TEA resulted in a suitable 
method to derivatize all H3K4 peptides (H3K4, H3K4me1, H3K4me2, H3K4me3), with abundances less than 
2% of incomplete reaction and C-terminal esterification, and more than 95% of complete reaction. 
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Figure 3.8. Summary of propionylation efficiency in H3K4me1 synthetic peptide using MeOH/Ambic/PAA 
and 2-PrOH/TEA/PAA. Graph shows relative abundances (in %) of (in green) complete reaction, (in blue) side 
reaction (esterified peptides) and (in yellow) incomplete reaction when H3K4me1 is propionylated with 
MeOH/Ambic/PAA and 2-PrOH/TEA/PAA. MeOH: methanol; Ambic: ammonium bicarbonate; 2-PrOH: isopropanol; 
TEA: triethylamine: PAA: propionic anhydride. 
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3.1.2 Retention improvement of hydrophilic peptides 
Once the new methodology for chemical derivatization of α- and Ɛ amino groups was established, 
propionylated H3K4 peptides were analyzed by liquid chromatography mass spectrometry (LC-
MS/MS). It is known that TKQTAR (H3K4) peptides are short and hydrophilic (Zhang et al. 2013), thus 
chemical modification is required to increase their hydrophobicity, in order to be retained by C18 
columns. Regarding these characteristics (shortness and hydrophilicity), two different packed-materials 
for C18 columns, both in-house packed, were tested. The first material corresponds to conventional 
silica-based RP column, and the second one corresponds to end-capped silica-based RP column. 
Figure 3.9 shows the performance of both columns when the four H3K4 peptides (H3K4, H3K4me1, 
H3K4me2, H3K4me3) were chromatographically separated. The end-capped silica-based C18 column 
showed the best result (Figure 3.9b), because the silanol groups in this stationary phase are blocked, 
increasing its hydrophobicity. Finally, as shown in Figure 3.9b and in Table 3.2, the four H3K4 peptides 
were properly and accurately retained from an equimolar mixture, with ratios of 0.9:1.2:1:1.2 for 
H3K4:H3K4me1:H3K4me2:H3K4me3, respectively. The ratios were calculated dividing the peak area of 
each H3K4 peptide by the XIC of an internal standard (Glu-1-Fibrinopeptide B) spiked into each sample.  
 
Table 3.2: Equimolar composition of H3K4 peptides. In the table are listed the extracted ion chromatograms 
(XIC) of H3K4 peptides (H3K4:H3K4me1:H3K4me2:H3K4me3). The ratios represent the equimolar composition of 
H3K4 peptides calculated dividing XIC of each H3K4 by an internal standard XIC.  
Peptide m/z H3K4 XIC Internal standard XIC ratio 
Pr-TK(pr)QTAR H3K4 408,73 4,54E+06 4,96E+06 0,91 
Pr-TK(pr/me1)QTAR H3K4me1 415,74 4,18E+06 3,39E+06 1,23 
Pr-TK(me2)QTAR H3K4me2 394,73 4,02E+06 4,16E+06 0,97 
Pr-TK(me3)QTAR H3K4me3 401,74 6,09E+06 4,98E+06 1,22 
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Figure 3.9. Chromatograms of 500 fmol/injection of propionylated H3K4 peptides using silica-based and 
end-capped silica-based C18 reversed phase HPLC columns. Base peak chromatogram of propionylated H3K4 
peptides (H3K4, H3K4me1, H3K4me2, H3K4me3). Figure (a) shows the performance of H3K4 peptides in a 
conventional silica-based C18 RP-HPLC column. Figure (b) shows the performance of H3K4 peptides in an end-
capped silica-based C18 RP-HPLC column 
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3.1.3 Application of propionylation method to histone protein standard 
The aim of this study is to develop an accurate methodology for derivatization of histones (with no 
undesired reactions) to further quantify histone PTMs by LC-MS/MS. Histone peptide standards used 
in previous experiments were useful to control all parameters and to develop a methodology for histone 
derivatization. However, it is now desired to derivatize histone proteins, then a standard from Calf 
Thymus, containing H1, H2A, H2B, H3 and H4 was derivatized and subjected to bottom-up MS 
approach. The obtained results with this experiment will give a close approximation to identify how the 
new protocol and column work with histone proteins.  
Considering that histone peptide standards got more than 95% of complete conversion with almost no 
undesired reaction (<2%), it is expected that with histone protein undesired reactions increase, but it is 
also expected that both, side and incomplete reactions, reach less than 10% and do not affect 
quantification of desired histone PTMs. 
 
a. Dynamic range:  
In order to determine the lowest and highest concentration in which the detector will have a linear 
response, the dynamic range was calculated. In this thesis, the linear response for all four propionylated 
forms isotopically labelled d10-H3K4 peptides (d10-H3K4, d10-H3K4me1, d10-H3K4me2, d10-H3K4me3) was 
achieved. Dilution series were performed which included 12 concentration points with linear response 
from 0.116 to 4082 fmol per injection. 87 fmol per injection of H3K4, H3K4me1, H3K4me2, H3K4me3 were 
used as internal standard (data not shown). The linear dynamic range was 5 orders of magnitude with 
correlation coefficient (R2) higher than 0.98, as shown in Figure 3.10.  
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Figure 3.10. Calibration curve and dynamic range of H3K4 peptides. Quantification of H3K4me0, H3K4me1, 
H3K4me2 and H3K4me3 was achieved using LTQ Orbitrap Velos MS. Calibration curves were obtained by analysing 
dilution series from 4082 to 0.116 fmol/injection of isotopically labelled (with d10-propionic anhydride) peptides. The 
inset shows a zoom-in of the first data points. 
 
 
The calibration curve kept the linearity from the lowest to the highest concentration injected into the 
column. Both, limit of detection (LOD) and limit of quantification (LOQ) were below 100 attomol on 
column for all H3K4 peptides. LOD and LOQ, were calculated 3 times and 10 times Signal to Noise 
(S/N), respectively. The relative standard deviation (RSD) values for 4 peptides were up to 7% with a 
precision (CV) not higher than 6.5%. These results demonstrated that lower and higher concentrations 
could have been achieved, which might increase the dynamic range.  
 
b. Propionylation of histone protein standard:  
As mentioned in section 3.1.1, incomplete and side reactions were identified in published methods 
(Peters et al. 2003; Bonaldi et al. 2004; Garcia et al. 2007) with high abundances, and therefore a new 
protocol for histone derivatization was developed. Since all previous experiments were based on 
histone peptide standards, it is now desired to derivatize histone proteins from Calf thymus (histone 
 
 
75 
protein standard) and identify whether all expected sites are derivatized, and to identify at which extent 
side reactions are present in H3 protein. 
Histone PTMs of purified H3 from Calf Thymus (commercial standard) were derivatized and analyzed 
by LC-MS/MS. Five independent replicates, containing 6 g of total protein, were loaded into SDS-
PAGE. H3-containing slices were excised and in-gel derivatized with propionic anhydride (PAA) in 
isopropanol (2-PrOH) and triethylamine (TEA) as buffer. Propionylated products were incubated 
overnight at room temperature to ensure complete conversion of lysine residues. Finally, samples were 
in-gel digested and propionylation of new N-termini was performed.  
About 30 modified H3 peptides were identified in a single LC-MS/MS analysis. Among these 30 different 
peptides, endogenous modifications as lysine acetylation and methylation, and no-endogenous 
modification like lysine propionylation were observed. Additionally, all N-termini of identified H3 peptides 
were propionylated, and no incomplete reactions on Ɛ-amine groups of free and monomethylated lysine 
were observed. However, unexpected side reactions were identified, O-propionylation of serine, 
threonine and tyrosine. These side reactions (O-propionylation) presented abundances up to 16%. As 
mentioned in section 3.1.1, Paternoster and co-workers reported the presence of the same type of 
undesired reactions when methanol and ammonium bicarbonate (Ambic) are used as solvent and 
buffer, respectively (Paternoster et al. 2016). Moreover, they also reported some additional side 
reactions like amidation of carboxyl groups and solvolysis, this last reaction converts glutamine and 
asparagine to glutamate and aspartate (Paternoster et al. 2016), that in this thesis were no identified. 
Then, Paternoster and co-workers suggested to use isopropanol and ammonium bicarbonate for 
derivatization of histone proteins to reduce S, T, and Y O-propionylation (Paternoster et al. 2016).  
Attempting to verify whether these new side reactions are also present in the methodology suggested 
by Paternoster and collaborators (and at which extent), five independent replicates of 6 g total protein 
from Calf Thymus (histone protein standard) were in-gel derivatized with 2-PrOH, Ambic and PAA 
(Paternoster et al. 2016). From now, derivatization of histones with Ambic/2-PrOH/PAA will be named 
“Paternoster protocol”, and derivatization of histones with TEA/2-PrOH/PAA will be named “Gallardo 
protocol”. When both methodologies (Paternoster and Gallardo protocols) were compared, slight 
differences in the abundances of O-propionylated peptides were identified. For instance, the abundance 
of O-propionylated S10 in the peptide K9S10TGGK14APR was up to 13% and 16% (and a standard 
deviation up to 3%) when Paternoster and Gallardo protocols were used, respectively (as shown in 
Figure 3.11). 
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Figure 3.11. Relative quantification of detected side reaction (O-propionylation) in H3 serine 10 from Calf 
Thymus. Relative quantification of side and complete reaction of H3K9-K14 (KSTGGKAPR). Side reaction 
corresponds to O-propionylation of serine and complete reaction corresponds to propionylation of Ɛ- and α amine 
groups of K and N-termini, respectively. Error bars correspond to five independent and two analytical replicates. 
 
 
Besides quantification of O-pripionylated S10 in the peptide K9S10TGGK14APR, abundances of O-
propionylated T22 and S28 were obtained in the H3 peptides K18QLAT22K23AAR and 
K27S28APATGGVK36K37PHR. O-propionylated peptides reached abundances up to 5% for T22 
K18QLAT22K23AAR and up to 13% for K27S28APATGGVK36K37PHR when Paternoster and Gallardo 
protocols were used (as shown in Suppl. Figure 5.1.2 and 5.1.3).  
Another H3 peptide, as YRPGTVALR, also showed O-propionylated Y and T. Both isoforms, 
YprRPGTVALR and YRPGTprVALR, reached in total 15% of abundance when Paternoster protocol was 
used, and 14% when Gallardo protocol was used (Suppl. Figure 5.1.4).  
Regarding abundances of O-propionylated peptides, it is clear that no major differences between both 
protocols (Paternoster and Gallardo) for derivatization of histones were observed. Although the 
contribution of this side reaction is up to 16%, it is possible to circumvent that abundances of O-
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propionylated peptides affect the final quantification of histone PTMs. The abundances of O-
propionylated peptides were added-up to their corresponding peptide that was not over-propionylated, 
and a single result was reported. For example, the abundance of the peptide KprSprTGGKprAPR was 
added-up to the abundance of KprSTGGKprAPR and reported as a single value.  
Additional to O-propionylated peptides, incomplete reaction of H3K4 was identified when Paternoster 
protocol was used. The abundances of incomplete reaction (as shown in experiment with synthetic 
peptide standards) of un- and mono-methylated H3K4 were up to 10%, as shown in Figure 3.12.  
Taken together, S, T and Y O-propionylation cannot be reduced or eliminated neither by using a less 
reactive alcohol (iPrOH) nor by using a more basic buffer (like TEA). Addition of buffer to propionylated 
H3 peptides was performed to verify whether O-propionylation of S, T and Y can be reversed, with no 
positive results. The abundances of this side reaction did not decrease (data not shown). 
Moreover, the total peak areas of all detected histone PTMs of H3 derivatized with Paternoster and 
Gallardo protocols were compared to identify whether both methodologies are quantitatively similar, as 
shown in Figure 3.12 (orange bars: Paternoster protocol, blue bars: Gallardo protocol). The total peak 
area was calculated by summing-up the extracted ion chromatogram (XIC) of all identified forms for 
each tryptic peptide. For example: the total peak area of K4 comprises the XIC of K4me0, plus XIC of 
K4me1, plus XIC of K4me2, plus XIC of K4me3 (un-, mono-, di-, and tri-methylated K4, respectively). The 
abundances of all detected H3 peptides included the contributions of side reactions (O-propionylated 
S, T and Y) already. Finally, these results demonstrated that quantification of propionylated peptides 
obtained through Gallardo protocol is more accurate than quantification of propionylated peptides 
obtained through Paternoster protocol.  
Data interpretation and histone PTM interpretation were done with Mascot v2.2 software (Matrix 
Science, London, UK) for peptides and PTMs identification. Manual inspection of each fragmentation 
spectra generated during the acquisition was done using Xcalibur v2.2 software (Thermo Fischer 
Scientific), in order to confirm Mascot identification. 
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Figure 3.12. Comparison of total peak area of tryptic H3 peptides from Calf Thymus. Total abundances of 
detected tryptic H3 peptides derivatized with Paternoster (orange bars) and Gallardo (blue bars) protocols are 
compared. Abundances were obtained from the extracted ion chromatogram (XIC) of each tryptic H3 peptide 
derivatized with both protocols. The inset shows a zoom-in of peptides K56 (YQKSTELLIR), K64 (KLPFQR) and 
K79 (EIAQDFKTDLR) with low total peak area.  
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Summarizing this section, quantification of histone PTMs by bottom-up MS approach requires 
derivatization of Ɛ- and α amino groups of K and N-termini, respectively. A common protocol for 
chemical derivatization with propionic anhydride was reported by several authors (as described in 
previous sections). The common method consists in methanol as solvent, ammonium bicarbonate as 
buffer and propionic anhydride. Synthetic H3K4 peptides (TKQTAR), non- and methylated forms, were 
derivatized using this protocol and analyzed by direct infusion mass spectrometry. Incomplete reaction 
and methyl-esterification (side reaction) were observed, therefore quantification of histone PTMs is not 
reliable. For that reason, one of the aims of this investigation was to develop an accurate derivatization 
methodology. Several solvents (like ethanol, 1-PrOH, 2-PrOH) and a different buffer, (like triethylamine, 
TEA), were tested. Accurate quantification of derivatized peptides was obtained with TEA, 2-propanol 
and PAA, with more than 95% of complete conversion and less than 2% of methyl-esterification for 
H3K4 synthetic peptides.  
Once the new method was defined, propionylated peptides were analyzed by LC-MS/MS. Two different 
packed-material of C18 columns were tested, and the best result was obtained with an end-capped 
silica based C18 column. Its high hydrophobicity enhanced the retention of the most hydrophilic 
peptides (H3K4me2 and H3K4me3). Moreover, this improvement allowed the determination of the dynamic 
range, which reached 5 orders of magnitude. 
As soon as the new protocol for derivatization of histone proteins and the optimal C18 packed-material 
were determined, a standard of histone protein from Calf thymus was derivatized and analyzed by LC-
MS/MS. The purpose of this experiment was to verify the yield of histone protein derivatization. 
Surprisingly, another side reaction (that did not affect H3K4 peptides) was identified, which corresponds 
to O-propionylation of S, T, and Y. A recent publication indicated the presence of this undesired 
reaction, and the authors recommended to use Ambic, 2-PrOH and PAA to reduce this side reaction. 
Therefore, this reported protocol (Ambic, 2-PrOH and PAA, here named as Paternoster protocol) was 
compared with the protocol here developed (TEA, 2-PrOH and PAA, here named as Gallardo protocol). 
In order to achieve this comparison, histone protein standard from Calf Thymus was derivatized using 
both protocol, Paternoster and Gallardo. Interestingly no significant variations were detected among 
both protocols, abundances of O-propionylated S, T and/or Y were low and similar when Paternoster 
and Gallardo protocols were used. The disadvantage of Paternoster protocols is the incomplete reaction 
of H3K4, which reached about 10%, while with Gallardo protocol it reached less than 2%.  
It is very important to identify side reactions when quantitative data is required, because it can be miss-
interpreted as a natural histone PTM. For example, over-propionylated H3K9me2K14pr has the same 
mass that H3K9prme1K14prme1 (m/z 549.31, 2+), therefore it was required to inspect manually each 
fragmentation spectra and verify the correct assignment of histone PTMs. Additionally, the contribution 
of O-propionylated S, T and/or Y did not affect the relative quantification of histone PTMs because their 
contributions were included in the final result. Finally, it is possible to conclude that Gallardo protocol is 
more accurate than Paternoster protocol, because loss of 10% (approx.) of abundances of the most 
hydrophilic peptides (H3K4), which are very important in transcriptional processes, were detected in 
Paternoster protocol. Besides, the total peak area of each detected tryptic H3 peptide from Calf thymus 
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demonstrated that Gallardo protocol was more accurate because no losses were found (when it was 
compared with Paternoster protocol). 
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3.2. Analysis of modified histone H3 from Saccharomyces cerevisiae (S.cerevisiae) by 
mass spectrometry. 
3.2.1. Identification of methylated and acetylated lysine residues by LC-MS/MS 
S. cerevisiae is a useful model system to study changes in the chromatin structure. This yeast has small 
number of genes compared to more complex eukaryotic cells like humans. Moreover, S.cerevisiae has 
a short cell cycle, and its genes are homologs to human genes. This last characteristic (homology of 
genes) allowed to researchers to get an approximation to human cells. Additionally, yeast genome 
presents histone and non-histone proteins that are conserved with its respective proteins in human 
cells. Together these advantages of S.cerevisiae have allowed to researchers to get a vast knowledge 
of chromatin structure and functions. 
Regarding advantages of S.cerevisiae and the intention to get a wide knowledge of the biological 
function of different chromatin states, several authors have been working with this model system 
(S.cerevisiae), besides mammalian cells. Indeed, according to Kouzarides several histone PTMs that 
play a crucial role in the regulation of transcriptional processes, like acetylation and methylation of 
H3K4, H3K9, H3K27, H3K36, H3K79, and H4K20 (Kouzarides 2007). Acetylation of lysine can produce 
changes in the chromatin structure producing an open or close chromatin structure, permitting that RNA 
Pol II and transcriptional factor can access to DNA. Methylation of lysine can recruit non-histone 
proteins (known also as readers) that are involved in transcriptional processes (Kouzarides 2007). 
These non-histone proteins can either recruit additional protein complex that can modulate chromatin, 
or can recruit transcriptional factors for transcriptional process (Kouzarides 2007). Therefore, there is a 
considerable interest in the scientific community to study and to understand the effect of histone 
modification state in genetic activities like regulation of gene expression in eukaryotic cells. 
This section will be focused mainly on H3K4 methylation because this histone modification is entirely 
associated with transcriptionally active chromatin (Shilatifard 2008). Regarding chapter 1 (Introduction), 
methylation of lysine residues occurs by transferring methyl group from a donor S-adenosyl-L-
methionine (SAM or AdoMet) and mediated by histone methyl transferases (HMTs). Lysine HMTs 
contain a conserved domain known as SET, which assembles to Set1C complex for maximal catalytic 
and biological activity. Set1C complex comprises eight subunits including Set1, the histone methyl 
transferase. Among Set1C or COMPASS members, Sdc1 and Bre2 form a heterodimer, which 
associates with Set1 to methylate H3K4. Methylation levels of this peptide (mono-, di-, and/or tri-
methylation of H3K4) correlate with an open or close chromatin structure. These methyl groups are 
histone marks that can be recognized by non-histone proteins involved in transcription or repression 
process (Roguev 2003; Dehé et al. 2005; Halbach et al. 2009; Wang et al. 2009; South et al. 2010; 
Tuukkanen et al. 2010; Workman and Abmayr 2014). 
Considering the importance of the association of Set1 with the heterodimer Sdc1-Bre2 for methylation 
of H3K4, it is desired to analyze the effect of several mutations at specific sites or deletion of Sdc1 
subunit on methylation levels of H3K4 by LC-MS/MS. It is expected that methylation levels of H3K4 
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decrease when Sdc1 is deleted or mutated, because it might not interact with Bre2 and Sdc1, impeding 
the formation of a heterodimer. 
Histone H3 was purified by C4 HPLC column, and two biological replicates of this protein were 
subjected to chemical derivatization, trypsin digestion and analyzed by LC-MS/MS. The set of samples 
were kindly provided by Prof. Dr. Francis Stewart from Biotechnology Center (BIOTEC) of the TU 
Dresden, and comprised wild type (WT), and three different mutations of Sdc1 protein: sdc1∆, which is 
the deletion of Sdc1 subunit; sdc1*, which is the substitution of amino acids V129A, L133A, L134A. The 
amino acids V129, L133, L134 substituted may be involved in the interaction with Bre2; finally, DPY30∆, 
which is the deletion of the DPY30 motif of the still active Sdc1 protein.  
To identify methylated and acetylated lysine residues of histone H3 in S.cerevisiae by LC-MS/MS, an 
accurate method was required. The chemical derivatization method described previously (section 3.1) 
together with bottom-up MS approach were applied to obtain H3K4 methylation pattern. Fractions from 
C4 HPLC separations containing histone H3 were subjected to chemical derivatization, followed by in-
gel digestion and analyzed by LC-MS/MS (as described in Chapter 2).  
Considering that methylation and acetylation of lysine at different positions have shown to play different 
roles in chromatin structure modulation, and taking advantage of mass spectrometry sensitivity and 
efficiency, the rest of H3-tail was also analyzed to identify the histone H3 PTM pattern. 
Chemical derivatization combined with LC-MS/MS provided excellent sensitivity and sequence 
coverage (Table 3.2.1). More than 60% sequence coverage resulted from the initial analysis of H3, 
which included about 25 modified peptides (Table 3.2.1 and Suppl. Tables 5.2.1 to 5.2.3). A data 
dependent analysis was applied (as described in Chapter 2) to identify and to quantify histone 
methylation and acetylation. To assess analytical reproducibility, three analytical and two biological 
replicates were analyzed with standard error up to 8%. Additionally, fragmentation spectra (MS/MS) 
were inspected manually (Figure 3.13) to verify the database (Mascot) assignments. 
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Figure 3.13. Manual Identification of fragmentation spectra of H3K4me3. HCD-MS/MS spectrum of 
trimethylated H3K4 peptide. Fragments are indicated in red (“y” ions) and blue (“b” ions) color. Additionally, water 
loss of precursor ion and methyl losses are indicated. 
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Table 3.3. List of tryptic peptides of purified histone H3 from wild type of S.cerevisiae. Listed are detected tryptic peptides of H3 by LC-MS/MS. H3 was propionylated 
before and after enzymatic digestion, therefore each listed peptide is propionylated at the N-termini as well. Besides, charges of detected tryptic peptides, observed and predicted 
masses, and delta (in ppm) or mass difference between observed and predicted masses are listed. In addition, detected modifications of K, S, T &/or Y, and mascot scores for 
MS/MS fragmentation spectra are listed.  
 
 
 
  
Peptide sequence  
(N-propionylated already) 
Charge Observed m/z Predicted m/z 
Delta 
(ppm) 
Modification 
Mascot 
score 
TKQTAR 2+, 1+ 408.7333, 815.4520 815.4501 2 Propionyl (K4) 32 
TKQTAR 2+, 1+ 415.7410, 829.4674 829.4658 2 Propionyl-methyl (K4) 29 
TKQTAR 2+ 394.7354 787.4552 2 Dimethyl (K4) 31 
TKQTAR 2+ 401.7426 801.4708 0 Trimethyl (K4) 26 
KSTGGKAPR 2+ 528.2959 1054.5771 0 Acetyl (K9 or K14), Propionyl (K9 or K14) 48 
KSTGGKAPR 2+ 535.3040 1068.5927 1 2 Propionyl (K9 & K14) 41 
KSTGGKAPR 2+ 549.3022 1096.5876 2 2 Acetyl (K9 & K14), Propionyl S10  21 
KQLASKAAR 2+ 556.8252 1111.6349 1 2 Acetyl (K18 & K23) 41 
KQLASKAAR 2+ 563.8312 1125.6506 -2 Acetyl (K18 or K23), Propionyl (K18 or K23) 65 
KQLASKAAR 2+ 570.8399 1139.6662 -1 2 Propionyl (K18 & K23) 54 
KSAPSTGGVKKPHR 3+ 553.9896 1658.9468 0 Trimethyl (K27 or K36 or K37), 2 Propionyl (K27 or K36 or K37) 20 
KSAPSTGGVKKPHR 2+ 858.4772 1714.9370 1 Acetyl (K27 or K36 or K37), 3 Propionyl (K27 or K36 or K37, & S28) 23 
KSAPSTGGVKKPHR 3+, 2+ 558.6505, 837.4725 1672.9260 3 3 Propionyl (K27, K36 & K37) 63 
KSAPSTGGVKKPHR 2+ 844.4767 1686.9417 -2 Propionyl-methyl (K27 or K36 or K37), 2 Propionyl (K27 or K36 or K37) 62 
KSAPSTGGVKKPHR 2+ 823.4742 1644.9311 2 Dimethyl (K27 or K36 or K37), 2 Propionyl (K27 or K36 or K37) 33 
KSAPSTGGVKKPHR 3+ 567.9912 1700.9574 -3 2 Propionyl-methyl (K27 or K36 or K37), Propionyl (K27 or K36 or K37) 18 
YKPGTVALR 2+ 586.8367 1171.6588 -1 2 Propionyl (K42 & Y41) 52 
RFQKSTELLIR 3+, 2+ 496.9557, 744.9321 1487.8460 0 Acetyl (K56) 38 
RFQKSTELLIR 3+, 2+ 501.6275, 751. 9395 1501.8616 2 Propionyl (K56) 42 
FQKSTELLIR 2+ 666.8798 1331.7449 0 Acetyl (K56) 38 
FQKSTELLIR 2+ 673.8886 1345.7605 2 Propionyl (K56) 31 
KLPFQR 2+ 450.7697 899.5229 2 Propionyl (K64) 23 
EIAQDFKTDLR 2+ 710.3781 1418.7405 1 Dimethyl (K79) 46 
EIAQDFKTDLR 2+ 724.3759 1446.7354 1 Propionyl (K79) 60 
EIAQDFKTDLR 2+ 731.3842 1460.7511 2 Propionyl-methyl (K79) 65 
VTIQKKDIKLAR 2+ 819.0033 1635.9923 0 3 Propionyl (K121, K122 & K125) 66 
 
 
85 
3.2.2. Relative quantification of methylated and acetylated lysine residues by LC-MS/MS 
In this section, relative quantification of identified methylated and acetylated lysine residues of H3 in 
S.cerevisiae is desired. To achieve this aim, label free relative quantification was performed by 
calculating the peak areas (extracted ion chromatogram, XIC) of the same peptide in all detected and 
modified forms (e.g. mono, di or trimethylated and acetylated or/and propionylated forms). Afterward, 
the sum of all areas is 100% and the relative quantity of each peptide can be calculated dividing its area 
by the total area (see an example on Figure 3.14).  
 
 
Figure 3.14. Example of relative quantification by LC-MS/MS. On the left side the base peak chromatograms 
are shown corresponding to different lysine modifications (propionyl, pr; monomethyl, me1-pr; dimethyl, me2; 
trimethyl, me3) of the same peptide H3K4 (TKQTAR) detected by LC-MS/MS. The extracted ion chromatograms 
(XIC) of each detected peptide are shown as “XIC H3K4x” (where x is K modification). Then, the total XIC for H3K4 
peptide is the sum of all detected modified H3K4 peptides (5.0x107). Finally, the relative abundance is calculated 
dividing the individual XIC by the total XIC for H3K4 peptide. 
 
 
Additionally, as explained in section 3.1.3b, O-propionylation of serine, tyrosine and/or threonine occur. 
This side reaction is because the hydroxyl groups of S, Y and T can also act as nucleophiles, interacting 
with propyl propionate. However, OH- are weaker nucleophiles than α- and ε- amino groups, and 
therefore O-propionylation of S, T and Y is only achieved partially (about 15% of abundance) (Figure 
3.15). However, as also explained in section 3.1.3b, this side reaction did not affect quantification of 
methylated or acetylated peptides, because the abundances of peptides containing O-propionylated S 
or T or Y were included during quantification of methylated and acetylated peptides. For example: if a 
diacetylated H3K9-K14 (KacSTGGKacAPR) peptide was identified in any sample, also the same peptide 
containing an O-propionylated S or T (KacSprTGGKacAPR or KacSTprGGKacAPR) was examined. If 
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indeed the sample contained both peptides (peptide with and without side reaction), then the 
abundances of both were added up and reported as a single value. 
 
 
 
Figure 3.15. Mechanisms of reaction of T O-propionylation (side reaction) using propionic anhydride in 
isopropanol with triethylamine as buffer. Mechanism of reaction of propionic anhydride and isopropanol to form 
2-propyl propanoate (propionylation reagent) (Figure a). Mechanism of reaction of propionylation reagent with 
hydroxyl groups of T side chain, side reaction (Figure b).  
 
 
a. Relative quantification of H3K4 peptides. 
Relative quantification of H3K4 methylation levels by LC-MS/MS are shown in Figure 3.16. The 
abundances of H3K4me2 and H3K4me3 in sdc1∆, sdc1* and DPY30∆ strain decreased when compared 
to wild type, from 20% (WT) to less than 1% (in mutants), approximately. It is an expected result which 
confirms that Bre2 and Sdc1 interaction were highly affected in all three mutations, and therefore the 
heterodimer Bre2-Sdc1 could not associate with Set1 to di- and tri-methylate H3K4. South and co-
workers reported a conserved (in yeast and human) protein-protein interaction domain between the C 
terminus of Bre2 and Dpy 30 domain of Sdc1, known as SDI (Sdc1 Dpy30 Interaction). They indicated 
that the heterodimer Sdc1-Bre2 associates with Set1 to methylate H3K4 activating transcription, and 
specific alterations of the region SDI result in disruption of Sdc1-Bre2 interaction. As a consequence of 
this disruption association with Set1 is prevented and methylation of H3K4 decreases (South et al. 
2010). 
Monomethylated H3K4 levels were not affected dramatically in sdc1∆, sdc1* and DPY30∆ strain 
compared to wild type, which might indicate that another subunit is involved to monomethylate H3K4. 
Mueller and co-workers reported multiple deletions of subunits from COMPASS or Set1C complex. 
They sought to better understand the function of each subunit, concluding that to mono- and di-
methylate H3K4 is required either Bre2 and Spp1 or Spp1 and Sdc1 to associate with Set1 (Mueller 
-O 
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2006). Then, since Bre2 was no deleted or mutated, it can be assumed that Spp1 and Bre2 together 
with Set1 were involved in H3K4 monomethylation in S.cerevisiae. 
Summarizing, Sdc1 deletion, amino acids substitution and motif deletion disrupted the interaction 
between Bre2 and Sdc1. Therefore, this heterodimer was impeded to associates properly with Set1 
affecting H3K4 di- and tri-methylation levels. Moreover, H3K4 monomethylation levels were not 
dramatically affected by Sdc1 mutation, which indicated that another subunit was involved. Therefore, 
it can be assumed that Spp1 and Bre2 were able to maintain constant H3K4me1 levels.  
 
 
Figure 3.16. Relative abundances of methylated and non-methylated H3K4 peptide. Relative quantification of 
methylated H3K4 (TKQTAR) between wild type, sdc1∆, sdc1* and DPY30∆ strains. Error bars represent the 
standard deviation from 2 biological replicates (<10%). 
 
 
b. Relative quantification of methylated and acetylated H3 K9K14, K18K23 and K27K36  
Regarding Chapter 1 (Introduction), methylation of lysine residues 9, 27 and 36 is catalyzed by SET 
domain-containing enzymes (Shilatifard, 2006). To name few Histone Methyl Transferases (HMTs), 
SUV39H1/H2 trimethylate H3K9, EHMT1/GLP and G9a mono- and di-methylate H3K9, Set2 methylates 
H3K36, EZH1/2 methylate H3K27 (Zhang et al. 2012).  
In this section, it is desired to analyze whether Sdc1 mutation or deletion produce an effect over lysine 
methylation and acetylation levels of H3K9, H3K27 and H3K36. It is expected that Sdc1 mutations do 
not produce any effect on H3K9, H3K27 and H3K36 methylation levels. Because, as shown above, the 
enzymes that methylate these lysine residues are different from Set1. Therefore, it is expected that 
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abundances of histone modifications of H3K9, H3K27 and H3K36 in wild type and sdc1∆, sdc1* and 
DPY30∆ strain do not vary significantly. Since it is expected that histone PTM levels in sdc1∆, sdc1* 
and DPY30∆ strains do not differ from wild type, it is also expected to observe acetylated lysine residues 
mostly. Because in “normal condition” as wild type is, transcriptionally active chromatin (euchromatin) 
should be the more abundant structure. Regarding Chapter 1 (Introduction), lysine acetylation is a 
known histone mark for euchromatin. 
In Figures 3.17, 3.18 and 3.19 the relative abundances of methylated and acetylated H3K9K14, 
H2K18K23 and H3K27K36 are shown, respectively in wild type, sdc1∆, sdc1* and DPY30∆ strain. As 
expected, no significant changes were observed between the four samples. Additionally, H3K9K14 and 
H3K18K23, with the amino acid sequences K9STGGK14APR and K18QLASK23AAR respectively, were 
detected in acetylated (mono- and di-acetylated lysine) and non-acetylated forms only in wild type and 
Sdc1 mutations. Mono- and di-acetylated H3K9K14 and H3K18K23 had abundances less than 14% 
(Figure 3.17 & Figure 3.18) in wild type and also in Sdc1 mutation. Moreover, H3K27K36, with the 
amino acid sequence K27SAPSTGGVK36K37PHR, was identified as methylated forms mostly. The most 
predominant histone modification was trimethylated H3K27K36, with 30% of abundance (Figure 3.19). 
The abundance of trimethylated H3K27K36 could be comprised by the isomers H3K27me3, H3K36me3, 
H3K27me2K36me1, H3K27me1K36me2. H3K37 is also a suitable site for histone PTMs, however, it is not 
expected to find this residue modified, because most reports are related to histone modifications on 
H3K27 and H3K36 (Latham and Dent 2007; Yuan et al. 2011; Cuomo et al. 2011; LeRoy et al. 2013; 
Soldi et al. 2013; Ferrari et al. 2014; Huang et al. 2015). Low resolution fragmentation spectra (IT-
MS/MS) of trimethylated H3K27K36 showed the presence of both, H3K27me3 and H3K36me3, however, 
the real contribution of each isomer was not determined in this part of the thesis. Nevertheless, no 
significant changes between mutations of Sdc1 and wild type were observed. 
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Figure 3.17. Relative quantification of acetylated H3K9K14 (K9STGGK14APR) in S.cerevisiae. The graph 
shows the relative quantification of: diacetylated H3K9K14 (K9ac-K14ac), monoacetylated H3K9K14 (K9ac and 
K14ac) and unmodified H3K9K14 (K9pr-K14pr) in wild type, sdc1∆, sdc1* and DPY30∆ strain. Monoacetylated 
peptide is represented as a single peptide but the acetyl group was identified in both residues (K9 and K14), then 
the abundance for this isomer represents both peptides KacSTGGKAPR and KSTGGKacAPR. Quantification was 
achieved by normalizing to 100% of all identified peptides (Figure 3.14). Error bars correspond to the standard 
deviation of two biological replicates (n=2). 
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Figure 3.18. Relative quantification of acetylated H3K18K23 (K18QLASK23AAR) in S.cerevisiae. The graph 
shows the relative quantification of: diacetylated H3K18K23 (K18ac-23ac), monoacetylated H3K28-K23 (K18ac and 
K23ac) and unmodified H3K18-K23 (K18pr-K23pr) in wild type, sdc1∆, sdc1* and DPY30∆ strain. Monoacetylated 
peptide is represented as a single peptide, the acetyl group was identified in both residues (K18 and K23), then 
the abundance for this particular peptide represents both isomers, KacQLASKAAR and KQLASKacAAR. 
Quantification was achieved by normalizing to 100% all identified peptides (Figure 3.14). Error bars correspond to 
the standard deviation of two biological replicates (n=2). 
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Figure 3.19. Relative quantification of methylated and acetylated H3K27K36 (K27SAPSTGGVK36K37PHR) 
in S.cerevisiae. The graph shows the relative quantification of doubly monomethylated H3K27K36 
(K27me1K36me1), monomethylated H3K27K36 (K27me1 and K36me1), dimethylated H3K27K36 (K27me2 and K36me2), 
unmodified H3K27K36 (K27prK36pr), trimethylated H3K27K36 (K27me3 and K36me3) and monoacetylated H3K27K36 
(K27ac and K36ac) in wild type, sdc1∆, sdc1* and DPY30∆ strain. All modifications (monomethyl, dimethyl, acetyl 
and trimethyl) were identified in both residues K27 and K36. Then, the abundances represent the contribution of 
both possible isomers (e.g. Kme2SAPSTGGVKKPHR & KSAPSTGGVKme2KPHR). Quantification was achieved by 
normalizing to 100% all identified peptides (Figure 3.14). Error bars correspond to the standard deviation of two 
biological replicates (n=2). 
 
 
As expected histone PTM pattern of Sdc1 were similar to wild type histone PTM pattern. 
Transcriptionally active histone marks like H3K9K14 and H3K18K23 acetylation were identified, as well 
as H3K36me3, with similar abundances. Zhang and co-workers review described histone PTMs 
associated with transcriptional activation or repression of genes, like H3K4me2, H3K36me3 or H3K27me3, 
H3K9me3 (Zhang et al. 2015). They described that transcriptionally active chromatin is characterized by 
(among others histone PTMs) acetylation of histone H3 and H4, because acetylated lysine residues are 
recognized by the motif bromodomain, which is found to be in several proteins that are related to 
transcription (Zhang et al. 2015). Moreover, histone acetylation produces changes in the chromatin 
structure by neutralizing the charges of lysine residues, this neutralization causes disruptions between 
DNA and nucleosomes, leading to an open structure and permitting transcriptional factors interact with 
genes (Bannister and Kouzarides 2011; Zhang et al. 2015). Mono-, di- and tri-methylation of H3K36 are 
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catalyzed by Set2, and the different modification states have different biological functions. For example, 
H3K36me3 is also a known histone mark related to transcription (Strahl et al. 2002).  
In normal conditions or wild type, H3K4 trimethylation binds with the tudor domain that a non-histone 
proteins or readers possesses. These readers have been found to be a member of histone 
acetyltransferases (HATs) complexes. For example, the non-histone protein SGF29 is a member of 
SAGA histone acetyltransferase complex, the tudor domain of this non-histone protein binds to H3K4 
trimethylation. Then lysine residues (like H3K9) are acetylated (Figure 3.20) (Bian et al. 2011). Similar 
to H3K4 trimethylation, H3K36 trimethylation is recognized by the bromodomain of EAF3 complex (non-
histone proteins), which recruits the histone deacetylase (HDAC) complex RPD3S, to prevent initiation 
of transcription during elongation of transcription (Figure 3.20).  
No changes in histone acetylated and methylated H3 K9, K27 and K36 patterns were observed in wild 
type and Sdc1 mutations. It was an expected result, however, the hypothesis was wrong. It was 
hypothesized that methylation levels of H3 K9, K27 and K36 are not affected by mutations on the Set1C 
member Sdc1, because different enzymes (that do not interact with Set1C complex) methylate H3 K9, 
K27 and K36. After analysis of results and literature revision, it can be assumed that Sdc1 mutation 
could affect methylation and acetylation levels in other lysine residues, but cells could have an 
alternative mechanism to compensate this fail (Set1C does not methylate properly H3K4). Either the 
low levels (<1%) of H3K4me3 are sufficient to recruits non-histone proteins of HAT complexes or another 
histone PTM is also involved in recruitment of HAT. 
 
Summarizing, no significant changes were observed in the histone PTM pattern of H3K9K14, 
H3K18K23 and H3K27K36, as expected. Wild type and Sdc1 mutations presented similar abundances 
of mono- and di-acetylated H3K9K14 and H3K18K23, while H3K36 presented similar abundances of 
transcriptionally active histone marks like H3K36me2/3. However, considering literature revision, 
trimethylation of H3K4 (mediated by COMPASS) should affects methylated and/or acetylated lysine 
residues levels, therefore it can be assumed that an alternative mechanism is involved. Either the low 
levels (<1%) of H3K4me3 are sufficient to recruits non-histone proteins of HAT complexes or another 
histone PTM is also involved in recruitment of HAT. To verify these putative hypotheses more 
experiments are required. 
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Figure 3.20. Interactions between H3K4 trimethylation, H3K36 trimethylation and histone acetylation. The 
figure shows the interaction of H3K4me3, H3K36me3 and histone acetylation during transcription in normal conditions 
or wild type. Tudor domain of a HAT-member complex binds to H3K4me3 to further acetylate lysine residues, like 
H3K9 or H3K27. Moreover, during transcription Set2 binds to RNA pol ll to catalyze H3K36me3, this histone PTM 
associates with HDAC to prevent initiation during elongation of transcription. At the same time, writers like 
NSD1/2/3 catalyze H3K36 mono- and di-methylation during elongation. Figure taken from (Zhang et al. 2015) 
 
 
c. Relative quantification H3K79 methylation 
Regarding Chapter 1 (Introduction), methylation of H3K79 is mediated by a non-SET domain-containing 
enzyme known as Dot1 (Singer et al. 1998). Similar to methylated and acetylated H3 K9, K27 and K36, 
it is desired to identify whether Sdc1 mutations produce any effect on H3K79 methylation levels. 
Although there was a report indicating that Paf1 complex is required for H3K79 methylation by Dot1 
and also for H3K4 methylation by Set1C (Krogan et al. 2003), it is no expected to identify significant 
changes in H3K79 methylation levels. Because thus far, an interaction between the Set1C member 
Sdc1 and Dot1 has not been reported.  
Relative quantification of H3K79 methylation was also analyzed by LC-MS/MS. Interesting differences 
were observed between wild type and mutated Sdc1 strains, as shown in Figure 3.21. Trimethylation 
H3K79 was the most predominant histone PTM identified in the three Sdc1 strains (sdc1∆, sdc1* and 
DPY30∆), while in wild type it was not identified. Moreover, abundances of un- and mono-methylated 
H3K79 decreased below 6 and 4%, respectively. Additionally, dimethylated H3K79 in sdc1∆, sdc1* and 
DPY30∆ strain decreased 3-fold compared to wild type, from 79% to 25% approx. Krogan and co-
workers reported interactions between H2B (H2BK123), H3 (H3K4 and H3K79) and Paf1 complex 
(Krogan et al. 2003). They also reported that Paf1 members are required to ubiquitinate H2BK123, 
which recruits COMPASS complex (or Set1C) to further methylate H3K4. A similar situation occurs with 
methylation of H3K79, Dot1 the enzyme that mediates methylation of H3K79 requires ubiquitinated 
H2BK123 (Krogan et al. 2003). Therefore, it can be assumed that elevated levels of H3K79me3 in 
mutated Sdc1 strains is because ubiquitinated H2BK123 (H2BK123ub) is not interacting with COMPASS 
in sdc1∆, sdc1* and DPY30∆, instead H2BK123ub is available to interact with Dot1 and trimethylate 
H3K79. This hypothesis is summarized in Figure 3.22. 
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Figure 3.21. Relative quantification of methylated H3K79 peptide (EIAQDFKTDLR) from S.cerevisiae. In this 
graph the relative abundance of non-, mono-, di- and tri-methylated H3K79 is shown in wild type, sdc1∆, sdc1* and 
DPY30∆ strain. No acetylated form was identified neither side reaction (O-propionylation of T). Quantification was 
achieved by normalizing to 100% all identified peptides, as before explained in Figure 3.14. Error bars correspond 
to the standard deviation of two biological replicates (n=2). 
 
 
 
95 
 
Figure 3.22. Summary of interaction between H2B123ub and Dot1 and Set1C (or COMPASS) wild type and 
mutation in S.cerevisiae. The figure summarizes the hypothesis that: Dot1 does not trimethylated H3K79 in wild 
type, because H2BK123 ubiquitination is recruiting COMPASS to di- and tri-methylate H3K4 (Figure A). While in 
mutations of Sdc1, H2BK123ub is available to recruit Dot1 and trimethylated H3K79, because COMPASS complex 
is not well assembled to di- and tri- methylate H3K4. Set1 cannot associate the heterodimer Sdc1-Bre2 because 
the interaction in the heterodimer is disrupted (Figure B). 
 
 
Summarizing, reduced levels of H3K4me2/3 affect methylation of H3K79. Considering the results 
obtained during this thesis and literature revision, it was assumed that elevated levels of H3K79me3 in 
mutated Sdc1 strains was because ubiquitinated H2BK123 (H2BK123ub) is not interacting with 
COMPASS in sdc1∆, sdc1* and DPY30∆, instead H2BK123ub is available to interact with Dot1 and 
trimethylate H3K79.  
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3.3. Quantification of histone post-translational modifications in mouse embryonic 
stem cells (mESCs) 
3.3.1. Identification of methylated and acetylated lysine residues by LC-MS/MS 
Mouse embryonic stem cells (mESCs) are good model system to study early mammalian development 
due to the ability to differentiate in distinct lineages (pluripotency) and self-renewal (Young 2011; Song 
et al. 2012). To maintain mESC undifferentiated, cells need to be grown in specific environments. Martin 
grew mESCs in a medium supplemented with fetal calf serum (serum-containing media) to maintain 
undifferentiated cells with continue proliferation (Martin 1981). Ying and co-workers reported that 
cultures of mESCs in serum-containing media presented some perturbations, like fluctuation in 
pluripotency factor levels and spontaneous differentiation (Ying et al. 2008). Considering this fact, they 
also reported that mESCs can grow and maintain cells undifferentiated replacing fetal calf serum by 
two inhibitors (2i-containing media), mitogen-activated protein kinase (MeK) and glycogen synthase 
kinase-3 (Gsk3) (Ying et al. 2008). Transcriptomic and epigenomic studies on cells grown in 2i-
containing media revealed some hallmarks of pluripotency, like DNA hyphomethylation, absence of 
bivalent chromatin, differentiation genes were silenced and pluripotency genes were expressed (Marks 
et al. 2012). Although all reports gave interesting insights, it is desired to obtain the histone PTM profiles 
for mESCs grown in serum- and in 2i- containing media. The information at the PTM level could 
contribute to identify pluripotency-associated PTMs, which can be useful to better understand the 
complex mechanisms to maintain pluripotency. 
From now cells grown in serum- and in 2i- containing media will be referred to “serum” and “2i” samples, 
respectively. As several authors reported (Bernstein et al. 2005; Pokholok et al. 2005; Bannister and 
Kouzarides 2011), methylation of H3K4, H3K36 and H3K79 are associated with open chromatin 
structures and therefore with active gene expression. On the other hand, methylation of H3K9, H3K27 
and H4K20 are related to condensed chromatin and therefore involved in gene silencing (Nakayama 
2001; Rice and Allis 2001; Lee et al. 2005; Evertts et al. 2013). Considering the functional impact of 
these modifications on transcription, it is probable that histone methylation participates in the regulation 
of pluripotent states. Particularly, it is probable that this histone modification (methylation of lysine) 
modulates the expression of pluripotency factors (Wang et al. 2014). 
Regarding the above reports, it is expected that histone PTM profiles (H3, specifically) for 2i samples 
show histone marks for open chromatin structure like acetylated H3K18 or H3K23. It is also expected 
to identify in 2i sample low abundances of histone marks for condensed chromatin structure, like 
trimethylated H3K9 and H3K27. Some authors (Ying et al. 2008; Marks et al. 2012) reported that 
mESCs grown in serum-containing media presented some perturbations. Thus, it is expected to identify 
histone marks for condensed chromatin in serum sample and with higher abundances than 2i sample.  
To obtain the histone PTM profiles of mESCs grown in both conditions (serum- and 2i-containing 
media), core histone proteins (H2A, H2B, H3 and H4) from two biological replicates were acid extracted, 
derivatized with propionic anhydride (as described in section 3.1) and digested with trypsin to further 
quantify by LC-MS/MS (three analytical replicates). Concerning lysine acetylation, methylation and 
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propionylation (this last one an artificial modification), about 70 modified peptides from canonical H3, 
H4, H2A, H2B and histone variants were identified in a single LC-MS/MS experiment in both samples 
(2i and serum). Table 3.4 shows all detected H3 peptides in both 2i and serum samples. Further, Suppl. 
Table 5.3.1 shows the identified peptides in H4, H2A, H2B and histone variants in both 2i and serum 
sample.  
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Table 3.4. List of tryptic peptides of histone H3 identified in mESCs. Listed are detected tryptic peptides of H3 by LC-MS/MS. H3 was propionylated before and after 
enzymatic digestion, therefore each listed peptide is propionylated at the N-termini as well. Besides, charges of detected tryptic peptides, observed and predicted masses, and 
delta (in ppm) or mass difference between observed and predicted masses are listed. In addition, detected modifications of K and mascot scores for MS/MS fragmentation 
spectra are listed.
Peptide sequence (N-propionylated) Charge Observed m/z 
Predicted 
m/z 
Delta 
(ppm) 
Modification 
Mascot 
score 
TKQTAR 2+, 1+ 408.7325, 815.4504 815.4501 0 Propionyl (K4) 43 
TKQTAR 2+, 1+ 415.7404, 829.4662 829.4658 0 Propionyl-methyl (K4) 35 
TKQTAR 2+ 394.7350 787.4552 1 Dimethyl (K4) 24 
TKQTAR 2+ 401.7424 801.4708 2 Trimethyl (K4) 15 
KSTGGKAPR 2+ 535.3036 1068.5927 0 Acetyl (K14), Propionyl-methyl (K9) 48 
KSTGGKAPR 2+ 521.3051 1040,5978 -1 Acetyl (K14), Trimethyl (K9) 33 
KSTGGKAPR 2+ 521.3058 1040,5978 0 Propionyl (K14), Dimethyl (K9) 35 
KSTGGKAPR 2+ 535.3033 1068.5927 0 2 Propionyl (K9 & K14) 59 
KSTGGKAPR 2+ 528.2938 1054.5771 0 Propionyl (K9), Acetyl (K14) 63 
KSTGGKAPR 2+ 542.3113 1082.6084 1 Propionyl-methyl (K9), Propionyl (K14) 54 
KSTGGKAPR 2+ 514.2977 1026,5822 -1 Acetyl (K14), Dimethyl (K9) 41 
KSTGGKAPR 2+ 521.2877 1040.5614 -1 2 Acetyl (K9 & K14)  51 
KQLATKAAR 2+ 563.8310 1125.6506 0 2 Acetyl (K18 & K23) 72 
KQLATKAAR 2+ 570.8397 1139.6662 -1 Acetyl & Propionyl (K18 or K23) 63 
KQLATKAAR 2+ 577.8469 1153.6819 1 2 Propionyl (K18 & K23) 68 
KSAPATGGVKKPHR 3+ 548.6567 1642.9519 1 Trimethyl (K27), 2Propionyl (K36 & K37) 65 
KSAPATGGVKKPHR 3+, 2+ 553.3163, 829.4709 1656.9311 0 3Propionyl (K27, K36 & K37) 62 
KSAPATGGVKKPHR 3+, 2+ 557.9888, 836.4781 1670.9468 0 Propionyl-methyl (K27), 2Propionyl (K36 & K37) 61 
KSAPATGGVKKPHR 3+, 2+ 557.9888, 836.4781 1670.9468 0 Propionyl-methyl (K36), 2Propionyl (K27 & K37) 51 
KSAPATGGVKKPHR 3+ 548.6567 1642.9519 0 Propionyl-methyl (K27), Dimethyl (K36), Propionyl (K37) 34 
KSAPATGGVKKPHR 3+ 548.6567 1642.9519 0 Propionyl-methyl (K36), Dimethyl (K27), Propionyl (K37) 40 
KSAPATGGVKKPHR 3+ 539.3121 1614.9205 1 Acetyl (K27), Dimethyl (K36), Propionyl (K37) 21 
KSAPATGGVKKPHR 3+ 534.6540 1600.9413 1 2Dimethyl (K27 & K36), Propionyl (K37) 48 
KSAPATGGVKKPHR 3+ 543.9847 1628.9362 1 Dimethyl (K36), 2Propionyl (K27 & K37) 62 
KSAPATGGVKKPHR 3+ 543.9847 1628.9362 1 Dimethyl (K27), 2Propionyl (K36 & K37) 52 
KSAPATGGVKKPHR 3+, 2+ 562.6618, 843.4916 1684.9624 0 2Propionyl-methyl (K27 & K36), Propionyl (K37) 27 
YRPGTVALR 2+ 572,8268 1143.6400 0 2 Propionyl (K42 & Y41) 36 
RFQKSTELLIR 2+ 759.9359 1517.8565 0 Propionyl (K56) 49 
YQKSTELLIR 2+ 681.8856 1361.7554 1 Propionyl (K56) 57 
KLPFQR 2+ 450.7682 899.5229 1 Propionyl (K64) 32 
EIAQDFKTDLR 2+ 710.3776 1418,7408 0 Dimethyl (K79) 38 
EIAQDFKTDLR 2+ 724.3753 1446.7354 1 Propionyl (K79) 71 
EIAQDFKTDLR 2+ 731.3829 1460.7514 1 Propionyl-methyl (K79) 51 
VTIMPKDIQLAR 2+ 756,9269 1511,8381 1 Propionyl (K122) 59 
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3.3.2. Relative quantification of methylated and acetylated lysine residues by LC-MS/MS 
Relative quantification of methylated and acetylated lysine residue of histones H3, H4, H2A, H2B and 
histone variants is desired. It was achieved, as described before, obtaining the peak areas (extracted 
ion chromatogram, XIC) of the same peptide in all detected forms (e.g. mono, di or trimethylated and 
acetylated or/and propionylated forms). The sum of all areas is 100% and the relative quantity of each 
peptide was calculated dividing its area by the total area (as shown in Figure 3.14).  
Additionally, during quantification of histone PTMs co-eluting isomeric peptides were identified. These 
peptides are identical but with different PTM position along the peptide chain (for example, when there 
are two or more available lysine residues that can be monomodified). Therefore, high resolution 
fragmentation was required to distinguish which lysine was modified and its abundance. For example, 
it was observed the monoacetylated peptide GK5GGK8GLGK12GGAK16R (H4K5K16) with m/z of 
768.9457. This peptide has four available lysine residues that can be monoacetylated, K5, K8, K12 and 
K16, and therefore four putative peptides can contribute to the total abundance of monomethylated 
H4K5K16. To quantify the abundance of each isomer, high resolution fragmentation was required and 
the identification of diagnostic ions gave the relative abundance of each isomer (Figure 3.23). 
Diagnostic ions are the characteristic molecular ion that indicate the presence and abundance of a 
substance and may assist in its identification (Vincenti 2011).  
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Figure 3.23. High resolution MS/MS of isomeric monoacetylated H4 K5K16. High resolution fragmentation 
spectra of monoacetylated peptide isomers of H4K5K16 are shown (H4K8ac, H4K12ac and H4K16ac) the precursor 
ion m/z is 754.9279, 2+. Fragment spectra was acquired and accumulated during isomeric peptide elution. 
Propionylation yields mass shift of +14Da. Diagnostic ions for quantification are shown in different color. 
 
 
Histone PTM patterns obtained in this work were compared with the only study that compared how the 
grown conditions affects the transcriptome and epigenome of mESCs (Marks et al. 2012). As just 
mentioned, Marks and collaborators analyzed and compared the transcriptome and epigenome of 
mESCs grown in 2i-containing media and in serum-containing media (Marks et al. 2012). According to 
MS data, there were no significant changes in histone PTM profiles of H3.1t, H4, H2A, H2B and histone 
variants when “serum” sample was compared with “2i” sample (as shown in Suppl. Tables 5.3.2 to 
5.3.5). However, when H3 PTM profiles of both samples (serum and 2i) were compared, several 
differences were observed as shown in Figure 3.24. In this Figure, the relative quantification of 
acetylated and methylated lysine residues of histone H3 in “serum” (blue bars) and “2i” (yellow bars) 
samples were compared. Besides, serum was compared to 2i sample, and the fold-changes of histone 
PTMs that increased more than 1.5-fold were assigned with a green arrow, while the histone PTMs that 
decreased more than 1.5-fold were assigned with a red arrow (Figure 3.24).  
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Figure 3.24. Relative quantification of methylated and acetylated H3 peptides in mESCs. Abundances of methylated and acetylated lysine residues of H3 peptides detected 
by LC-MS/MS in serum (blue bars) and 2i (yellow bars) samples in mESCs. Comparison of histone PTM abundances of serum sample with 2i sample are indicated by green and 
red arrows. Green and red arrows indicate increasing and decreasing of >1.5-fold, respectively. Error bars represent the standard deviation (<10%) from 2 biological replicates.   
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The differences observed in histone H3 PTM pattern (Figure 3.24) could be related to two different 
states of pluripotency as some authors suggested. In fact, Marks and Stunnenberg review indicated 
that differences in histone PTM pattern between both 2i and serum samples, could indicate two different 
states of pluripotency for mESCs. Precisely, they indicated that 2i sample could correspond to early 
blastocyst cells of the ICM (inner cell mass) or earlier stages; whereas serum sample could indicate 
later stages (Marks and Stunnenberg 2014). 
 
a. Quantification of H3K4 methylation 
Considering the residue H3K4, relative quantification of H3K4me3 in serum and 2i samples by mass 
spectrometry did not show significant changes (as shown in Figure 3.24 and 3.25). Marks and 
collaborators reported similar results. They indicated that according to ChIP-seq analysis, relative 
abundances of H3K4me3  in both samples (2i and serum samples) did not change (Marks et al. 2012). 
Moreover, unmodified and monomethylated H3K4 did not show significant changes in 2i and serum 
samples. However, H3K4me2 decreased about 2-fold in serum sample (Figure 3.24), which was not 
reported previously. 
 
 
Figure 3.25. Relative quantification of methylated and non-methylated H3K4 in mESCs. Relative 
quantification of H3K4 methylation levels between serum (blue bars) and 2i (yellow bars) samples. Error bars 
represent the standard deviation (<10%) from 2 biological replicates.  
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b. Quantification of methylated and acetylated H3K9K14  
Considering the residues H3K9K14, non-modified, monoacetylated and diacetylated H3K9K14 
decreased more than 1.5 fold (1.6, 2 and 2 fold, respectively) in serum sample. Whereas H3K9me2, 
H3K9me3K14ac, and H3K9me2K14ac increased more than 1.5 fold (1.5, 2 and 1.5, respectively) in the 
same serum sample (Figure 3.24 and Figure 3.26). According to several reports, methylated H3K9 is 
associated with heterochromatin assembly (Nakayama 2001; Bernstein et al. 2005; Bannister and 
Kouzarides 2011). According to other reports, differentiated cells have more heterochromatin than 
undifferentiated cells (Park et al. 2002; Marks et al. 2012). The relative quantification of H3K9 indicated 
that methylated H3K9 in serum was more abundant than 2i samples, and acetylated H3K9 was less 
abundant than 2i sample. Considering the previous reports (Nakayama 2001; Park et al. 2002; 
Bernstein et al. 2005; Bannister and Kouzarides 2011; Marks et al. 2012), chromatin has to be a globally 
open and dynamic structure to maintain undifferentiated cells. Therefore, it can be assumed from MS 
data of 2i and serum sample (concerning H3K9K14), that less open chromatin structures are present 
in serum sample compared to 2i sample.  
 
 
Figure 3.26. Relative quantification of methylated and acetylated H3K9K14 in mESCs. Relative quantification 
of methylated and acetylated lysine residues of H3K9K14 between serum (blue bars) and 2i (yellow bars) samples. 
Error bars represent the standard deviation (<10%) from 2 biological replicates. 
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c. Quantification of methylated H3K27K36 
Considering the residue H3K27, the trimethylated H3K27 is a known histone mark that has been 
associated with condensed chromatin structure (Bannister and Kouzarides 2011). As shown in Figure 
3.24 and Figure 3.27, H3K27me3 increased about 3-fold in serum sample. Marks and co-workers 
reported similar results. They found differences in H3K27me3 patterns between 2i and serum samples 
(Marks et al. 2012). They indicated that abundance of H3K27me3 in 2i sample was lower than in serum 
sample (Marks et al. 2012). Additionally, Marks and co-workers indicated that H3K27me3 is present 
across intergenic regions and inactive genes according to Chip-seq analysis, but the abundance of this 
histone mark at the promoter in 2i sample is diminished (Marks et al. 2012). Surprisingly, among all 
detected isoforms of H3K27K36 (K27SAPATGGVK36K37APR), H3K27me2 abundance in 2i sample was 
about 50% (Figure 3.24 and Figure 3.27); whereas in serum sample the same histone PTM was only 
about 20%. Thus far, there are no reports indicating that the inhibitors MeK and Gsk3 (2i) might 
influence or how might influence any mechanism on the control of dimethylated H3K27. Ferrari and co-
workers reported that the function of this histone PTM in mESCs grown in serum-containing media is 
mainly structural and protective. They indicated that efficient conversion to H3K27me3 requires a stable 
binding site which is given by H3K27me2 (Ferrari et al. 2014). Additionally, Ferrari and co-workers 
proposed the main activity of the complex PRC2 (complex that mediates methylation of H3K27), which 
is to dimethylate H3K27. Moreover, they suggested that an additional mechanism might control the 
PRC2 enzymatic activity for H3K27me1 and H3K27me3. Finally, they proposed that deposition of 
dimethylated H3K27 protects this residue from histone acetyltransferase activity (Ferrari et al. 2014). 
 
Figure 3.27. Relative quantification of methylated and acetylated H3K27K36 in mESCs. Relative 
quantification of methylated and acetylated lysine residues of H3K27K36 between serum (blue bars) and 2i (yellow 
bars) samples. Error bars represent the standard deviation (<10%) from 2 biological replicates. 
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d. Quantification of methylated H3K79 
Considering now the peptide EIAQDFK79TDLR, the unmodified H3K79 (or H3K79pr) was the most 
abundant detected form, followed by monomethylated and dimethylated H3K79 (Figure 3.28). MS data 
indicated that H3K79me2 decreased 2-fold in serum samples, albeit its low abundance (Figure 3.24. and 
Figure 3.28). Some reports indicated different biological functions for H3K79 methylation, which depend 
on the methylation state of K79. For instance, dimethylated H3K79 is a histone mark for open chromatin 
structure (Nguyen and Zhang 2011), while H3K79me3 is associated with heterochromatin formation (Ong 
et al. 2004). Barry and co-workers indicated that H3K79me2 levels increase at M-phase of the cell cycle, 
and in undifferentiated cells the levels of this histone PTM are low (Barry et al. 2009). Moreover, the 
high abundance of unmodified H3K79 might be explained by Barry and collaborators. They indicated 
that Dot1 (the enzyme that catalyzes methylation of H3K79) dimethylates this residue as soon as the 
differentiation of ESCs starts (Barry et al. 2009), therefore unmodified H3K79 is the available residue 
to be dimethylated once the cell cycle initiates.  
 
 
Figure 3.28. Relative quantification of methylated and non-methylated H3K79 in mESCs. Relative 
quantification of methylated lysine residue of H3K79 between serum (blue bars) and 2i (yellow bars) samples. Error 
bars represent the standard deviation (<10%) from 2 biological replicates. 
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e. Quantification of methylated H4K5K16  
As explained before, there were no differences on histone H4 PTM patterns between both grown 
conditions, serum and 2i samples (Suppl. Table 5.3.2). Considering the peptide 
GK5GGK8GLGK12GGAK16R (H4K5K16), the unmodified H4K5K16 was the most abundant form 
followed by monoacetylated H4K5K16. Since the peptide GK5GGK8GLGK12GGAK16R has four 
available lysine residues to be modified, a monoacetylated H4K5K16 might present four isomeric 
peptides (H4K5acK16, H4K5K8acK16, H4K5K12acK16, H4K5K16ac). According to MS data of 2i and 
serum samples, the four isomeric peptides were identified; among these four isomers, H4K5K16ac was 
the most abundant. It is an expected result, since several reports indicated that H4K5K16ac is 
associated with pluripotency state of ESCs (Taylor et al. 2013; Chen and Dent 2013; Ravens et al. 
2014). Mof, the enzyme that catalyzes acetylation of H4 lysine 16, is a catalytic unit of MSL (male 
specific lethal) and NSL (non-specific lethal) complexes (Ravens et al. 2014). MSL complex stablishes 
high acetylation levels for mESCs pluripotency, because this histone PTM contributes to a more open 
chromatin structure. Whereas NSL complex regulates proliferation of mESCs (Ravens et al. 2014). Li 
and co-workers also reported that deletion of Mof (known also as Kat8) leads to loss of ESC self-
renewal, which is accompanied by reduction of H4K5K16ac abundance (Li et al. 2012). Together, this 
indicates that growth condition (serum or 2i containing media) of mESCs does not affect 
monoacetylated H4K5K16 levels, and consequently the growth condition does not affect Mof enzymatic 
activity. Moreover, it was reported that Mof-containing complex recruits WRD5 (WD repeat domain 5), 
which is a core component of MLL complex (or SET complex in yeast) and subsequently H3K4 is 
trimethylated (as in red highlighted in Figure 3.29). These complexes (MOF, WRD5 and MLL) were 
associated to maintain ESC pluripotency (Chen and Dent 2013). Considering MS data, it might be 
concluding that the synchronized interaction between MOF, WRD5 and MLL was not affected by growth 
condition (serum and 2i samples); and this interaction also might explain the unvarying levels of 
H3K4me3 and H4K5K16ac in both samples. 
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Figure 3.29. Schematic representation of synchronized interaction between MOF, WRD5 and MLL 
complexes to maintain pluripotency. In red circle is highlighted the mechanism of interactions between three 
different complexes reported to be associated to maintain ESC pluripotency. Mof-containing complex recruits 
WRD5 (WD repeat domain 5), WRD5 is a core component of MLL complex, and subsequent H3K4 is trimethylated 
by Set-containing complex (MLL complex). Figure taken from (Chen and Dent 2013). 
 
 
f. Quantification of histone PTMs of H2A, H2B and histone variants 
To recently, histone PTMs of H2A, H2B and histone variant received little attention. For instance, most 
of histone PTM patterns of these proteins in 2i and serum sample seem to be novel identifications. 
Among these novel identifications, there was a histone PTM identified only in serum sample. All novel 
histone PTMs detected in both sample are summarized in Table 3.5, and the PTM identified only in 
serum sample is highlighted with a black arrow.  
 
 
Table 3.5. List of novel modified histone peptides identified in serum and 2i samples by LC-MS/MS. Listed 
are novel modified histone tryptic peptides of H3.1T, H2A.1, H2A.X and H2A.Z detected by LC-MS/MS in serum 
and 2i samples. Listed peptides were identified in both samples, but H2A.Z K37me1 (indicated with a black arrow) 
was identified in serum sample only.  
Novel identified isoforms (serum and 2i) Abbreviation 
Kme1QLATKprVAR H3.1T K18me1 
KprQLATKme1VAR H3.1T K23me1 
KprQLATKprVAR H3.1T K18K23 
GKacQGGKprAR H2A.1 K5ac 
AKme2AKprTR H2A.1 K13me2 
DNKacKprTR H2A.1 K74ac 
GKacTGGKprAR H2A.X K5ac 
HLKme1SR                   H2A.Z K37me1        
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Regarding relative quantification of histone PTMs in H2A, H2B and histone variant in serum and 2i 
samples, there were no significant differences in the histone PTM pattern between both samples (as 
shown in Suppl. Tables 5.3.3 and 5.3.4). As explained before, little information exists about histone 
PTMs of H2A, H2B and histone variants (like H2A.Z, H2A.X, H3.3, among others), indicating only why 
or how is the incorporation of these proteins to the nucleosome. Skene and Henikoff described that 
histone variants are required for ESC self-renewal (Skene and Henikoff 2013). Moreover, Hu and co-
workers indicated that H2A.Z promotes pluripotency of ESCs, because this protein is incorporated at 
the promoter and enhancers in mESCs (Hu et al. 2013). They also reported that deletion of H2A.Z led 
to a more compact chromatin structure; therefore, a reduced accessibility of the underlying DNA (Hu et 
al. 2013). As a consequence of the reduced accessibility of DNA, transcription factor (like Oct4) is 
impeded to bind to regulatory sites as shown in Figure 3.30 (Hu et al. 2013). The authors also indicated 
that it is still unknown why H2A.Z led to a more open chromatin structure and therefore to a more 
accessible DNA for transcriptional factors (Hu et al. 2013). Some hypothesis indicated that post-
translational modifications, like lysine acetylation of H2A.Z, could be involved in this process, since this 
histone PTM (acetylation) neutralizes the charges of lysine leading to an open chromatin structure 
(Bonisch and Hake 2012). Another hypothesis indicated that an additional histone PTM might recruit 
non-histone proteins modulating chromatin accessibility (Bonisch and Hake 2012). Gaspar-Maia and 
collaborators identified a non-histone protein, the chromatin remodeler Chd1, in a screen of genes 
required for ESC self-renewal and pluripotency (Gaspar-Maia et al. 2009). They indicated that deletion 
of Chd1 led to a less open chromatin structure and an increase of the heterochromatin mark H3K9me3 
(Gaspar-Maia et al. 2009).  
Together, it is still unclear how the identified PTMs of H2A, H2B, and histone variants by MS in serum 
and 2i sample are involved either in structural changes of chromatin or in recruiting non-histone proteins 
to further modulate chromatin accessibility. Nevertheless, histone PTM profiles obtained by mass 
spectrometry contributed to identify that culture media do not alter PTM abundances of H2A, H2B and 
histone variants. Besides, more studies would be required to identify the exact role or putative role for 
histone PTMs reported during this thesis in mESCs. 
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Figure 3.30. Schematic representation of incorporation of histone variant H2A.Z to nucleosome in mESCs 
and its consequence. Figure A shows the incorporation of H2A.Z to nucleosomes leading a more open chromatin 
structure; as consequence, the access to transcriptional factor (TF) to DNA is enabled, and cells maintain 
pluripotency. Figure B shows that loss of H2A.Z led to a condensed chromatin structure, as consequence TF is 
impeded to access to DNA and heterochromatin formation takes place. Figure taken from (Skene and Henikoff 
2013) 
 
 
Summarizing, in this section the PTM profiles of canonical histones and histone variants of mESCs 
grown in serum- and in 2i-containing media was shown. Additionally, relative quantification of PTMs of 
H4, H2A, H2B and histone variants by LC-MS/MS showed slight differences between both samples, 
indicating that culture media do not affect abundances of histone PTMs of H4, H2A, H2B and variants. 
However, significant changes were identified in H3 PTM profiles in serum and 2i samples. MS data 
indicated that levels of heterochromatin marks like H3K9me3 and H3K27me3 are higher in serum sample 
than in 2i. On the other hand, histone marks for open chromatin structures like mono- and di-acetylated 
H3K9K14 were more abundant in 2i sample than in serum. Regarding MS data, it can be assumed that 
there are insights of heterochromatin formation in serum sample, while in 2i sample, chromatin has a 
more open structure (compared to serum sample). These conclusions are supported by Marks and 
Stunnenberg report (Marks and Stunnenberg 2014). They indicated that there might exist two different 
states of pluripotency of mESCs, like early blastocyst cells of the ICM or earlier stages in 2i sample and 
later stages in serum samples (Marks and Stunnenberg 2014). Finally, several modified peptides were 
identified for the first time in this work. All novel histone modifications were shared in both samples, and 
monomethylated H2A.Z K37 was identified only in serum sample.  
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3.4. Quantification of histone post-translational modifications in human cell lines 
3.4.1. Identification of methylated and acetylated lysine residues by LC-MS/MS in human cell 
lines. 
The human cell lines HeK-293T (Human Embryonic Kidney 293T), HeLa (cervical cancer), MDA-MB231 
and MCF-7 (Human breast cancer) are simple and useful biological models to understand more 
complex biological systems. These cell lines are often used by researchers because all 
physicochemical properties during cell cultures can be regulated having a precise control over its 
growth. Besides, human cell lines are homogeneous, have a short generation time and have the ability 
to produce proteins and PTMs similar to those synthesized naturally by humans (Ghaderi et al. 2010; 
Jain et al. 2012). In this section, proliferating and confluent HeLa, HEK-293T, MCF-7 and MDA-MB231 
were used. Although there are several studies that reported quantification of histone PTMs in human 
cell lines, most of them are related to cells subjected to induced perturbations, like specific mutations 
or drugs addition (Robin et al. 2007; Gelman et al. 2011; Tang et al. 2013). Thus far, there are only a 
few studies that reported PTM patterns of histones H3 and H4 with no induced perturbation like drugs 
addition or any kind of mutation (Garcia et al. 2006; Cuomo et al. 2011; LeRoy et al. 2013; Evertts et 
al. 2013). Garcia and coworkers examined the histone H3 and H4 PTM profiles of several organisms, 
like Saccharomyces cerevisiae, Tetrahymena thermophile and mammalian cells (mouse and human). 
They sought to examine at which extend the histone code is conserved among these organisms (Garcia 
et al. 2006). Cuomo and co-workers compared histone PTM patterns of H3 and H4 from four cell lines 
(MCF7, MDA-MB231, MDA-MB453 and T-47D) in physiological and disease condition. They intended 
to identify how specific changes in histone PTM pattern correlate to tumor features (Cuomo et al. 2011). 
Leroy and co-workers intended to understand the unique molecular properties in different cancer types. 
To find such molecular properties, they looked at the histone PTM patterns of H3 and H4 of 24 different 
cell lines (Leroy et al. 2013). Finally, Evertts and co-workers sought to identified changes in histone H3 
and H4 PTMs levels during proliferation and quiescence. They expected that changes in chromatin 
states of human fibroblast can regulate cell cycle exit (Evertts et al. 2013). 
To study the relationship between global dynamics of chromatin structure and histone PTMs in cell 
proliferation and confluence, it is required to quantify histone PTMs. Therefore, the aim was to identify 
lysine methylation and acetylation patterns of histones H3, H4, H2A, H2B in HeLa, HEK-293T, MCF-7 
and MDA-MB231 during proliferation and confluence (100% confluence) by LC-MS/MS. Both, 
proliferating and confluent cells could give insights of changes in histone PTM patterns when no 
perturbation occurs during the cell cycle (proliferating cells), and when natural perturbation occurs 
(confluent cells) because of contact inhibition and cells exit the cell cycle. Here, cells were harvested to 
100% confluence in all samples to achieve consistent results among cell lines; because immortalized 
cells can continue dividing and forming layers on top of parent cells. Additionally, lysine acetylation and 
methylation patterns can help to understand the global dynamics of chromatin structure and function 
during proliferation and confluence. 
It is expected to observe histone marks for open chromatin structures (like trimethylated H3K4, 
acetylated H3K18K23 and acetylated H4K16) with higher abundances in proliferating cells than in 
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confluent cells. In contrast, it is expected to observe histone marks for condensed chromatin (like 
trimethylated H3K9, trimethylated H3K27) with higher abundances in confluent cells than in proliferating 
cells. Additionally, it is expected to identify any (or some) histone PTM(s) in a particular cell line only, 
or in proliferating or confluent cells only, that might become in cell line–mark or marks.  
The four human cell lines, HeK-293T, HeLa, MDA-MB231 and MCF-7, were kindly prepared by Dr. 
Alexandra Schambony from Friedrich-Alexander Universität Erlangen, Nürnberg. For each cell line 
three biological replicates for proliferating cells were prepared, and three biological replicates for 
confluent cells were also prepared. About 70 modified histone peptides (H3, H4, H2A, H2B and histone 
variants) were identified by LC-MS/MS in a single cell line and in a single experimental condition 
(proliferation or confluency). In Table 3.6 are summarized all acetylated and methylated lysine residues 
of histone H3 identified in all four cell lines in proliferating and confluent cells. Acetylated and methylated 
lysine residues identified in proliferating and confluent human cell lines with their respective details 
given by mascot database are shown in Suppl. Tables 5.4.1 to 5.4.4 for H3, H4, H2A, H2B and histone 
variants.  
Identification of methylated and acetylated lysine residues of histone H3 and H4 in HeK-293T in the 
present study matched in about 90% of the same histone modifications in H3 and H4 in HeK-293T 
reported by García and co-workers (Garcia et al. 2006). Likewise, identification of histone PTMs of H3 
and H4 in MCF-7 reported in this work matched also in about 90% of the same histone modifications 
reported by Cuomo and co-workers (Cuomo et al. 2011). Finally, identification of histone PTMs in H3 
in HeK-293T, Hela, MDA-MB231 and MCF-7 matched in about 90% of the same histone modifications 
reported by Leroy and co-workers (Leroy et al. 2013). In the three reports mentioned before (Garcia et 
al. 2007a; Cuomo et al. 2011; Leroy et al. 2013) were not indicated whether the extracted histones from 
human cell lines correspond to proliferating or confluent cells.  
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Table 3.6. Summary of methylated and acetylated lysine residues of histone H3 identified in proliferating and confluent human cell lines by LC-MS/MS. Listed are 
detected methylated and acetylated lysine residues of H3 by LC-MS/MS in proliferating (prolif.) and confluent (conf.) HeK-293T, HeLa, MDA-MB231 and MCF-7. H3 was 
propionylated before and after enzymatic digestion (trypsin), therefore each peptide in the table is also propionylated at the N-termini. Modified lysine residues are described as 
Kac, Kprme1, Kme2, Kme3, Kpr for acetylated, mono-, di-, tri-methylated and propionylated lysine, respectively 
 
 
 
HeK-293T HeLa MDA-MB231 MCF-7 
Prolif. cells Conf. cells Prolif. cells Conf. cells Prolif. cells Conf. cells Prolif. cells Conf. cells 
H3K4me3 H3K4me3 H3K4me3 H3K4me3 H3K4me3 H3K4me3 H3K4me3 H3K4me3 
H3K4me2 H3K4me2 H3K4me2 H3K4me2 H3K4me2 H3K4me2 H3K4me2 H3K4me2 
H3K4prme1 H3K4prme1 H3K4prme1 H3K4prme1 H3K4prme1 H3K4prme1 H3K4prme1 H3K4prme1 
H3K4pr H3K4pr H3K4pr H3K4pr H3K4pr H3K4pr H3K4pr H3K4pr 
H3K9prK14pr H3K9prK14pr H3K9prK14pr H3K9prK14pr H3K9prK14pr H3K9prK14pr H3K9prK14pr H3K9prK14pr 
H3K9prme1K14ac H3K9prme1K14ac H3K9prme1K14ac H3K9prme1K14ac H3K9prme1K14ac H3K9prme1K14ac H3K9prme1K14ac H3K9prme1K14ac 
H3K9acK14ac H3K9acK14ac H3K9acK14ac H3K9acK14ac H3K9acK14ac H3K9acK14ac H3K9acK14ac H3K9acK14ac 
H3K9me3K14pr H3K9me3K14pr           
H3K9prK14ac H3K9prK14ac H3K9prK14ac H3K9prK14ac H3K9prK14ac H3K9prK14ac H3K9prK14ac H3K9prK14ac 
H3K9prme1K14pr H3K9prme1K14pr H3K9prme1K14pr H3K9prme1K14pr H3K9prme1K14pr H3K9prme1K14pr H3K9prme1K14pr H3K9prme1K14pr 
H3K9me2K14pr H3K9me2K14pr H3K9me2K14pr H3K9me2K14pr H3K9me2K14pr H3K9me2K14pr H3K9me2K14pr H3K9me2K14pr 
H3K9me3K14ac H3K9me3K14ac H3K9me3K14ac H3K9me3K14ac H3K9me3K14ac H3K9me3K14ac H3K9me3K14ac H3K9me3K14ac 
H3K9me2K14ac H3K9me2K14ac H3K9me2K14ac H3K9me2K14ac H3K9me2K14ac H3K9me2K14ac   H3K9me2K14ac 
H3K18acK23ac H3K18acK23ac H3K18acK23ac H3K18acK23ac H3K18acK23ac H3K18acK23ac H3K18acK23ac H3K18acK23ac 
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HeK-293T HeLa MDA-MB231 MCF-7 
Prolif. cells Conf. cells Conf. cells Conf. cells Prolif. cells Conf. cells Prolif. cells Conf. cells 
H3K18prK23ac H3K18prK23ac H3K18prK23ac H3K18prK23ac H3K18prK23ac H3K18prK23ac H3K18prK23ac H3K18prK23ac 
H3K18prTK23pr H3K18prTK23pr H3K18prTK23pr H3K18prTK23pr H3K18prTK23pr H3K18prTK23pr H3K18prTK23pr H3K18prTK23pr 
H3 K27prK36prK37pr H3 K27prK36prK37pr H3K27prK36prK37pr H3K27prK36prK37pr H3  K27prK36prK37pr H3  K27prK36prK37pr H3 K27prK36prK37pr H3  K27prK36prK37pr 
H3 K27prme1K36prK37pr H3 K27prme1K36prK37pr H3K27prme1K36prK37pr H3K27prme1K36prK37pr   H3 K27prme1K36prK37pr H3K27prme1K36prK37pr H3K27prme1K36prK37pr 
H3 K27prK36prme1K37pr 
H3 K27prK36prme1K37pr H3 K27prK36prme1K37pr H3 K27prK36prme1K37pr 
  
H3 K27prK36prme1K37pr H3K27prK36prme1 K37pr H3 K27prK36prme1K37pr 
H3 K27me2K36prK37pr H3 K27me2K36prK37pr H3 K27me2K36prK37pr H3 K27me2K36prK37pr H3 K27me2K36prK37pr H3 K27me2K36prK37pr H3 K27me2K36prK37pr H3 K27me2K36prK37pr 
H3 K27me2K36me2K37pr H3 K27me2K36me2K37pr H3 K27me2K36me2K37pr H3 K27me2K36me2K37pr H3 K27me2K36me2K37pr H3 K27me2K36me2K37pr H3K27me2K36me2 K37pr H3 K27me2K36me2K37pr 
H3K27prme1K36me2 K37pr H3K27prme1K36me2 K37pr H3K27prme1K36me2 K37pr H3K27prme1K36me2 K37pr H3K27prme1K36me2 K37pr H3K27prme1K36me2 K37pr H3K27prme1K36me2K37pr H3K27prme1K36me2 K37pr 
H3K27prme1K36prme1K37pr H3K27prme1K36prme1K37pr H3K27prme1K36prme1K37pr H3K27prme1K36prme1K37pr     H3K27prme1K36prme1K37pr 
H3K27me2K36prme1 K37pr H3K27me2K36prme1 K37pr H3K27me2K36prme1 K37pr H3K27me2K36prme1 K37pr H3K27me2K36prme1 K37pr H3K27me2K36prme1 K37pr H3K27me2K36prme1K37pr H3K27me2K36prme1 K37pr 
H3 K27me3K36prK37pr H3 K27me3K36prK37pr H3 K27me3K36prK37pr H3 K27me3K36prK37pr H3 K27me3K36prK37pr H3 K27me3K36prK37pr H3 K27me3K36prK37pr H3 K27me3K36prK37pr 
H3 K27prK36me2K37pr   H3 K27prK36me2K37pr H3 K27prK36me2K37pr H3 K27prK36me2K37pr H3 K27prK36me2K37pr H3 K27prK36me2K37pr H3 K27prK36me2K37pr 
K56pr K56pr K56pr K56pr K56pr K56pr K56pr K56pr 
K64pr K64pr K64pr K64pr K64pr K64pr K64pr K64pr 
K79me2 K79me2 K79me2 K79me2 K79me2 K79me2 K79me2 K79me2 
K79prme0 K79prme1 K79prme1 K79prme1 K79prme1 K79prme1 K79prme1 K79prme1 
K79pr K79pr K79pr K79pr K79pr K79pr K79pr K79pr 
K122pr K122pr K122pr K122pr K122pr K122pr K122pr K122pr 
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3.4.2. Quantification of methylated and acetylated lysine residues by LC-MS/MS in human cell 
lines. 
Quantification of methylated and acetylated lysine residues levels of histones (H3, H4, H2B, H2A and 
histone variants) in proliferating and confluent human cell lines is desired to characterize changes in 
chromatin states. Changes in histone PTM patterns during proliferation and confluence (100% 
confluency) might give insights about differences between cell cycle process and when contact 
inhibition starts, and therefore cells are arrested. As it has been often reported, transcription and 
translation of canonical histones (H3, H4, H2A and H2B) occur during S phase (Heintz et al. 1983; 
Graves et al. 1987). Subsequently, newly synthesized histones form the new nucleosomes, and they 
are located between preexisting canonical nucleosomes, randomly (Xu et al. 2010). However, fewer 
reports indicated whether all histone PTMs are newly synthesized during cell cycle or are transmitted 
to daughter cells, and as consequence histone PTM abundances might change when contact inhibition 
occurs (Zee et al. 2012; Evertts et al. 2013; Alabert et al. 2015). Therefore, profiling histone PTMs in 
human cell lines by LC-MS/MS can provide some answers indicating whether certain histone PTMs are 
found during proliferation only, or when cells are naturally arrested by contact inhibition. 
According to Evertts and co-workers, contact-inhibited human fibroblasts exhibited more tightly packed 
chromatin than proliferating cells (Evertts et al. 2013). Alabert and collaborators looked for histone PTM 
pattern through the cell cycle, and they showed that some histone PTMs are transmitted from parent to 
daughter cells and other are newly synthesized, demonstrating that chromatin state changes in the cell 
cycle (Alabert et al. 2015). Together, in this study it is expected that histone PTM profiles of confluent 
HeK-293T, HeLa, MDA-MB231 and MCF-7 would reveal histone marks for condensed chromatin 
structures (like H3K9me3, H3K27me3), and with higher abundances than in proliferating human cell lines. 
Additionally, it is expected low abundances of transcriptionally active histone marks (like H3K4me3, 
acetylated H3K9, H3K18K23) because as it was indicated by Bou Kheir and Lund low levels of 
transcriptionally active histone marks ensure a correct packaging of nucleosomes (Kheir and Lund 
2010). 
 
a. Quantification of H3K4 and H3K18K23 methylation and acetylation levels in Human cell lines 
Relative quantification of methylated H3K4 (TQK4TAR) did not show significant changes neither in 
proliferating HeK-293T, HeLa, MDA-MB231, MCF-7 nor in confluent cells, as shown in Figure 3.31. 
Several researchers reported similar abundances of methylated H3K4 (Cuomo et al. 2011; LeRoy et 
al. 2013). They revealed that abundances of di- and tri-methylated H3K4 in these immortalized cells 
(HeK-293T, HeLa, MDA-MB231, MCF-7) are below 1% (Cuomo et al. 2011; LeRoy et al. 2013), which 
agreed with what has been shown in this study (Figure 3.31). Additionally, Muramoto and co-workers 
indicated that H3K4 methylation, a conserved histone PTM usually associated with open chromatin 
structure (as explained in Chapter 1), is transmitted from mother to daughter cells during cell cycle 
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(Muramoto et al. 2010). Furthermore, they indicated that this transmission can be detected after the cell 
cycle is completed only (Muramoto et al. 2010).  
Together, it can be assumed that methylated H3K4 patterns were not affected by contact inhibition. 
This assumption is supported by Scharf and co-workers, they sought to look into the histone PTM 
patterns during replication to understand the maintenance of chromatin structures. However they limited 
their analysis of histone PTMs after chromatin assembly to H3 K9, K27 and K36 because K4 was mostly 
unmodified (Scharf et al. 2009a). Besides, if it is desired to look for any particular histone mark that 
could characterize this stress condition (contact inhibition), it is suggested to look at different lysine 
residue of the same histone H3 or other histones (H4, H2A or H2B).  
 
 
Figure 3.31. Relative quantification of methylated lysine 4 of histone H3 in human cell lines. Abundances (in 
%) of methylation levels of H3K4 (TK4QTAR) in MCF-7 (Figure A), in MDA-MB231 (Figure B), in Hela (Figure C), 
and in HeK-293T (Figure D). Three biological replicates of proliferating cells (orange bars) are compared with three 
biological replicates of confluent cell (yellow bars). Error bars represent standard deviation (<5%) of biological 
replicates. Propionylated, mono-, di- and tri-methylated lysine residues are abbreviated as K4pr, K4prme1, K4me2 and 
K4me3, respectively.  
 
 
A B 
C D 
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Similar to H3K4 methylation profile, relative quantification of acetylated H3K18K23 did not show 
significant changes neither in proliferating HeK-293T, HeLa, MDA-MB231 and MCF-7 nor in confluent 
cells (Figure 3.32). It was reported that among others histone PTMs, H3K18K23ac in the newly 
synthesized H3 presented similar levels compared to the abundance of this histone PTM in the 
preexisting H3. Additionally, H3K18K23ac levels are maintained only during the incorporation of the new 
H3 to the nucleosome (Loyola et al. 2006; Alabert et al. 2015). As it was expected, abundance of 
diacetylated H3K18K23, a known histone mark for transcriptionally active chromatin, was low (<4%) 
among all four histone cell lines. Low levels of this histone mark ensure a correct packaging of 
nucleosomes (Kheir and Lund 2010). 
 
 
Figure 3.32. Relative quantification of acetylated lysine 18 and lysine 23 of histone H3 in human cell lines. 
Abundances (in %) of acetylation levels of H3K18K23 (K18QLATK23AAR) in MCF-7 (Figure A), in MDA-MB231 
(Figure B), in Hela (Figure C), and in HeK-293T (Figure D). Three biological replicates of proliferating cells (orange 
bars) are compared with three biological replicates of confluent cell (yellow bars). Error bars represent standard 
deviation (<5%) of biological replicates. Acetylated and propionylated lysine residues are abbreviated as K(x)pr and 
K(x)ac, respectively. “x” can be K18 or K23.  
 
 
 
A B 
C D 
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b. Quantification of H3K9K14 methylation and acetylation levels in Human cell lines 
Relative quantification of H3K9K14 methylation and acetylation in HeK-293T, HeLa, MDA-MB231 and 
MCF-7 by LC-MS/MS, varied between proliferating and confluent cells (Figure 3.33). The peptide 
K9STGGK14APR contains two lysine residues (K9 and K14) that can be post-translational methylated 
or acetylated. Among the four human cell lines, MDA-MB231 and MCF-7 (both breast cancer cell lines) 
showed the most similar methylated and acetylated H3K9K14 profiles. This result is supported by Leroy 
and co-workers, since they indicated “cell lines of similar tissue origin have similar chromatin 
modification profiles” (LeRoy et al. 2013).  
Additionally, on HeK-293T, HeLa, MDA-MB231 and MCF-7, H3K9 was found unmodified, acetylated, 
mono-, dimethylated and trimethylated (H3K9me3 was found in HeK-293T only), H3K14 was found 
unmodified and acetylated only (as shown in Figure 3.33). Unmodified H3K9K14 and dimethylated 
H3K9 were the most predominant histone modifications in HeLa, MDA-MB231 and MCF-7, while 
H3K9me2 and H3K9me2K14ac were the most predominant histone PTMs in HeK-293T. Zee and co-
workers indicated that dimethylated H3K9 is produced by two distinct pathways: first, H3K9me2 is 
synthesized from a preexisting monomethylated H3K9 during G1 phase; and second, H3K9me2 is newly 
synthesized from an unmodified H3K9 during G2 and M phases (Zee et al. 2012). The dually modified 
H3K9me2K14ac contains PTMs with opposing epigenetic functions (known also as binary switch), 
because H3K9me2 is a histone mark of condensed chromatin structure, while H3K14ac is a histone mark 
of open chromatin structure (Bernstein et al. 2006). Plazas-Mayorca and co-workers indicated that the 
histone methyltransferase G9a dimethylates preferentially H3K9 when the adjacent lysine (H3K14) is 
acetylated (Plazas-Mayorca et al. 2010). They also indicated that H3K9me2K14ac may act as a 
combinatorial switch, because it (H3K9me2K14ac) can become either a transcriptionally active (H3K14ac) 
or repressed (H3K9me2) histone mark, depending on the requirements of the cells (Bernstein et al. 2006; 
Plazas-Mayorca et al. 2010).  
Trimethylated H3K9 (H3K9me3) was only identified in H3K-293T, and with low abundance (<2%). This 
histone modification was also reported by Cuomo and co-workers, they observed for the first time (by 
mass spectrometry) loss of H3K9me3 in MCF-7 and MDA-MB231, and this observation was also 
confirmed by Western blot analysis (Cuomo et al. 2011). Several reports indicated that the histone 
methyltransferase (HMT) that trimethylates H3K9 is Suv39h1/h2 (as mentioned in Chapter 1, 
Introduction), and G9a (another HMT) mono- and di-methylates the same residue (Tachibana 2002; 
Peters et al. 2003; Rice et al. 2003). However, Yokochi and co-workers reported that G9a is also 
involved in trimethylation of H3K9 in vivo (Yokochi et al. 2009). Similar to the dually modified 
H3K9me2K14ac, it was detected H3K9me3K14ac. Its abundance (H3K9me3K14ac) slightly varies among 
proliferating and confluent HeK-293T, MDA-MB231 and MCF-7. However, H3K9me3K14ac increased 
about 3-fold in confluent HeLa (Figure 3.33).  
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Figure 3.33. Relative quantification of methylated and acetylated lysine 9 and lysine 14 of histone H3 in 
human cell lines. Abundances (in %) of methylation and acetylation levels of H3K9K14 (K9STGGK14APR) in MCF-
7 (Figure A), in MDA-MB231 (Figure B), in Hela (Figure C), and in HeK-293T (Figure D). Three biological replicates 
of proliferating cells (orange bars) are compared with three biological replicates of confluent cell (yellow bars). Error 
bars represent standard deviation (<5%) of biological replicates. Acetylated, propionylated, mono-, di- and tri-
methylated lysine residues are abbreviated as K(x)ac, K(x)pr, K(x)prme1, K(x)me2 and K(x)me3, respectively. “x” can 
be K9 or K14.  
 
 
c. Quantification of H3K27K36 methylation levels in Human cell lines 
H3K27K36 are two known sites for post-translational modifications (PTMs) related to activation and 
repression of transcription (Kouzarides 2007). The function of modified H3K27K36 depends on the 
histone PTM that binds to lysine residue, for example H3K27me3 is a heterochromatic mark while 
H3K36me3 is a euchromatic mark (Kouzarides 2007).  
Relative quantification of methylated H3K27K36 in HeK-293T, HeLa, MDA-MB231 and MCF-7 showed 
dimethylated H3K27 (H3K27me2) as the most predominant histone modification (>35% of abundance), 
and slightly variations in abundances between confluent and proliferating cells were also observed 
(Figure 3.34). This result is supported by Evertts and co-workers, since they reported that methylation 
of H3K27 in proliferating and contact-inhibited (arrested cells) fibroblasts slightly changed over the cell 
A B 
C D 
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cycle. Evertts and co-workers also indicated that dimethylated H3K27 was the most prominent histone 
modification (Evertts et al. 2013). Zee and co-workers reported two different pathways to dimethylate 
H3K27: first, they indicated that histone methyltransferases (HMTs) bind to unmodified H3K27 to further 
dimethylate this lysine residue. Second, they indicated that HMTs first transfer one methyl group, then 
it release the histone, and finally HMTs re-bind to methylate for a second time H3K27 and to form 
H3K27me2 (Zee et al. 2012).  
Relative quantification of mono- and tri-methylated H3K27 reached up to 7% of abundance in 
proliferating and confluent HeK-293T, HeLa, MDA-MB231 and MCF-7, as shown in Figure 3.34. Scharf 
and colleagues reported that H3K27 is monomethylated by the histone methyltransferase EZH2 right 
after the newly synthesized histone is deposited in the nucleosome. They also observed that H3K27me1 
is required for further methylations and higher levels of di and tri-methylation of H3K27 are slowly 
reached (Scharf et al. 2009b). Additionally, Zee and collaborators reported that trimethylation of H3K27 
is formed by two pathways: first, by methylation of the preexisting H3K27me2 during G1 phase, and 
second, by trimethylation of the unmodified H3K27 during S and G2/M phases (Zee et al. 2012). Finally, 
they concluded that H3K27me3 is not transmitted through the cell cycle from mother to daughter cells 
because to reach the steady-state of this histone modification, HMT requires unmodified and 
dimethylated H3K27 (Zee et al. 2012).  
Relative quantification of methylated H3K36 showed low levels compared to H3K27 methylation in the 
four human cell lines (HeK-293T, HeLa, MDA-MB231 and MCF-7). Mono- and di-methylated H3K36 
(H3K36me1 and H3K36me2) did not reach more than 7% of abundance. It is an expected result because 
methylated H3K36 is a global histone mark associated with transcriptionally active chromatin 
(Kouzarides 2007), and as explained before low levels of transcriptionally active histone marks ensure 
a correct packaging of nucleosomes (Kheir and Lund 2010). Moreover, no significant differences were 
observed in H3K36me1 and H3K36me2 abundances between proliferating and confluent human cell lines. 
Similar observation was reported by Zee and co-workers, they indicated that abundance of H3K36 
methylation did not change during the cell cycle, concluding that H3K36me1 and H3K36me2 are cell cycle 
independent (Zee et al. 2012). 
Bernstein and colleagues reported the presence of some dually modified peptides which contain PTMs 
with opposing epigenetic functions. These peptides are known as binary switches, because there is a 
histone mark of condensed chromatin structure and a histone mark of open chromatin structure 
(Bernstein et al. 2006), for example H3K27me3K36me2. In the present study, four hypermethylated states 
of H3K27K36 were observed, H3K27me1K36me1, H3K27me2K36me2, H3K27me1K36me2, and 
H3K27me2K36me1. Leroy and co-workers also reported that several human cell lines, like MDA-MB231, 
MCF-7, among others, exhibited abundant dually modified peptides. Some of these peptides were 
H3K27me2K36me2, H3K27me3K36me2, H3K27me2K36me1, and H3K27me3K36me1 (LeRoy et al. 2013). The 
authors suggested that there might be a direct or indirect functional correlation between EZH2 and 
NSD1, the two histone methyltransferases related to methylation of H3K27 and H3K36, respectively 
(LeRoy et al. 2013).  
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Acetylated H3K27 or H3K36 was not identified in any human cell lines in this study, and H3K37 was 
always identified as unmodified residue. In Huang and colleagues review is summarized that this 
residue (H3K37) has been reported to be acetylated, methylated and ADP ribosylated (Huang et al. 
2015). However, as mentioned before no modification was observed in the present study.   
 
 
 
Figure 3.34. Relative quantification of methylated lysine 27 and lysine 36 of histone H3 in human cell lines. 
Abundances (in %) of methylation levels of H3K27K36 (K27SAPATGGVK36KPHR) in MCF-7 (Figure A), in MDA-
MB231 (Figure B), in Hela (Figure C), and in HeK-293T (Figure D). Three biological replicates of proliferating cells 
(orange bars) are compared with three biological replicates of confluent cell (yellow bars). Error bars represent 
standard deviation (<5%) of biological replicates. Propionylated, mono-, di- and tri-methylated lysine residues are 
abbreviated as K(x)pr, K(x)prme1, K(x)me2 and K(x)me3, respectively. “x” can be K27 or K36.  
 
 
d. Quantification of H3K79 methylation levels in Human cell lines 
Methylation (mono-, di- and tri-methylation) of H3K79 is catalyzed by the conserved enzyme Dot1 (as 
mentioned in Chapter 1, Introduction) (van Leeuwen et al. 2002). H3K79me1/me2 have been associated 
with transcriptionally active chromatin while H3K79me3 has been associated with heterochromatin 
formation (Ng 2002). 
A B 
C D 
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Relative quantification of un-, mono- and di-methylated H3K79 HeK-293T, HeLa, MDA-MB231 and 
MCF-7 did not show significant differences in proliferating and confluent cells (Figure 3.35). The 
unmethylated H3K79 was the most predominant form followed by mono- and dimethylated H3K79, 
whereas trimethylated H3K79 was not identified. Leroy and co-workers reported similar results. They 
quantified by mass spectrometry the same histone residue in human cells and found that the H3K79 
methylation pattern was: 77% of H3K79, 20% of H3K79me1, 2.5% of H3K79me2 and H3K79me3 was not 
detected (LeRoy et al. 2013). Unmodified H3K79 is the most abundant form found in human cells 
(Garcia et al. 2005; Thomas et al. 2006).  
It has been suggested that methylation of newly synthesized H3K79 occurs during S phase or right 
after (Sweet et al. 2010). Additionally, several researchers found that abundances of monomethylation 
on the “new” (newly synthesized) H3K79 are lower than abundances of monomethylated H3K79 on 
“old” (pre-existing) histones after S phase (Scharf et al. 2009a; Sweet et al. 2010). Moreover, Sweet 
and co-workers indicated that in human cells, unmodified K79 of “old” histones H3 are monomethylated 
at the same rate (slow rate) than monomethylation of K79 of “new” histones H3. Similar situation occurs 
for dimethylation of “new” and “old” H3K79, but the rate of dimethylation lysine is slower than H3K79 
monomethylation (Sweet et al. 2010). Then, the authors suggested that considering that “old” H3K79 
are mono- and di-methylated at the same rate that the “new” ones, there must exist a structural change 
of the nucleosome during the cell cycle. They suggested that either it exists an alteration on the 
localization of old nucleosomes (old nucleosomes do not go back to the same loci) or an alteration of 
mono- or di-methylation H3K79 (for example, old un- or mono-methylated H3K79 gets mono- or di-
methylated after S phase) (Sweet et al. 2010). Together, these abovementioned reports clarify the 
results obtained in the present study, low abundances of H3K79me1/me2. Both H3K79me1 and H3K79me2 
are known to be associated with transcriptionally active chromatin, and once histones are newly 
synthesized, histones need to be modified to further packed the nucleosomes and modulate the 
chromatin. Therefore, histone marks for transcriptionally active chromatin need to be reduced to ensure 
correct packaging of chromatin.  
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Figure 3.35. Relative quantification of methylated lysine 79 of histone H3 in human cell lines. Abundances 
(in %) of methylation levels of H3K79 (EIAQDFK79TDLR) in MCF-7 (Figure A), in MDA-MB231 (Figure B), in Hela 
(Figure C), and in HeK-293T (Figure D). Three biological replicates of proliferating cells (orange bars) are compared 
with three biological replicates of confluent cell (yellow bars). Error bars represent standard deviation (<5%) of 
biological replicates. Propionylated, mono- and di-methylated lysine residues are abbreviated as Kpr, Kprme1 and 
Kme2, respectively.  
 
 
e. Quantification of H4K5K16 acetylation levels in Human cell lines 
Relative quantification of acetylated K5, K8, K12 and K16 of H4 are shown in Figure 3.36. No significant 
changes (>2 fold) were found between proliferating and confluent cells. The most predominant form of 
the peptide GK5GGK8GLGK12GGAK16R (H4K5K16) was the non-acetylated H4K5K16 with abundances 
of 50% approximately. It is an expected result because acetylation is a well-known histone mark 
associated to euchromatin. This histone PTM neutralizes the charges of histones, and therefore the 
interactions between DNA and the proteins (histones) are disrupted. Consequently, the nucleosome 
loss compaction and an open chromatin structure is formed (Kouzarides 2007). Thus, considering that 
after replication the new histones need to be packed to further modulate chromatin, it is important that 
histone marks for euchromatin (like acetylated H4K5K16) maintain low levels. 
A B 
C D 
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Monoacetylated H4K5K16 was found to be the second most abundant modification state in the peptide 
GK5GGK8GLGK12GGAK16R (Figure 3.36). This peptide possesses four putative lysine residues to be 
monoacetylated, but only three isoforms were identified (as shown in Figure 3.37): H4K8ac, H4K12ac, 
and H4K16ac. Among these three detected isomers, H4K16ac was the most abundant isoform. 
Additionally, the abundance on monoacetylated peptide (shown as “1xAc” in the Figure 3.36) reported 
in Figure 3.36 includes the abundances of all three detected isomers (H4K8ac, H4K12ac, and H4K16ac). 
It was unexpected the high contribution of monoacetylated H4K5K16, and specifically H4K16ac (about 
40% of abundance). The reason of this unexpected result is because H4K16ac is a well-known histone 
mark, which produces an structural effect in chromatin, contributing to its decondensation (Shogren-
Knaak 2006). However, this unexpected result could be answered by Robin and collaborators report. 
Robin and co-workers described an alternative function for H4K16ac. They suggested that, besides 
other non-histone proteins, the histone methyltransferases Suv39h1 and G9a associate to H4K16ac in 
a replication-dependent manner, because this particular residue (K16) is the first to be acetylated after 
replication (but become deacetylated quickly after incorporation into chromatin), and both enzymes 
(Suv39h1 and G9a) are also related to DNA replication (Robin et al. 2007). However, the function of 
this particular association is not reported.  
Jasencakova and co-workers indicated that H4K5ac abundances are at the minimum level during mid-
S phase in the cell cycle (Jasencakova 2000), which could explain why this isoform was not identified 
in the quantification of monoacetylated GK5GGK8GLGK12GGAK16R in this study. The authors also 
indicated that by fluorescence in situ hybridization or DAPI staining could detect an increase of 
hyperacetylation states of GK5GGK8GLGK12GGAK16R (di- tri- and tetra-acetylated peptide) during 
mitosis, which start to decrease from G1 to mid-S, and to further increase again from late S onward 
(Jasencakova 2000).  
Finally, similar histone PTM pattern were identified in the rest of H4 tail, as shown in Suppl. Table 5.4.5.  
 
Together, during quantification of acetylated H4K5K16 was found that: 
 Unacetylated GK5GGK8GLGK12GGAK16R is the most abundant peptide. It is an expected result 
because during replication transcriptionally active histone marks, like acetylated H4K5K16, need to be 
reduced to ensure correct packaging of newly synthesized histones. 
 The second most abundant peptide was monoacetylated H4K5K16, which comprises the 
isoforms H4K8ac, H4K12ac and H4K16ac, being monoacetylated H4K16 the most abundant. This result 
was unexpected, because transcriptionally active histone marks need to be reduced. However, it was 
reported an alternative function for this histone modification. The histone methyltransferases Suv39h1 
and G9a (enzymes that catalyzes methylation at H3K9 and H3K27) associate firstly with H4K16ac, in a 
replication-dependent manner (Robin et al. 2007). 
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 The hyperacetylated GK5GGK8GLGK12GGAK16R peptide (di- tri- and tetra-acetylated peptide) 
showed low abundances. As mentioned, transcriptionally active histone marks need to be reduced, 
therefore low abundances of di- tri- and tetra-acetylated peptide is an expected result.  
 Considering the abundances of un-, mono-, di-, tri-, and tetra-acetylated 
GK5GGK8GLGK12GGAK16R can be deduced that during proliferation cells were mostly at the S phase, 
and arrested cells (confluent cells) were at the M phase early G1 phase. Jasencakova and co-workers 
indicated an increase of hyperacetylated states during mitosis. And although the abundances of 
hyperacetylated H4K5K16 between proliferating and confluent cells did not show changes of more than 
2-fold, there is a slight increase of these states in confluent cells. Moreover, it is worth to mention that 
immortalized cells indeed present low abundances of these transcriptionally active histone marks 
compared to normal cells (Cuomo et al. 2011).  
 
 
Figure 3.36. Relative quantification of acetylated lysine 5, 8, 12 and 16 of histone H4 in human cell lines. 
Abundances (in %) of acetylation levels of H4K5K8K12K16 (GK5GGK8GLGK12GGAK16R) in MCF-7 (Figure A), in 
MDA-MB231 (Figure B), in Hela (Figure C), and in HeK-293T (Figure D). Three biological replicates of proliferating 
cells (gray bars) are compared with three biological replicates of confluent cell (green bars). Error bars represent 
standard deviation (<5%) of biological replicates. Acetylated lysine residues are abbreviated as Ac, and the 
frequency of acetylation in the peptide GK5GGK8GLGK12GGAK16R is abbreviated as 1xAc, 2xAc, 3xAc and 4xAc 
for mono-, di-, tri- and tetra-acetylated lysine residues, respectively. “Unmodified” corresponds to non-acetylated 
peptide. 
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Figure 3.37. Fragmentation spectra of acetylated lysine 8, 12 and 16 of histone H4 in human cell lines. High 
resolution MS/MS of isomeric peptide GK5GGK8GLGK12GGAK16R in human cell lines. Acetylation was identified in 
lysine 8, 12 and 16. y and b ions are assigned. In red and brown are assigned the ions corresponding to isomers. 
Furthermore, the immonium ions are indicated as Im(Kpr) and Im(Kac) for propionylated and acetylated lysine 
residues, respectively. 
 
 
f. Quantification of histone PTMs of H2A, H2B and histone variants in human cell lines 
Histone post-translational modification of histones H2A, H2B and histone variants are less studied than 
H3 and H4 histone PTMs. Most reports are related to replacement of canonical histones by specific 
histone variants (non-canonical histones) influencing chromatin states (McKittrick et al. 2004; Bonenfant 
2005; Bonisch and Hake 2012). These non-canonical histones may vary in only few amino acids (like 
H3 variants) or many (like H2A variants). Moreover, histone PTMs, as it has been explained along this 
thesis, can also influence chromatin states, either by heterochromatin or euchromatin formation. Mass 
spectrometry has the advantage to analyze all known and unknown histone PTMs in a single 
experiment, therefore in this work histone PTMs of H2A, H2B and histone variants in proliferating and 
confluent human cell lines (MCF-7, MDA-MB231, HeK-293T and HeLa) are reported.  
More than 35 modified peptides were identified in total regarding H2A, H2B and histone variants in 
proliferating and confluent MCF-7, MDA-MB231, HeK-293T and HeLa. The histone variants identified 
in these human cell lines were H2A.1C, H2A.1B, H2A.2B, H2A.X, H2A.V, H2A.Z, H2B.FS, H2B.3B, and 
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H3.3. Variations in amino sequences of H2A, H2B and H3 are shown in Figure 3.38a-c, respectively. 
The amino acids sequences shared among H2A and its variants are 73 positions, while in H2B and its 
variants are 102 positions shared, finally 127 positions are shared between H3 and its variants. The 
conserved amino acids are highlighted by an asterisk (*) in Figure 3.38a-c.  
 
 
Figure 3.38. Alignment of amino acid sequences of H2A, H2B and their respective variants. a) Alignment of 
amino acid sequences of detected canonical H2A (H2A1) and its respective variants: H2A1C, H2A1B, H2A2B, 
H2AX, H2AV, and H2AZ. b) Alignment of amino acid sequences of detected canonical H2B (H2B1 and H2B2) and 
their respective variants: H2BFS, and H2B3B. c) Alignment of amino acid sequences of detected canonical H3 and 
its variant H3.3. 
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Quantification of histone PTMs in H3 variant 
H3.3 possesses four amino acids different from canonical H3 (H3.1), as shown in figure 3.38c. This 
histone variant was reported to be involved in transcriptional regulation (Ahmad and Henikoff 2002). 
Incorporation of canonical H3 has been observed to be in a replication-dependent manner, because 
canonical H3 are incorporated into nucleosome after S phase. However, H3.3 was reported to be 
incorporated into nucleosomes at transcribed genes in a replication-independent manner, because this 
histone variant can be incorporated at any phase during the cell cycle (Ahmad and Henikoff 2002).  
Besides incorporation of the histone variant H3.3 into the nucleosome to modulate chromatin to an open 
structure and facilitates transcription, histone post-translational modifications of histone variant can also 
produce an effect in chromatin structure. Therefore, in this thesis relative quantification of histone PTMs 
of H3.3 in proliferating and confluent MCF-7, MDA-MB231, HeK-293T and HeLa are shown. Differences 
in histone PTM abundances of human cell lines during proliferation and confluence (arrested cells) may 
give insights in how histone PTM profiles change during cell cycle, or when cells exit the cell cycle. In 
Figure 3.39 the abundances of the tryptic peptide KSAPS31TGGVKKPHR are shown, which differs from 
canonical H3 in the amino acid 31 (Alanine in H3, and Serine in H3.3). Three different histone PTMs 
were identified in this particular peptide, K27 dimethylation, K27 trimethylation and K27 
dimethylation/K36 monomethylation. Dimethylated K27 was the most abundant histone PTM detected 
in the peptide KSAPSTGGVKKPHR in H3.3 (H3.3 K27me2) in MCF-7, MDA-MB231, HeK-293T and 
HeLa, being the only histone PTM detected in proliferating and confluent MDA-MB231. It was an 
unexpected result, because H3.3 is involved in active transcriptional regulation, and therefore it was 
expected to identify any histone mark related to H3.3 function, like acetylated H3.3K27 or trimethylated 
H3.3K36. However, Santenard and co-workers analyzed mouse embryos and found that 
heterochromatin formation requires specifics PTMs in histone variants. They observed di- and tri-
methylation of H3.3 K27 in paternal chromatin, indicating that these histone modifications (H3.3 K27me2 
and H3.3 K27me3) can mediate heterochromatin formation in absence of H3K9me3 (Santenard et al. 
2010). Therefore, a hypothesis can be generated considering Santenard and co-workers report. 
Predominance of dimethylated H3.3K27 could be related to heterochromatin formation since (regarding 
quantification of H3K9me3) trimethylation H3K9 was not detected in any human cell line studied in this 
thesis (MCF-7, MDA-MB231, HeK-293T and HeLa). 
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Figure 3.39. Relative quantification of methylated lysine 27 and 36 of histone H3.3 in human cell lines. 
Abundances (in %) of methylation levels of H3.3 K27K36 (K27SAPSTGGVK36KPHR) in MCF-7 (Figure A), in MDA-
MB231 (Figure B), in Hela (Figure C), and in HeK-293T (Figure D). Three biological replicates of proliferating cells 
(bue bars) are compared with three biological replicates of confluent cells (orange bars). Error bars represent 
standard deviation (<5%) of biological replicates. Methylated lysine residues are abbreviated as prme1, me2 and 
me3 for mono-, di, and tri-methylated lysine.  
 
 
H2A, H2B and their variants 
Analysis of global levels of histone post-translational modifications is very important for better 
understanding of chromatin structure dynamics, and to identify a putative function for a particular or a 
group of histone PTMs, as it has been explained along this thesis. With this information (global levels 
of histone PTMs) is provided a first knowledge of histone PTM influences over chromatin structure in 
proliferating and confluent HeK-293T, HeLa, MDA-MB231, and MCF-7.  
In order to complement the analysis of histone PTM of H3, H4 and H3.3, histones H2A, H2B and their 
variants (H2A.1C, H2A.1B, H2A.2B, H2A.X, H2A.V, H2A.Z, H2B.FS, H2B.3B) were also subjected to 
bottom-up MS approach. About 30 modified tryptic peptides were identified in H2A, H2B, and their 
variants in proliferating and confluent HeK-293T, HeLa, MDA-MB231, and MCF-7, as shown in Suppl. 
Table 5.4.1-4, respectively.  
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Quantification of histone PTMs of H2A and its variants:  
In general, no significant changes between proliferating and confluent HeK-293T, HeLa, MDA-MB231, 
and MCF-7 were observed, as shown in Table 3.7. In H2A.1 and H2A.X the only natural histone PTM 
identified in the four human cell lines was acetylated lysine 5 with abundances of 10% approximately 
(as shown in Table 3.7a & e). Zhang and co-workers reported hyper-acetylation of H2A, H2AZ and H4 
in Tetrahymena thermophila. The lysine residues of H2A and H2A.Z K5, K9, K13 and K15 were 
acetylated when abundances of H3K27 methylation decreased (Zhang et al. 2014). In S.pombe and 
S.cerevisiae the same lysine residue, K5 (in mammalian), together with lysine 9 (in mammalian) of H2A 
were acetylated (Tannous and Teng 2011). The authors also indicated that acetylated K5 has been 
associated to efficient silencing of genes, however, they recommended to further investigate about this 
putative biological function (Tannous and Teng 2011).  
Moreover, monomethylated H2A.Z K31 was observed only in confluent HeK-293 and MCF-7 with 
abundances of 18 and 27%, respectively (Figure 3.40). Recently, this histone modification was also 
identified for the first time in human sperm, however the authors do not indicate a possible role for 
H2A.ZK31me1 (Luense et al. 2016). The histone variant H2A.Z is associated with gene repression, 
however the H2A variant was reported to be associated with gene activation when K14 was acetylated 
in yeast and in Toxoplasma gondii (Millar 2006; Nardelli et al. 2013).  
Taken together and regarding the few reports about histone PTMs in H2A and variants, it can be 
summarized that in HeK-293T, HeLa, MDA-MB231, and MCF-7 acetylated K5 of H2A and H2A.X can 
also be associated with repressive state of chromatin, as reported by (Tannous and Teng 2011). And 
although biological function for H2A.ZK37 monomethylation has not been reported yet, it can be 
assumed that might be also related to repressive state of chromatin, and specifically in arrested HeK-
293T and MCF-7. 
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Table 3.7. Relative quantification of histone PTMs in H2A. Listed are the modified tryptic peptides detected by 
LC-MS/MS of H2A (Table a), H2A.1C (Table b), H2A.1B (Table c), H2A.2B (Table d), H2A.X (Table e), H2A.V 
(Table f) and H2A.Z (Table g). Standard deviation corresponds to three biological replicates.  
Table a) histone PTM abundances of H2A.1 HEK-293T  HeLa MDA-MB231 MCF-7 
Peptide sequence 
Abbreviated 
name 
m/z (2+) 
Prolif. 
(in %) 
conf. 
(in %)  
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
GK5QGGK9AR K5pr-K9pr 485.2756 90±1 87±2 93±1 92±2 90±1 88±1 92±1 97±1 
GK5QGGK9AR K5ac-K9pr 478.2697 10±1 12±2 7±1 7±2 10±1 11±1 8±1 3±1 
AK13AK15TR K13pr-K15pr 421.7585 100±0 100±0 100±0 100±0 100±0 100±0 100±0 100±0 
K36GNYAER K36pr 503.2535 100±0 100±0 100±0 100±0 100±0 100±0 100±0 100±0 
AGLQFPVGR  500.7815 100±0 100±0 100±0 100±0 100±0 100±0 100±0 100±0 
DNK74K75TR K74pr-K75pr 465.2552 100±0 100±0 100±0 100±0 100±0 100±0 100±0 100±0 
HLQLAIR  453.7787 100±0 100±0 100±0 100±0 100±0 100±0 100±0 100±0 
Table b) histone PTM abundances of H2A.1C HEK-293T  HeLa MDA-MB231 MCF-7 
Peptide sequence 
Abbreviated 
name 
m/z (2+) 
Prolif. 
(in %) 
conf. 
(in %)  
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
AK13AK15SR K13me3-K15pr 407.7423 1±1 0.4±0 
0.3±0 0±0 0.±0 0±0 0±0 0±0 
AK13AK15SR K13pr-K15pr 414.7508 99±1 99±0 
99±0 99±2 99±0 99±0 98±1 99±0 
AK13AK15SR K13pr-K15ac 407.7423 
0±0 0±0 0.1±0 0.3±0 0.4±0 0.3±0 0.4±0 0.4±0 
AK13AK15SR K13ac-K15pr 407.7423 
0±0 0.3±0 0.3±0 1.1±1 0.3±0 0.2±1 1.1±1 0.6±0 
NDEELNK95LLGR K95pr 706.8724 100±0 100±0 
100±0 100±0 100±0 100±0 100±0 100±0 
Table c) histone PTM abundances of H2A.3  HEK-293T  HeLa MDA-MB231 MCF-7 
Peptide sequence 
Abbreviated 
name 
m/z (2+) 
Prolif. 
(in %) 
conf. 
(in %)  
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
K36GNY39SER K36 pr-Y39pr 511.2509 100±0 100±0 
100±0 100±0 100±0 100±0 100±0 100±0 
Table d) histone PTM abundances of H2A.2B HEK-293T  HeLa MDA-MB231 MCF-7 
Peptide sequence 
Abbreviated 
name 
m/z (2+) 
Prolif. 
(in %) 
conf. 
(in %)  
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
HLQLAVR  446.7717 100±0 100±0 100±0 100±0 100±0 100±0 100±0 100±0 
Table e) histone PTM abundances of H2A.X HEK-293T  HeLa MDA-MB231 MCF-7 
Peptide sequence 
Abbreviated 
name 
m/z (2+) 
Prolif. 
(in %) 
conf. 
(in %)  
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
GK5TGGK9AR K5ac-K9pr 464.7647 8±1 9±2 
6±1 5±1 9±1 10±0 8±1 6±2 
GK5TGGK9AR K5pr-K9pr 471.7708 92±1 91±0 
94±1 95±1 91±1 90±0 92±1 94±2 
K36GHYAER K36pr 514.7614 
100±0 100±0 100±0 100±0 100±0 100±0 100±0 100±0 
Table f) histone PTM abundances of H2A.V HEK-293T  HeLa MDA-MB231 MCF-7 
Peptide sequence 
Abbreviated 
name 
m/z (2+) 
Prolif. 
(in %) 
conf. 
(in %)  
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
HLK37TR K37pr 383.7327 
100±0 100±0 100±0 100±0 100±0 100±0 100±0 100±0 
TTSHGR  385.6928 100±0 100±0 100±0 100±0 100±0 100±0 100±0 100±0 
Table g) histone PTM abundances of H2A.Z HEK-293T  HeLa MDA-MB231 MCF-7 
Peptide sequence 
Abbreviated 
name 
m/z (2+) 
Prolif. 
(in %) 
conf. 
(in %)  
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
HLK37SR K37pr 376.7242 
100±0 82±3 100±0 99±0 100±0 100±0 100±0 73±1 
HLK37SR K37prme1 383.7327 
0±0 18±3 0±0 0.3±0 0±0 0±0 0±0 27±1 
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Figure 3.40. Relative quantification of methylated lysine 37 of histone H2A.Z in human cell lines. 
Abundances (in %) of methylation levels of H2A.Z K37 (HLK37SR) in MCF-7 (Figure A), in MDA-MB231 (Figure B), 
in Hela (Figure C), and in HeK-293T (Figure D). Three biological replicates of proliferating cells (blue bars) are 
compared with three biological replicates of confluent cells (orange bars). Error bars represent standard deviation 
(<5%) of biological replicates. Methylated lysine residue is abbreviated as prme1 for monomethylated lysine. And 
Kpr corresponds to unmodified lysine residue. 
 
 
Quantification of histone PTMs of H2B and its variants:  
Analyzing histone PTMs of H2B and its variants in the four human cell lines did not result in a complex 
pattern, in fact no endogenous histone modification (like acetylation and/or methylation) was identified 
(as shown in Table 3.8). Although in the next table it is reported trimethylated K66 of H2B, its abundance 
is below 0.5% and therefore the contribution of H2B K66me3 is meaningless. Wang and co-workers 
reported acetylated K5, K10 and K15 of H2B in S.pombe. However, they do not know the exact 
biological function of acetylated K5, K10 and K15 of H2B (Tannous and Teng 2011). Moreover, it was 
reported that acetylation of the previous mentioned lysine residues of H2B in S.cerevisiae are 
associated with active transcription of genes involved in NAD biosynthesis and vitamin metabolism 
(Parra et al. 2006). Additionally, Bonnenfant and colleagues showed changes of histone PTMs and 
 
132 
 
histone variants during cell cycle in HeLa cells. They reported that the histone variant H2B.A was mostly 
mono- and di-acetylated in G1 phase, while in G2/M phase acetylated H2B.A was not identified. Finally, 
they concluded that acetylation of H2 variants decrease in the mitotic phase (Bonenfant et al. 2007).  
Summarizing the above mentioned reports, it was expected to identify acetylated lysine residues, 
however no histone PTM was identified neither in canonical H2B (H2B.1) nor in the detected H2B 
variants. The results obtained in the proliferating and confluent four human cell lines during this study 
could indicate that human cells were mostly in G2/M phase, or perhaps the biological function of these 
particular histone variants, H2B.FS and H2B.3B, during the cell cycle is different. Therefore, a more 
exhaustive investigation is necessary to identify the putative biological function of H2B.FS and H2B.3B. 
 
Table 3.8. Relative quantification of histone PTMs in H2B. Listed are the modified tryptic peptides detected by 
LC-MS/MS of H2B.1B (Table a), H2B.FS (Table b) and H2B.3B (Table c). Standard deviation corresponds to three 
biological replicates.  
Table a) histone PTM abundances of H2B.1B HEK-293T  HeLa MDA-MB231 MCF-7 
Peptide sequence 
Abbreviated 
name 
m/z (2+) 
Prolif. 
(in %) 
conf. 
(in %)  
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
LAHYNK66R K66pr 535.2919 99±0 99±0 100±0 99±0 99±0 99±0 99±0 99±0 
LAHYNK66R K66me3 528.3044 0.4±0 0.3±0 0±0 0.3±0 0.3±0 0.3±0 0.4±0 0.3±0 
IAGEASR  380.2032 100±0 100±0 100±0 100±0 100±0 100±0 100±0 100±0 
STITSREIQTAVR  759.4175 100±0 100±0 100±0 100±0 100±0 100±0 100±0 100±0 
EIQTAVR  436.7433 100±0 100±0 100±0 100±0 100±0 100±0 100±0 100±0 
Table b) histone PTM abundances of H2B.FS HEK-293T  HeLa MDA-MB231 MCF-7 
Peptide sequence 
Abbreviated 
name 
m/z (2+) 
Prolif. 
(in %) 
conf. 
(in %)  
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
LPHY64NK66R K66pr-Y64pr 548.301 100±0 100±0 100±0 100±0 100±0 100±0 100±0 100±0 
Table c) histone PTM abundances of H2B.3B HEK-293T  HeLa MDA-MB231 MCF-7 
Peptide sequence 
Abbreviated 
name 
m/z (2+) 
Prolif. 
(in %) 
conf. 
(in %)  
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
prolif. 
(in %) 
conf. 
(in %) 
IASEASR  395.21 100±0 100±0 100±0 100±0 100±0 100±0 100±0 100±0 
EVQTAVR  429.7377 100±0 100±0 100±0 100±0 100±0 100±0 100±0 100±0 
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Chapter 4: Concluding remarks 
 
The main aim for this dissertation was to obtain the histone PTM profiles by quantifying acetylated and 
methylated lysine of histones H3, H4, H2A and H2B in different model systems using a bottom-up MS 
approach. Although all histone PTMs are important, here only lysine methylation and acetylation were 
analyzed because they are known to be related with transcriptional activities.  
 
To achieve the main aim, it was first needed to develop an accurate methodology to derivatize histone 
lysine residues, here by using propionic anhydride. In several reports propionic anhydride has been 
used to derivatize histones, however, all of them share the same problems: incomplete reactions and 
undesired esterification (side reaction). The main consequences of incomplete and side reactions are, 
unreliable quantification of histone PTMs and misinterpretation of undesired esterification as 
endogenous histone modification. Therefore, it was required to develop a new protocol for histone 
derivatization. Besides propionic anhydride, a less reactive alcohol like isopropanol and a more basic 
buffer like triethylamine were used to derivatize histones. With this new protocol about 95% of complete 
reaction on histone synthetic peptides was achieved, and almost no noticeable undesired esterification 
(<2%) was identified. The new methodology demonstrated to be reproducible (R2 >0.98) for hydrophilic 
peptides like methylated H3K4 (TKXQTAR), and sensible (quantification at the attomole level, 0.116 
fmol). Moreover, it demonstrated to have a high dynamic range with more than 5 orders of magnitude.  
The new methodology was also applied to histone protein standard from Calf Thymus, and 
propionylated tryptic peptides of H3, H4, H2A and H2B were analyzed by LC-MS/MS. The specific aim 
for this experiment was to verify the yield of histone lysine derivatization in histone proteins. As 
expected, no noticeable undesired reactions were identified, like incomplete reaction and esterification 
at the C-terminal arginine. Unpredictably, another side reaction was identified, which was serine, 
threonine and tyrosine O-propionylation. Hydroxyl groups from side chains of S, T and Y can also act 
as nucleophile, although they are not better nucleophiles than amino groups can also interact with 
propionylation reagent. To solve this problem, some reports recommended the use of isopropanol and 
ammonium bicarbonate to reduce this side reaction, however, the levels of S, T and Y propionylation 
were about 15% of abundance. The levels of S, T and Y propionylation with the methodology developed 
during this thesis were similar (about 16%). Thus, considering that this new side reaction was not 
possible to reduce it more, their contribution was considered for final results preventing then to affect 
quantification of histone PTMs.  Finally, it can be assumed that the aim to develop an accurate 
methodology for histone lysine derivatization and for quantification of histone lysine acetylation and 
methylation levels using a bottom-up MS approach was achieved. 
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This new methodology was then applied to analyze histone H3 PTM profiles in S.cerevisiae. The aim 
of these experiments was to identify changes in the histone H3 PTM pattern in budding yeast, when a 
member of Set1C (or COMPASS) complex is altered. The Set1C member Sdc1 was subjected to 
several mutations, like deletion, amino acid substitution and specific motif deletion. These mutations 
showed a dramatic effect over H3K4me2/me3 levels. This reduction was produced because the interaction 
between Sdc1-Bre2 was disrupted, therefore this fail in the heterodimer (Sdc1-Bre2) impeded the 
association with Set1 to further methylate H3K4. Monomethylation levels of H3K4 were not affected as 
H3K4me2/me3 levels, which indicated that another Set1C member is involved. Considering previous 
reports, it could be that Spp1 associates with Bre2. Moreover, no significant changes were observed in 
the histone PTM pattern of H3K9K14, H3K18K23 and H3K27K36 in wild type and Sdc1 mutations. 
H3K9K14 and H3K18K23 were identified as acetylated forms, while H3K27K36 was found to be 
methylated mostly. Considering literature revision, trimethylation of H3K4 (mediated by Set1C) should 
affect methylated or acetylated lysine residues levels, therefore it was assumed that an alternative 
mechanism was involved to explain the same histone PTM pattern in Sdc1 mutations and wild type. 
Either the low levels (<1%) of H3K4me3 are sufficient to recruit non-histone proteins of HAT complexes 
or another histone PTM is also involved in recruitment of HAT. To verify these putative hypotheses 
more experiments will be required. Additionally, reduction on H3K4me2/3 levels affect methylation of 
H3K79. Considering that H2BK123ub is required for H3K4 methylation by Set1C and H3K79 methylation 
by Dot1, it was assumed that fails in H3K4 methylation by Set1C complex allowed to H2BK123ub to 
interact with Dot1 and trimethylate H3K79 in sdc1∆, sdc1* and DPY30∆. Finally, it can be concluded 
that several changes in the H3 PTM pattern in budding yeast were produced by deletion or specific 
mutation of the Set1C member Sdc1. Specifically, the methylated H3K4 and H3K79 pattern. In addition, 
acetylated and methylated H3K9, K27 and K36 PTM patterns were invariable, therefore it was assumed 
that an alternative mechanism could be involved that needs to be investigated.  
 
Additionally, the histone (H3, H4, H2A and H2B) PTM profiles of mESCs grown in serum- and in 2i-
containing media (serum and 2i samples) were obtained. Several reports indicated that both media are 
considered to be suitable to maintain pluripotency of mESCs. However, some authors recently reported 
that besides to maintain pluripotency of cells, some perturbations were observed when mESCs were 
grown in serum-containing media. Then, the aim was to identify changes in the histone PTM patterns 
when mESCs are grown in serum- and 2i- containing media. Relative quantification of PTMs of H4, 
H2A, H2B and histone variants by LC-MS/MS showed no significant differences between both serum 
and 2i samples, which might indicate that culture media do not affect abundances of PTMs of H4, H2A, 
H2B and histone variants. However, significant changes were identified in H3 PTM profiles in serum 
and 2i samples. Levels of heterochromatin marks like H3K9me3 and H3K27me3 were higher in serum 
sample, while euchromatin marks like mono- and di-acetylated H3K9K14 were more abundant in 2i 
sample. Regarding some reports and MS data obtained during these experiments, it was assumed that 
two different states of pluripotency for mESCs might exist, because histone marks of heterochromatin 
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structures were more abundant in serum sample, while histone marks for open chromatin structures 
were more abundant in 2i sample. In addition, several modified peptides were identified for the first time 
in this work, which were shared in both samples, and monomethylated H2A.Z K37 was identified in 
serum sample only. Finally, it was concluded that serum- and 2i- containing media modified histone H3 
PTM pattern only, which could indicate two possible states in pluripotent mESCs. 
 
Finally, the histone (H3, H4, H2A and H2B) PTM patterns of proliferating and confluent human cell lines, 
specifically HeK-293T, HeLa, MCF-7 and MDA-MB231, were obtained. The aim of these experiments 
was to identify changes in the histone PTM profiles of proliferating and confluent HeK-293T, HeLa, 
MCF-7 and MDA-MB231. Proliferation represented cells during cell cycle while the cell cycle exit was 
represented by confluent cells. It was desired to analyze proliferating and confluent human cell lines 
because in order to understand the maintenance of chromatin structures, it is important to understand 
histone modification patterns during cell cycle. Methylated H3K4 and acetylated H3K18K23 patterns 
did not show changes in both proliferation and confluence. Both, H3K4me and acetylated H3K18K23, 
are well known as histone marks for transcriptionally active chromatin, which need to maintain low levels 
during replication to ensure correct packaging of nucleosomes. H3K9 dimethylation was the most 
predominant histone modification in proliferating and confluent HeK-293T, HeLa, MDA-MB231 and 
MCF-7. Two possible pathways exist to form H3K9me2, synthesis from a preexisting monomethylated 
H3K9 during G1 phase; and synthesis from an unmodified H3K9 during G2 and M phases. It was 
expected to find high abundances of H3K9 trimethylation in all four human cell lines because it is a well-
known histone mark for heterochromatin, however it was identified only in HeK-293T with low 
abundance (<2%). Whether H3K9 dimethylation could work as substrate for histone methyltransferases 
in these four human cell lines was not studied during this thesis. Moreover, it is reported that 
trimethylation of H3K9 on newly deposited histones is slow, because it prevents the condensation of 
chromatin prematurely. Moreover, dually modified KSTGGKAPR peptides were identified, like 
H3K9me2K14ac and H3K9me3K14ac. The histone methyltransferase G9a was reported to dimethylate 
H3K9 preferentially when the proximal lysine (K14) was acetylated. Whether the histone 
methyltransferase Suv39h1/h2 has the same preferences as G9a is not reported so far. Additionally, 
these dually modified peptides are important to define chromatin states, because as these peptides 
present opposing epigenetic functions (histone marks heterochromatin and euchromatin) may act as 
combinatorial switch. It means that dually modified peptides can become either in a transcriptionally 
active (H3K14ac) or repressed (H3K9me2) histone mark depending on the requirements of the cells. 
H3K27 dimethylation was the most predominant histone PTM in proliferating and confluent HeK-293T, 
HeLa, MDA-MB231 and MCF-7. Two different pathways exist to dimethylate H3K27: first, the histone 
methyltransferases (HMTs) bind to H3K27 to dimethylate it, and second, the HMTs transfer one methyl 
group to H3K27, then it releases the histone, and finally HMTs re-bind to methylate for a second time 
this lysine residue. Additionally, monomethylation of H3K27 showed low abundances in all four human 
cell lines. It could be explained because this histone PTM is required for further methylations and higher 
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levels of di- and tri-methylation of H3K27. Therefore, it can be assumed that histone methyltransferases 
(HMTs) used the available monomethylated H3K27 as substrate to form H3K27me2, explaining the low 
levels of H3K27me1. Moreover, H3K27me3 presented also low levels. Two pathways exist to form 
trimethylated H3K27: methylation of the preexisting H3K27me2 during G1 phase, and second, 
trimethylation of the unmodified H3K27 during S and G2/M phases. Therefore, it can be assumed either 
that H3K27me3 formation was not complete when cells were during proliferation and when cells were 
arrested (confluent cells), or the cells reached the steady state of this histone modification.  
Global levels of H3K36 methylation were low compared to H3K27 methylation, which is expected since 
it is a histone mark associated with transcriptionally active chromatin. Moreover, no changes were found 
in the methylated H3K36 pattern in all four human cell lines, because as some reports indicated, this 
histone PTM is cell cycle independent.  
Similar to H3K9K14, dually modified peptides were identified. Hypermethylated states of H3K27K36 
were identified in proliferating and confluent cell lines, like H3K27me1K36me1, H3K27me2K36me2, 
H3K27me1K36me2, and H3K27me2K36me1. These combinations of histone PTMs seem to have a direct or 
indirect functional correlation between EZH2 and NSD1, the two histone methyltransferases related to 
methylation of H3K27 and H3K36, respectively. However, how these functional correlations specifically 
work, is not reported and cannot be concluded from MS data. 
H3K79 methylation patterns did also show no significant changes between proliferating and confluent 
human cell lines. Additionally, it was expected to obtain low levels of H3K79 mono- and di-methylation, 
because these histone PTMs are known to be histone marks for transcriptionally active chromatin. 
Besides, these histone PTMs are cell cycle dependent, and H3K79 slowly gets mono- and di-
methylated. Therefore, two possible mechanisms exist to explain the similar rate of modification, either 
it exists an alteration on the localization of old nucleosomes (old nucleosomes do not go back to the 
same loci) or an alteration of mono- or di-methylation H3K79 (for example, old un- or mono-methylated 
H3K79 gets mono- or di-methylated after S phase). 
H4K5K16 acetylation patterns did also show only few changes in proliferating and confluent human cell 
lines. During analysis of this histone PTM pattern, unmodified H4K5K16 was the most abundant form. 
This result was consistent with what it was expected, because acetylated (mono-, di-, tri-, or/and tetra- 
acetylated) H4K5K16 is a well-known transcriptionally active histone mark. The second most abundant 
histone PTM was monoacetylated H4K5K16, specifically H4K16ac. Although it was not expected to 
identify H4K16ac (or abundant (>30%) H4K16ac), an alternative function might exist for this histone PTM. 
The histone methyltransferases Suv39h1 and G9a (enzymes that catalyzes methylation at H3K9 and 
H3K27) associate firstly with H4K16ac, in a replication-dependent manner. As it has been explained 
along this thesis, the four human cell lines were harvested during proliferation and arrested when 100% 
of confluence was reached. However, it is not possible to determine whether cells were in any specific 
phase during cell cycle. But considering only abundances of hyperacetylated 
GK5GGK8GLGK12GGAK16R, it might be possible to assume that during proliferation cells were mostly 
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at the S phase and arrested cells (confluent cells) were at the M phase early G1 phase. Because during 
mitosis hyperacetylated states increased, while during S phase the same hyperacetylated states 
decreased.  
As explained before, reports about PTMs of histone variants have been mainly related to the biological 
functions of histone variant incorporation to the nucleosome, but histone PTM patterns is scarcely 
known. In proliferating and confluent human cell lines, MCF-7, MDA-MB231, HeK-293T and HeLa, three 
different histone PTMs were identified; K27 dimethylation, K27 trimethylation and K27 
dimethylation/K36 monomethylation. It was unexpected to find a heterochromatin mark (methylated 
H3K27) in a histone variant that is known to be involved in active transcriptional regulation. However, 
an alternative function might exist for H3K27 methylation. H3.3 K27me2 and H3.3 K27me3 could mediate 
heterochromatin formation in absence of H3K9me3. In the four human cell lines H3K9 trimethylation was 
not identified (or with low abundance in a single sample), therefore it could be assumed that H3.3 H27 
methylation can compensate the H3K9 trimethylation absence in the heterochromatin formation.  
PTM pattern of H2A and its variants did show no significant changes between proliferating and confluent 
cells. Regarding histone PTMs of H2A and variants in the four human cell lines analyzed during this 
thesis, and considering also few reports, it could be assumed that in HeK-293T, HeLa, MDA-MB231, 
and MCF-7 acetylated K5 of H2A and H2A.X might be associated with repressive state of chromatin. 
And although biological function for H2A.Z K37 monomethylation has not been reported yet, it might be 
also assumed that H2A.Z K37me1 was related to repressive state of chromatin, and specifically in 
arrested HeK-293T and MCF-7. 
Finally, the histone PTM pattern of H2B and its variants did also show no significant changes. In fact, 
no histone modification was identified in any sample, neither in canonical H2B nor in H2B variants. 
Moreover, the two histone variants identified in the four human cell lines have been poorly studied, 
therefore a more exhaustive investigation is necessary to identify the putative biological function of 
H2B.FS and H2B.3B. 
Taken together, it can be concluded that the proliferating human cell lines MCF-7, MDA-MB231, HeK-
293T and HeLa shared a chromatin state characterized by elevated H3K9me2 and H3K27me2 levels. And 
the confluent human cell lines were also characterized by the same histone PTMs, but with less 
abundances than proliferating cell. Moreover, it can be concluded that to obtain information about 
histone PTM patterns during cell cycle is recommended to concentrate the analysis on methylated and 
acetylated H3K9 and H3K27 patterns, since these residues showed the more variable profiles. Finally, 
the histone PTM patterns obtained in the four human cell lines can be a starting point for future studies 
in the analysis of cells during cell cycle with specific mutation or inhibitors, for better understanding of 
the global and dynamic changes of chromatin states. 
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Chapter 5: Supplemental information 
 
5.1 Development and optimization of LC-MS/MS method for PTM quantification  
Suppl. Figure 5.1.1. Relative quantification of incomplete and side reactions of H3K4 synthetic peptides by direct infusion mass spectrometry. Abundance of incomplete 
and side reactions of H3K4 propionylation, using synthetic peptides. Propionylation was achieved using several mixtures of solvents and buffers, like: methanol/Ammonium 
bicarbonate (MeOH/Ambic), ethanol/Ammonium bicarbonate (EtOH/Ambic); 1-propanol/Ammonium bicarbonate (1-PrOH/Ambic), 2-propanol/Ammonium bicarbonate (2-
PrOH/Ambic), methanol/triethylamine (MeOH/TEA), ethanol/triethylamine (EtOH/TEA); 1-propanol/triethylamine (1-PrOH/TEA), 2-propanol/triethylamine (2-PrOH/TEA). Side 
reactions correspond to esterification of carboxyl-terminal of arginine. Synthetic peptide sequence of H3K4 is TK4QTAR, and several methylation states were used, as mono-, 
di-, tri-, and non-methylated H3K4 (H3K4me1, H3K4me2, H3K4me3, H3K4, respectively). 
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Suppl. Figure 5.1.2. Relative quantification of threonine O-propionylation of the H3 tryptic peptide KQLATKAAR from Calf thymus by LC-MS/MS. Abundance of T22 O-
propionylation (side reaction or Side rxn) in the peptide K18QLAT22K23AAR using propionic anhydride (PAA) in isopropanol as solvent, and as buffers Ambic (orange bar) or TEA 
(yellow bar). Besides, abundance of complete reaction of K18QLATK23AAR propionylation in both, PAA/2-PrOH/Ambic (blue bar) and PAA/2-PrOH/TEA (green bar), mixtures. 
Error bars represent standard deviation of 5 independent replicates. 
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Suppl. Figure 5.1.3. Relative quantification of serine O-propionylation of the H3 tryptic peptide KSAPATGGVKKPHR from Calf thymus by LC-MS/MS. Abundance of 
S28 O-propionylation (Side rxn) in the peptide K27S28APATGGVK36K37PHR using propionic anhydride (PAA) in isopropanol as solvent, and as buffers Ambic (orange bar) or TEA 
(yellow bar). Besides, abundance of complete reaction of K27S28APATGGVK36K37PHR propionylation in both, PAA/2-PrOH/Ambic (blue bar) and PAA/2-PrOH/TEA (green bar), 
mixtures. Error bars represent standard deviation of 5 independent replicates. T32 was not O-propionylated. 
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Suppl. Figure 5.1.4. Relative quantification of tyrosine and threonine O-propionylation of the H3 tryptic peptide YRPGTVALR from Calf thymus by LC-MS/MS. 
Abundance of Y41 and T45 O-propionylation (Side rxn) in the peptide Y41RPGT45VALR using propionic anhydride (PAA) in isopropanol as solvent, and as buffers Ambic (orange 
bar) or TEA (yellow bar). Besides, abundance of complete reaction of Y41RPGT45VALR propionylation in both, PAA/2-PrOH/Ambic (blue bar) and PAA/2-PrOH/TEA (green bar), 
mixtures. Error bars represent standard deviation of 5 independent replicates.  
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5.2. Analysis of modified histone H3 from Saccharomyces cerevisiae (S.cerevisiae) by mass spectrometry. 
Suppl. Table 5.2.1. List of tryptic peptides of purified histone H3 from DPY-30Δ strain (S.cerevisiae). Listed are detected tryptic peptides of H3 by LC-MS/MS. H3 was 
propionylated before and after enzymatic digestion, therefore each listed peptide is propionylated at the N-termini as well. Besides, charges of detected tryptic peptides, observed 
and predicted masses, and delta (in ppm) or mass difference between observed and predicted masses are listed. In addition, detected modifications of K, S, T &/or Y, and mascot 
scores for MS/MS fragmentation spectra are listed. Peptides in red font were detected manually only, verifying their MS/MS spectra. 
 
  
Start-
end  
Peptide sequence  
(N-propionylated already) 
Charge Observed m/z Predicted m/z 
Delta 
(ppm) 
Modification 
Mascot 
score 
3-8 TKQTAR 2+, 1+ 408.7330, 815.4514 815.4501 2 Propionyl (K4) 30 
3-8 TKQTAR 2+, 1+ 415.7404, 829.4662 829.4658 1 Propionyl-methyl (K4) 30 
9-17 KSTGGKAPR 2+ 528.2952 1054.5771 -1 Acetyl (K9 or K14), Propionyl (K9 or K14) 58 
9-17 KSTGGKAPR     2 Acetyl (K9 & K14)  
9-17 KSTGGKAPR 2+ 535.3037 1068.5927 0 2 Propionyl (K9 & K14) 38 
18-26 KQLASKAAR 2+ 556.8258 1111.6349 2 2 Acetyl (K18 & K23) 44 
18-26 KQLASKAAR 2+ 563.8329 1125.6506  Acetyl & Propionyl (K18 or K23) 55 
18-26 KQLASKAAR 2+ 570.8392 1139.6662  2 Propionyl (K18 & K23) 43 
27-40 KSAPSTGGVKKPHR 3+ 553.9883 1658.9468 -2 Trimethyl (K27 or K36 or K37), 2 Propionyl (K27 or K36 or K37) 14 
27-40 KSAPSTGGVKKPHR   1658.9104  Acetyl (K27 or K36 or K37), 2 Propionyl (K27 or K36 or K37)  
27-40 KSAPSTGGVKKPHR 3+, 2+ 558.6490, 837.4717 1672.9260 -1 3 Propionyl (K27, K36 & K37) 61 
27-40 KSAPSTGGVKKPHR 3+ 563.3220 1686.9417 1 
Propionyl-methyl (K27 or K36 or K37), 2 Propionyl (K27 or K36 or 
K37) 
15 
27-40 KSAPSTGGVKKPHR 2+ 549.3181 1644.9311 1 Dimethyl (K27 or K36 or K37), 2 Propionyl (K27 or K36 or K37) 16 
27-40 KSAPSTGGVKKPHR 3+ 567.9910 1700.9574 -4 
2 Propionyl-methyl (K27 or K36 or K37), Propionyl (K27 or K36 or 
K37) 
19 
41-49 YKPGTVALR 2+ 586.8374 1171.6588 0 2 Propionyl (K42 & Y41) 46 
53-63 RFQKSTELLIR 3+, 2+ 496.9566, 744.9307 1487.8460 1 Acetyl (K56) 22 
53-63 RFQKSTELLIR 2+ 751. 9374 1501.8616 -1 Propionyl (K56) 42 
54-63 FQKSTELLIR 2+ 666.8797 1331.7449 0 Acetyl (K56) 43 
54-63 FQKSTELLIR 2+ 673.8873 1345.7605 0 Propionyl (K56) 34 
64-69 KLPFQR 2+ 450.7681 899.5229 -1 Propionyl (K64) 22 
73-83 EIAQDFKTDLR 2+ 710.3785 1418.7405 1 Dimethyl (K79) 41 
73-83 EIAQDFKTDLR 2+ 724.3758 1446.7354 1 Propionyl (K79) 68 
73-83 EIAQDFKTDLR 2+ 731.3849 1460.7511 1 Propionyl-methyl (K79) 63 
73-83 EIAQDFKTDLR 2+ 717.3855 1432.7562 0 Trimethyl (K79) 31 
117-128 VTIQKKDIKLAR 2+ 819.0023 1635.9923 -1 3 Propionyl (K121, K122 & K125) 69 
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Suppl. Table 5.2.2. List of tryptic peptides of purified histone H3 from Sdc1*Δ strain (S.cerevisiae). Listed are detected tryptic peptides of H3 by LC-MS/MS. H3 was 
propionylated before and after enzymatic digestion, therefore each listed peptide is propionylated at the N-termini as well. Besides, charges of detected tryptic peptides, observed 
and predicted masses, and delta (in ppm) or mass difference between observed and predicted masses are listed. In addition, detected modifications of K, S, T &/or Y, and mascot 
scores for MS/MS fragmentation spectra are listed. Peptides in red font were detected manually only, verifying their MS/MS spectra. 
 
 
  
Start-
end  
Peptide sequence  
(N-propionylated already) 
Charge Observed m/z Predicted m/z 
Delta 
(ppm) 
Modification 
Mascot 
score 
3-8 TKQTAR 2+, 1+ 408.7321, 815.4514 815.4501 -1 Propionyl (K4) 39 
3-8 TKQTAR 2+, 1+ 415.7404, 829.4662 829.4658 1 Propionyl-methyl (K4) 33 
9-17 KSTGGKAPR 2+ 528.2972 1054.5771 3 Acetyl (K9 or K14), Propionyl (K9 or K14) 49 
9-17 KSTGGKAPR 2+ 521.2879 1040.5614 0 2 Acetyl (K9 & K14) 45 
9-17 KSTGGKAPR 2+ 535.3030 1068.5927 -1 2 Propionyl (K9 & K14) 57 
18-26 KQLASKAAR 2+ 556.8251 1111.6349 1 2 Acetyl (K18 & K23) 51 
18-26 KQLASKAAR 2+ 563.8330 1125.6506 1 Acetyl & Propionyl (K18 or K23) 52 
18-26 KQLASKAAR 2+ 570.8393 1139.6662 -2 2 Propionyl (K18 & K23) 68 
27-40 KSAPSTGGVKKPHR   1658.9468  Trimethyl (K27 or K36 or K37), 2 Propionyl (K27 or K36 or K37)  
27-40 KSAPSTGGVKKPHR 3+ 553.9767 1658.9104 -1 Acetyl (K27 or K36 or K37), 2 Propionyl (K27 or K36 or K37) 16 
27-40 KSAPSTGGVKKPHR 3+ 558.6505 1672.9260 2 3 Propionyl (K27, K36 & K37) 43 
27-40 KSAPSTGGVKKPHR 2+ 844.4786 1686.9417 1 
Propionyl-methyl (K27 or K36 or K37), 2 Propionyl (K27 or K36 or 
K37) 
77 
27-40 KSAPSTGGVKKPHR 2+ 549.3162 1644.9311 -3 Dimethyl (K27 or K36 or K37), 2 Propionyl (K27 or K36 or K37) 18 
27-40 KSAPSTGGVKKPHR 3+ 567.9925 1700.9574 -1 
2 Propionyl-methyl (K27 or K36 or K37), Propionyl (K27 or K36 or 
K37) 
15 
41-49 YKPGTVALR 2+ 586.8377 1171.6588 1 2 Propionyl (K42 & Y41) 53 
53-63 RFQKSTELLIR 3+, 2+ 496.9555, 744.9292 1487.8460 -1 Acetyl (K56) 31 
53-63 RFQKSTELLIR 3+, 2+ 501.6270, 751.9370 1501.8616 -2 Propionyl (K56) 43 
54-63 FQKSTELLIR 2+ 666.8804 1331.7449 1 Acetyl (K56) 46 
54-63 FQKSTELLIR 2+ 673.8883 1345.7605 1 Propionyl (K56) 36 
64-69 KLPFQR 2+ 450.7691 899.5229 1 Propionyl (K64) 22 
73-83 EIAQDFKTDLR 2+ 710.3780 1418.7405 1 Dimethyl (K79) 44 
73-83 EIAQDFKTDLR 2+ 724.3778 1446.7354 4 Propionyl (K79) 64 
73-83 EIAQDFKTDLR 2+ 731.3834 1460.7511 1 Propionyl-methyl (K79) 63 
73-83 EIAQDFKTDLR 2+ 717.3845 1432.7562 1 Trimethyl (K79) 31 
117-128 VTIQKKDIKLAR 2+ 819.0033 1635.9923 0 3 Propionyl (K121, K122 & K125) 68 
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Suppl. Table 5.2.3. List of tryptic peptides of purified histone H3 from Sdc1Δ strain (S.cerevisiae). Listed are detected tryptic peptides of H3 by LC-MS/MS. H3 was 
propionylated before and after enzymatic digestion, therefore each listed peptide is propionylated at the N-termini as well. Besides, charges of detected tryptic peptides, observed 
and predicted masses, and delta (in ppm) or mass difference between observed and predicted masses are listed. In addition, detected modifications of K, S, T &/or Y, and mascot 
scores for MS/MS fragmentation spectra are listed. Peptides in red font were detected manually only, verifying their MS/MS spectra. 
 
 
  
Start-
end  
Peptide sequence  
(N-propionylated already) 
Charge Observed m/z Predicted m/z 
Delta 
(ppm) 
Modification 
Mascot 
score 
3-8 TKQTAR 2+, 1+ 408.7328, 815.4510 815.4501 1 Propionyl (K4) 37 
3-8 TKQTAR 2+, 1+ 415.7404, 829.4662 829.4658 1 Propionyl-methyl (K4) 32 
9-17 KSTGGKAPR 2+ 528.2962 1054.5771 1 Acetyl (K9 or K14), Propionyl (K9 or K14) 51 
9-17 KSTGGKAPR 2+ 521.2880 1040.5614 0 2 Acetyl (K9 & K14) 48 
9-17 KSTGGKAPR 2+ 535.3031 1068.5927 -1 2 Propionyl (K9 & K14) 55 
18-26 KQLASKAAR 2+ 556.8239 1111.6349 -1 2 Acetyl (K18 & K23) 40 
18-26 KQLASKAAR 2+ 563.8327 1125.6506 0 Acetyl & Propionyl (K18 or K23) 57 
18-26 KQLASKAAR 2+ 570.8402 1139.6662 0 2 Propionyl (K18 & K23) 51 
27-40 KSAPSTGGVKKPHR 3+ 553.9901 1658.9468 1 Trimethyl (K27 or K36 or K37), 2 Propionyl (K27 or K36 or K37) 19 
27-40 KSAPSTGGVKKPHR   1658.9104  Acetyl (K27 or K36 or K37), 2 Propionyl (K27 or K36 or K37)  
27-40 KSAPSTGGVKKPHR 2+ 837.4711 1672.9260 1 3 Propionyl (K27, K36 & K37) 62 
27-40 KSAPSTGGVKKPHR 2+ 844.4786 1686.9417 1 
Propionyl-methyl (K27 or K36 or K37), 2 Propionyl (K27 or K36 or 
K37) 
78 
27-40 KSAPSTGGVKKPHR 2+ 823.4763 1644.9311 4 Dimethyl (K27 or K36 or K37), 2 Propionyl (K27 or K36 or K37) 34 
27-40 KSAPSTGGVKKPHR 3+ 567.9914 1700.9574 -3 
2 Propionyl-methyl (K27 or K36 or K37), Propionyl (K27 or K36 or 
K37) 
26 
41-49 YKPGTVALR 2+ 586.8376 1171.6588 0 2 Propionyl (K42 & Y41) 53 
53-63 RFQKSTELLIR 2+ 744.9298 1487.8460 -1 Acetyl (K56) 39 
53-63 RFQKSTELLIR 2+ 751.9368 1501.8616 -2 Propionyl (K56) 44 
54-63 FQKSTELLIR 2+ 666.8799 1331.7449 0 Acetyl (K56) 37 
54-63 FQKSTELLIR 2+ 673.8865 1345.7605 -2 Propionyl (K56) 36 
64-69 KLPFQR 2+ 450.7687 899.5229 0 Propionyl (K64) 23 
73-83 EIAQDFKTDLR 2+ 710.3777 1418.7405 0 Dimethyl (K79) 43 
73-83 EIAQDFKTDLR 2+ 724.3744 1446.7354 -1 Propionyl (K79) 64 
73-83 EIAQDFKTDLR 2+ 731.3817 1460.7511 -2 Propionyl-methyl (K79) 69 
73-83 EIAQDFKTDLR 2+ 717.3857 1432.7562 0 Trimethyl (K79) 30 
117-128 VTIQKKDIKLAR 2+ 819.0017 1635.9923 -2 3 Propionyl (K121, K122 & K125) 57 
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5.3. Quantification of histone post-translational modifications in mouse embryonic stem cells (mESCs) 
Suppl. Table 5.3.1. List of tryptic peptides of histones H4, H2A, H2B and histone variants (HV) identified by LC-MS/MS in mESCs. Listed are histone PTMs detected by 
LC-MS/MS in proliferating and confluent cells. Histones were propionylated before and after enzymatic digestion, therefore each listed peptide is propionylated at the N-termini 
(N-propionylated) as well. Besides, charges of detected tryptic peptides, observed and predicted masses, and mass difference between observed and predicted masses (in Da) 
are listed. In addition, histone modifications of K and mascot scores for MS/MS fragmentation spectra can be found in the following table. 
Protein 
Peptide sequence  
(N-propionylated) 
Charge 
Observed  
m/z 
Predicted  
m/z 
Delta (Da) Modification 
Mascot 
score 
H3.1t KQLATKVAR 2+ 598,8715   Monomethyl (K18), Propionyl (K23)  
H3.1t KQLATKVAR 2+ 598,8715   Monomethyl (K23), Propionyl (K18)  
H3.1t KQLATKVAR 2+ 591,8638   2 Propionyl (K18, K23)  
H4 GKGGKGLGKGGAKR 2+ 768.9465 1535.8784 0.0001 Acetyl & 3 Propionyl (K5, K8, K12, K16)  83 
H4 GKGGKGLGKGGAKR 2+ 747.9249 1493.8314 0.0038 4 Acetyl (K5, K8, K12, K16) 93 
H4 GKGGKGLGKGGAKR 2+ 754.9310 1507.8470 0.0005 3 Acetyl & Propionyl (K5, K8, K12, K16) 79 
H4 GKGGKGLGKGGAKR 2+ 761.9391 1521.8627 0.0009 2 Acetyl & Propionyl (K5, K8, K12, K16) 66 
H4 GKGGKGLGKGGAKR 2+ 775.9538 1549.894 -0.0010 4 Propionyl (K5, K8, K12, K16) 81 
H4 DNIQGITKPAIR   1422.7831  Acetyl (K31)  
H4 DNIQGITKPAIR 2+ 719.4064 1436.7987 -0.0004 Propionyl (K31) 44 
H4 ISGLIYEETR 2+ 618.8273 1235.6397 0.0004  45 
H4 DAVTYTEHAKR 2+ 701.8517 1401.6888 0.0001 Propionyl (K76) 66 
H4 KTVTAMDVVYALKR 2+ 889.9903 1777.9648 0.0012 2 Propionyl (K81, K93), Oxidation (M86) 70 
H2A.1 GKQGGKAR 2+ 485.2709 968.5403 -0.0001 2 Propionyl (K5, K9) 49 
H2A.1 GKQGGKAR 2+ 478.2696 954.5247 0.0000 Propionyl (K5), Acetyl (K9) 45 
H2A.1 AKAKTR 2+ 421.7584 841.5021 0.0000 2 Propionyl (K13, K15) 42 
H2A.1 AKAKTR 2+ 414.7508 827.4865 0.0006 Acetyl (K13), Propionyl (K15) 36 
H2A.1 AKAKTR 2+ 407.7426 813.4708 -0.0001 2 Acetyl (K13, K15) 21 
H2A.1 KGNYAER 2+ 503.2537 1004.4927 0.0001 2 Propionyl (K36, Y39) 45 
H2A.1 AGLQFPVGR 2+ 500.7821 999.5502 -0.0006  58 
H2A.1 DNKKTR 2+ 465.2557 928.4978 -0.0009 2 Propionyl (K74, K75) 36 
H2A.1 DNKKTR 2+ 458.2487 914.4821 0.0007 Acetyl (K74), Propionyl (K75) 30 
H2A.1 HLQLAIR 2+ 453.7791 905.5447 -0.0009  47 
H2A.1C AKAKSR 2+ 414.7508 827.4865 0.0006 2 Propionyl (K13, K15) 41 
H2A.1C AKAKSR 
2+ 407.7426 813.4708 -0.0001 
Propionyl (K13), Acetyl (K15) 
19 
H2A.1C AKAKSR Propionyl (K15), Acetyl (K13)  
H2A.1C NDEELNKLLGR 2+ 706.8728 1411.7307 0.0004 Propionyl (K95) 59 
H2A.3 KGNYSER 2+ 511.2512 1020.4876 0.0002 2 Propionyl (K36, Y39) 45 
H2A2B HLQLAVR 2+ 446.7717 891.5290    
H2A.X GKTGGKAR 2+ 464.7640 927.5138 -0.0004 Propionyl (K9), Acetyl (K5) 53 
H2A.X GKTGGKAR 2+ 471.7718 941.5294 -0.0005 2 Propionyl (K5, K9) 32 
H2A.X KGHYAER 2+ 514.7612 1027.5087 -0.0009 2 Propionyl (K36, Y39) 36 
H2A.V HLKTR 2+ 383.7319 765.4497 -0.0004 Propionyl (K37) 25 
H2A.V TTSHGR 2+ 385.6932 769.3719 -0.0001 Propionyl (S42) 40 
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Table continuation 
H2A.Z HLKSR 2+ 404.7378 807.4603 0.0009 2 Propionyl (K37, S38) 25 
H2A.Z HLKSR 2+ 383.7310 765.4497 -0.0004 Propionyl-methyl (K37) 19 
H2B.1B LAHYNKR 2+ 535.2926 1068.5716 -0.0009 2 Propionyl (K66, Y64) 37 
H2B.1B LAHYNKR 2+ 528.3031 1054.5923 -0.0006 Trimethyl (K66), Propionyl (Y64) 36 
H2B.1B IAGEASR 2+ 380.2033 758.3922 -0.0001  48 
H2B.1B STITSREIQTAVR 2+ 759.4181 1516.8209 0.0007  51 
H2B.1B EIQTAVR 2+ 464.7578 927.5025 -0.0014 Propionyl (T96) 41 
H2B.3B IASEASR 2+ 395.2086 788.4028 -0.0001  44 
H2B.3B EVQTAVR 2+ 429.7377 857.4607 0.0002  49 
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Suppl. Table 5.3.2. Relative quantification of histone H3.1t PTMs identified in serum and 2i samples by LC-MS/MS. Listed are the abundances of histone H3.1t PTMs 
detected by LC-MS/MS in serum and 2i samples. Serum sample corresponds to mESCs grown in serum-containing medium, and 2i sample corresponds to mESCs grown in 2 
inhibitor- (mitogen-activated protein kinase (MeK) and glycogen synthase kinase-3 (Gsk3)) containing medium. Standard deviation represent error between 2 biological replicates. 
Abbreviations: prme1, monomethyl; pr, propionyl. 
H3.1T peptide sequence PTMs Observed mass Serum sample 2i sample 
KQLATKVAR K18prme1-K23pr 598.8715 17 ± 0.2% 12 ± 2.1% 
KQLATKVAR K18pr-K23prme1 598.8715 37 ± 1.5% 34 ± 0.2% 
KQLATKVAR K18pr-K23pr 591.8638 45 ± 1.6% 53 ± 1.8% 
 
Suppl. Table 5.3.3. Relative quantification of histone H4 PTMs identified in serum and 2i samples by LC-MS/MS. Listed are the abundances of histone H4 PTMs detected 
by LC-MS/MS in serum and 2i samples. Serum sample corresponds to mESCs grown in serum-containing medium, and 2i sample corresponds to mESCs grown in 2 inhibitor- 
(mitogen-activated protein kinase (MeK) and glycogen synthase kinase-3 (Gsk3)) containing medium. Standard deviation represent error between 2 biological replicates. ND: no 
detected. Abbreviations: pr, propionyl; ac, acetyl; O, oxidation. 
H4 peptide sequence PTMs Observed mass Serum sample 2i sample 
GKGGKGLGKGGAKR K5-K16 (1xac 3xpr) 768.9457 34 ± 0.1% 31 ± 1.0% 
GKGGKGLGKGGAKR K5-K16 (4xac) 747.9202 1 ± 0.2% 1 ± 0.2% 
GKGGKGLGKGGAKR K5-K16 (1xpr 3xac) 754.9279 5 ± 0.7% 4 ± 1.2% 
GKGGKGLGKGGAKR K5-K16 (2xac 2xpr) 761.9360 14 ± 0.2% 13 ± 0.4% 
GKGGKGLGKGGAKR K5-K16 (4xpr) 775.9515 46 ± 0.6% 51 ± 2.8% 
DNIQGITKPAIR K31pr 719.4033 100 ± 0% 100 ± 0% 
ISGLIYEETR no PTM 618.8246 100 ± 0% 100 ± 0% 
DAVTYTEHAKR K76prY71pr 729.8612 100 ± 0% 100 ± 0% 
KTVTAMDVVYALKR K81pr-K93pr-M86O 889.9877 100 ± 0% ND 
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Suppl. Table 5.3.4. Relative quantification of histone H2A and H2A variant PTMs identified in serum and 2i samples by LC-MS/MS. Listed are the abundances of histone 
H2A and H2A variant PTMs detected by LC-MS/MS in serum and 2i samples. Serum sample corresponds to mESCs grown in serum-containing medium, and 2i sample 
corresponds to mESCs grown in 2 inhibitor- (mitogen-activated protein kinase (MeK) and glycogen synthase kinase-3 (Gsk3)) containing medium. Standard deviation represents 
error between 2 biological replicates. ND: no detected. Abbreviations: pr, propionyl; ac, acetyl; prme1, monomethyl. 
H2A.1 peptide sequence PTMs Observed mass Serum sample 2i sample 
GKQGGKAR K5pr-K9pr 485.2756 86 ± 0.4% 89 ± 0% 
GKQGGKAR K5ac-K9pr 478.2697 14 ± 0.4% 11 ± 0% 
AKAKTR K13pr-K15pr 421.7585 99 ± 0.6% 99 ± 0% 
AKAKTR K13me2-K15pr 407.7423 1 ± 0.5% 1 ± 0% 
AGLQFPVGR no PTM 500.7815 100 ± 0% 100 ± 0% 
KGNYAER K36pr-Y39pr 503.2535 100 ± 0% ND 
DNKKTR K74pr-K75pr 465.2552 99,6 ± 0% 100 ± 0% 
DNKKTR K74ac-K75pr  458.2482 0,4 ± 0% ND 
HLQLAIR no PTM 453.7787 100 ± 0% 100 ± 0% 
     
H2A.1C peptide sequence PTMs Observed mass Serum sample 2i sample 
AKAKSR K13pr-K15pr  414.7508 100 ± 0% 100 ± 0% 
NDEELNKLLGR K95pr  706.8724 100 ± 0% 100 ± 0% 
     
H2A.1B peptide sequence PTMs Observed mass Serum sample 2i sample 
KGNYSER K36pr  483.2385 100 ± 0% 100 ± 0% 
     
H2A.J peptide sequence PTMs Observed mass Serum sample 2i sample 
GKQGGKVR K5pr-K9pr 499.2929 100 ± 0% ND 
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H2A.X peptide sequence PTMs Observed mass Serum sample 2i sample 
GKTGGKAR K5ac-K9pr 464.7647 11 ± 0.4% 9 ± 0.6% 
GKTGGKAR K5pr-K9pr 471.7708 89 ± 0.4% 91 ± 0.6% 
KGHYAER K36pr-Y39pr 514.7614 100 ± 0% 100 ± 0% 
     
H2A.V peptide sequence PTMs Observed mass Serum sample 2i sample 
HLKTR K37pr 383.7327 100 ± 0% 100 ± 0% 
TTSHGR T41pr 385.6928 100 ± 0% 100 ± 0% 
     
H2A.Z peptide sequence PTMs Observed mass Serum sample 2i sample 
HLKSR K37pr 376.7242 93 ± 0.2% 100 ± 0% 
HLKSR K37prme1 383.7327 7 ± 0.2% ND 
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Suppl. Table 5.3.5. Relative quantification of histone H2B and H2B variant PTMs identified in serum and 2i samples by LC-MS/MS. Listed are the abundances of histone 
H2B and H2B variant PTMs detected by LC-MS/MS in serum and 2i samples. Serum sample corresponds to mESCs grown in serum-containing medium, and 2i sample 
corresponds to mESCs grown in 2 inhibitor- (mitogen-activated protein kinase (MeK) and glycogen synthase kinase-3 (Gsk3)) containing medium. Standard deviation represents 
error between 2 biological replicates. ND: no detected. Abbreviations: pr, propionyl. 
H2B.1B peptide sequence PTMs Observed mass mESC mESC + 2i 
IAGEASR no PTM 380,2032 100 ± 0% 100 ± 0% 
LAHYNKR K66pr-Y64pr 535,2919 100 ± 0% 100 ± 0% 
STITSREIQTAVR no PTM 759,4175 100 ± 0% 100 ± 0% 
EIQTAVR T77pr 464,7563 100 ± 0% 100 ± 0% 
     
H2B.FS peptide sequence PTMs Observed mass mESC mESC + 2i 
LPHYNKR K66pr-Y64pr 548,301 100 ± 0% 100 ± 0% 
     
H2B3B peptide sequence PTMs Observed mass mESC mESC + 2i 
IASEASR no PTM 395,2086 100 ± 0% 100 ± 0% 
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5.4. Quantification of histone post-translational modifications in human cell lines 
Suppl. Table 5.4.1. List of tryptic peptides of histones H3, H4, H2A, H2B and histone variants (HV) identified by LC-MS/MS in confluent and proliferating HeK-293T. 
Listed are histone PTMs detected by LC-MS/MS in proliferating and confluent cells. Histones were propionylated before and after enzymatic digestion, therefore each listed 
peptide is propionylated at the N-termini (N-propionylated) as well. Besides, charges of detected tryptic peptides, observed and predicted masses, and mass difference between 
observed and predicted masses (in Da) are listed. In addition, histone modifications of K and mascot scores for MS/MS fragmentation spectra can be found in the following table.  
Protein 
Peptide sequence  
(N-propionylated) 
Charge 
Observed  
m/z 
Predicted  
m/z 
Delta (Da) Modification 
Mascot 
score 
H3 TKQTAR 2+, 1+ 408.7335, 815.4524 815.4501 0.0023 Propionyl (K4) 32 
H3 TKQTAR 2+, 1+ 415.7395, 829.4644 829.4658 -0.0013 Propionyl-methyl (K4) 26 
H3 TKQTAR   787.4552  Dimethyl (K4)  
H3 TKQTAR 2+ 401.7424 801.4708 -0.0006 Trimethyl (K4) 19 
H3 KSTGGKAPR 2+ 535.3046 1068.5927 0.0019 2 Propionyl (K9 & K14) 40 
H3 KSTGGKAPR 2+ 521.3063 1040,5978 0.0002 Dimethyl (K9), Propionyl (K14) 39 
H3 KSTGGKAPR 2+ 521.3051 1040,5978 -0.0022 Trimethyl (K9), Acetyl (K14) 28 
H3 KSTGGKAPR 2+ 528.3130 1054.6135 -0.0020 Trimethyl (K9), Propionyl (K14) 35 
H3 KSTGGKAPR 2+ 528.2953 1054.5771 -0.0010 Propionyl (K9), Acetyl (K14) 47 
H3 KSTGGKAPR 2+ 542.3107 1082.6084 -0.0015 Propionyl-methyl (K9), Propionyl (K14) 30 
H3 KSTGGKAPR 2+ 535.3041 1068.5927 0.0015 Propionyl-methyl (K9), Acetyl (K14) 22 
H3 KSTGGKAPR 2+ 521.2874 1040.5614 -0.0010 2 Acetyl (K9, K14) 51 
H3 KSTGGKAPR 2+ 514.2986 1026.5822 0.0005 Dimethyl (K9), Acetyl (K14) 38 
H3 KQLATKAAR 2+ 577.8465 1153.6819 -0.0034 2 Propionyl (K18, K23) 65 
H3 KQLATKAAR 2+ 570.8407 1139.6662 -0.0002 Propionyl (K18), Acetyl (K23) 59 
H3 KQLATKAAR 2+ 563.8309 1125.6506 -0.0063 2 Acetyl (K18, K23) 64 
H3 KSAPATGGVKKPHR 4+ 401.2412 1600.9413 -0.0056 2 Dimethyl (K27 & K36), Propionyl (K37)  24 
H3 KSAPATGGVKKPHR 3+ 543.9856 1628.9362 -0.0012 Dimethyl (K27), 2 Propionyl (K36 & K37) 40 
H3 KSAPATGGVKKPHR 4+ 408.2411 1628.9362 -0.0009 Dimethyl (K36), 2 Propionyl (K27, K37) 29 
H3 KSAPATGGVKKPHR 3+ 548.6573 1642.9519 -0.0018 Propionyl-methyl (K27), Dimethyl (K36), Propionyl (K37) 34 
H3 KSAPATGGVKKPHR 3+ 548.6580 1642.9519 0.0003 Propionyl-methyl (K36), Dimethyl (K27), Propionyl (K37) 43 
H3 KSAPATGGVKKPHR 2+ 822.4665 1642.9519 0.0030 Trimethyl (K27), 2 Propionyl (K36, K37) 54 
H3 KSAPATGGVKKPHR 2+ 829.4741 1656.9311 0.0025 3 Propionyl (K27, K36 & K37) 40 
H3 KSAPATGGVKKPHR 2+ 836.4803 1670.9468 -0.0007 Propionyl-methyl (K36), 2 Propionyl (K27, K37) 64 
H3 KSAPATGGVKKPHR 3+ 557.9899 1670.9468 0.0011 Propionyl-methyl (K27), 2 Propionyl (K36, K37) 28 
H3 KSAPATGGVKKPHR 2+ 843.4882 1684.9624 -0.0006 2 Propionyl-methyl (K27, K36), Propionyl (K37) 30 
H3 YRPGTVALR 2+ 544.8128 1087.6138 -0.0028  43 
H3 YQKSTELLIR 2+ 681.8853 1361.7554 0.0006 Propionyl (K56) 59 
H3 KLPFQR 2+ 450.7695 899.5229 0.0016 Propionyl (K64) 24 
H3 EIAQDFKTDLR 2+ 710.3785 1418.7405 0.0019 Dimethyl (K79) 29 
H3 EIAQDFKTDLR 2+ 724.3743 1446.7354 -0.0014 Propionyl (K79) 75 
H3 EIAQDFKTDLR 2+ 731.3826 1460.7511 -0.0005 Propionyl-methyl (K79) 55 
H3 VTIMPKDIQLAR 2+ 756.9263 1511.8381 -0.0001 Propionyl (K122), Oxidation (M120) 58 
H3.3 KSAPSTGGVKKPHR 3+ 549.3153 1644.9311 -0.007 Dimethyl (K27), 2 Propionyl (K36, K37) 34 
 
 
155 
Red color: histone PTM fragmentation spectra identified manually. No identified by mascot database.  
Table continuation 
H3.3 KSAPSTGGVKKPHR 3+ 553.9922 1658.9468 0.008 Propionyl-methyl (K36), Dimethyl (K27), Propionyl (K37) 22 
H3.3 KSAPSTGGVKKPHR 3+ 553.9901 1658.9468 0.0017 Trimethyl (K27), 2 Propionyl (K36, K37)  18 
H4 GKGGKGLGKGGAKR 2+ 768.9494 1535.8784 0.0059 Acetyl & 3 Propionyl (K5, K8, K12, K16)  59 
H4 GKGGKGLGKGGAKR 2+ 747.9229 1493.8314 0.0001 4 Acetyl (K5, K8, K12, K16) 84 
H4 GKGGKGLGKGGAKR 2+ 754.9286 1507.8470 0.0044 3 Acetyl & Propionyl (K5, K8, K12, K16) 65 
H4 GKGGKGLGKGGAKR 2+ 761.9379 1521.8627 -0.0015 2 Acetyl & Propionyl (K5, K8, K12, K16) 48 
H4 GKGGKGLGKGGAKR 2+ 775.9542 1549.894 0.0002 4 Propionyl (K5, K8, K12, K16) 63 
H4 DNIQGITKPAIR 2+ 719.4059 1436.7987 -0.0015 Propionyl (K31) 51 
H4 ISGLIYEETR 2+ 618.8266 1235.6397 -0.0011  53 
H4 DAVTYTEHAKR 2+ 701.8494 1401.6888 -0.0046 Propionyl (K76) 47 
H4 KTVTAMDVVYALKR 2+ 899.9893 1777.9648 -0.0011 2 Propionyl (K81, K93), Oxidation (M86) 37 
H2A.1 GKQGGKAR 2+ 457.2639 912.5141 -0.0009 2 Propionyl (K5, K9) 36 
H2A.1 GKQGGKAR 2+ 478.2709 954.5247 0.0026 Propionyl (K5), Acetyl (K9) 40 
H2A.1 AKAKTR 2+ 421.7585 841.5021 0.0003 2 Propionyl (K13, K15) 36 
H2A.1 AKAKTR 2+ 414.7507 827.4865 0.0004 Acetyl (K13), Propionyl (K15) 22 
H2A.1 KGNYAER 2+ 503.2536 1004.4927 0.0000 2 Propionyl (K36, Y39) 26 
H2A.1 AGLQFPVGR 2+ 500.7822 999.5502 -0.0003  45 
H2A.1 DNKKTR 2+ 465.2552 928.4978 -0.0019 2 Propionyl (K74, K75) 34 
H2A.1 HLQLAIR 2+ 453.7792 905.5447 -0.0008  41 
H2A.1C AKAKSR     Trimethyl (K13), Propionyl (K15)  
H2A.1C AKAKSR 2+ 414.7507 827.4865 0.0004 2 Propionyl (K13, K15) 35 
H2A.1C AKAKSR 
2+ 407.7428 813.4708 0.0002 
Propionyl (K13), Acetyl (K15) 
19 
H2A.1C AKAKSR Propionyl (K15), Acetyl (K13)  
H2A.1C NDEELNKLLGR 2+ 706.8694 1411.7307 -0.0064 Propionyl (K95) 40 
H2A.3 KGNYSER 2+ 511.2509 1020.4876 -0.0003 2 Propionyl (K36, Y39) 21 
H2A2B HLQLAVR 2+ 446.7717 891.5290 -0.0002  35 
H2A.X GKTGGKAR 2+ 464.7657 927.5138 0.0031 Propionyl (K9), Acetyl (K5) 26 
H2A.X GKTGGKAR 2+ 471.7709 941.5294 -0.0022 2 Propionyl (K5, K9) 27 
H2A.X KGHYAER 2+ 514.7615 1027.5087 -0.0002 2 Propionyl (K36, Y39) 21 
H2A.V HLKTR 2+ 383.7319 765.4497 -0.0005 Propionyl (K37) 19 
H2A.V TTSHGR 2+ 385.6941 769.3719 0.0018 Propionyl (S42) 24 
H2A.Z HLKSR 2+ 376.7242 751.4341 -0.0002 Propionyl (K37) 17 
H2A.Z HLKSR 2+ 383.7327 765.4497 0.0011 Propionyl-methyl (K37) 15 
H2B.1B LAHYNKR 2+ 535.2927 1068.5716 -0.0007 2 Propionyl (K66, Y64) 32 
H2B.1B LAHYNKR 2+ 528.3044 1054.5923 0.0019 Trimethyl (K66), Propionyl (Y64) 26 
H2B.1B IAGEAGR 2+ 380.2030 758.3922 -0.0008  35 
H2B.1B STITSREIQTAVR 2+ 759.4183 1516.8209 0.0011  20 
H2B.1B EIQTAVR 2+ 464.7588 927.5025 0.0005 Propionyl (T96) 35 
H2B.FS LPHYNKR 2+ 548.3011 1094.5873 0.0004 2 Propionyl (K66, Y64) 26 
Table continuation 
H2B.3B IASEASR 2+ 395.2082 788.4028 -0.0010  41 
H2B.3B EVQTAVR 2+ 429.7377 857.4607 0.0002  37 
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Suppl. Table 5.4.2. List of tryptic peptides of histones H3, H4, H2A, H2B and histone variants (HV) identified by LC-MS/MS in HeLa. Listed are detected tryptic peptides 
of core histones by LC-MS/MS. H3 was propionylated before and after enzymatic digestion, therefore each listed peptide is propionylated at the N-termini as well. Besides, 
charges of detected tryptic peptides, observed and predicted masses, and delta (in ppm) or mass difference between observed and predicted masses are listed. In addition, 
detected modifications of K and mascot scores for MS/MS fragmentation spectra can be found in the following table. The Table shows information of all detected peptides in 
proliferating and confluent cells. 
Protein 
Peptide sequence  
(N-propionylated) 
Charge 
Observed  
m/z 
Predicted  
m/z 
Delta (Da) Modification 
Mascot 
score 
H3 TKQTAR 2+, 1+ 408.7334, 815.4522 815.4501 0.0021 Propionyl (K4) 32 
H3 TKQTAR 2+, 1+ 415.7397, 829.4648 829.4658 -0.0009 Propionyl-methyl (K4) 30 
H3 TKQTAR 2+ 394.7346 787.4552 -0.0005 Dimethyl (K4) 23 
H3 TKQTAR 2+ 401.7426 801.4708 -0.0002 Trimethyl (K4) 16 
H3 KSTGGKAPR 2+ 535.3044 1068.5927 0.0015 2 Propionyl (K9 & K14) 42 
H3 KSTGGKAPR 2+ 521.3058 1040,5978 -0.0008 Dimethyl (K9), Propionyl (K14) 34 
H3 KSTGGKAPR 2+ 521.3056 1040,5978 -0.0012 Trimethyl (K9), Acetyl (K14) 37 
H3 KSTGGKAPR 2+ 528.2948 1054.5771 -0.0020 Propionyl (K9), Acetyl (K14) 48 
H3 KSTGGKAPR 2+ 542.3127 1082.6084 0.0024 Propionyl-methyl (K9), Propionyl (K14) 41 
H3 KSTGGKAPR 2+ 535.3040 1068.5927 0.0007 Propionyl-methyl (K9), Acetyl (K14) 37 
H3 KSTGGKAPR 2+ 521.2872 1040.5614 -0.0016 2 Acetyl (K9, K14) 48 
H3 KSTGGKAPR 2+ 514.2979 1026.5822 -0.0009 Dimethyl (K9), Acetyl (K14) 25 
H3 KQLATKAAR 2+ 577.8487 1153.6819 0.0010 2 Propionyl (K18, K23) 49 
H3 KQLATKAAR 2+ 570.8402 1139.6662 -0.0004 Propionyl (K18), Acetyl (K23) 68 
H3 KQLATKAAR 2+ 563.8324 1125.6506 -0.0003 2 Acetyl (K18, K23) 48 
H3 KSAPATGGVKKPHR 3+ 534.6540 1600.9413 -0.0011 2 Dimethyl (K27 & K36), Propionyl (K37)  18 
H3 KSAPATGGVKKPHR 3+ 543.9862 1628.9362 0.0006 Dimethyl (K27), 2 Propionyl (K36 & K37) 46 
H3 KSAPATGGVKKPHR 4+ 408.2420 1628.9362 0.0027 Dimethyl (K36), 2 Propionyl (K27, K37) 33 
H3 KSAPATGGVKKPHR 4+ 411.7443 1642.9519 -0.0038 Propionyl-methyl (K27), Dimethyl (K36), Propionyl (K37) 25 
H3 KSAPATGGVKKPHR 3+ 548.6583 1642.9519 0.0012 Propionyl-methyl (K36), Dimethyl (K27), Propionyl (K37) 27 
H3 KSAPATGGVKKPHR 2+ 822.4662 1642.9519 0.0024 Trimethyl (K27), 2 Propionyl (K36, K37) 34 
H3 KSAPATGGVKKPHR 2+ 829.4713 1656.9311 -0.0031 3 Propionyl (K27, K36 & K37) 61 
H3 KSAPATGGVKKPHR 2+ 836.4811 1670.9468 0.0009 Propionyl-methyl (K27), 2 Propionyl (K36, K37) 32 
H3 KSAPATGGVKKPHR 2+ 843.4886 1684.9624 0.0002 2 Propionyl-methyl (K27, K36), Propionyl (K37) 30 
H3 YRPGTVALR 2+ 544.8121 1087.6138 -0.0042  33 
H3 YQKSTELLIR 2+ 681.8846 1361.7554 -0.0008 Propionyl (K56) 41 
H3 KLPFQR 2+ 450.7681 899.5229 -0.0012 Propionyl (K64) 19 
H3 EIAQDFKTDLR 2+ 710.3765 1418.7405 -0.0021 Dimethyl (K79) 40 
H3 EIAQDFKTDLR 2+ 724.3752 1446.7354 0.0004 Propionyl (K79) 71 
H3 EIAQDFKTDLR 2+ 731.3844 1460.7511 0.0031 Propionyl-methyl (K79) 37 
H3 VTIMPKDIQLAR 2+ 756.9287 1511.8381 0.0047 Propionyl (K122), Oxidation (M120) 32 
H3.3 KSAPSTGGVKKPHR 3+ 549.3179 1644.9311 0.0008 Dimethyl (K27), 2 Propionyl (K36, K37) 36 
H3.3 KSAPSTGGVKKPHR 3+ 553.9899 1658.9468 0.0011 Propionyl-methyl (K36), Dimethyl (K27), Propionyl (K37) 34 
H4 GKGGKGLGKGGAKR 2+ 768.9499 1535.8784 0.0069 Acetyl & 3 Propionyl (K5, K8, K12, K16)  50 
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Red color: histone PTM fragmentation spectra identified manually. No identified by mascot database.  
Table continuation 
H4 GKGGKGLGKGGAKR 2+ 747.9238 1493.8314 0.0017 4 Acetyl (K5, K8, K12, K16) 85 
H4 GKGGKGLGKGGAKR 2+ 754.9325 1507.8470 0.0034 3 Acetyl & Propionyl (K5, K8, K12, K16) 58 
H4 GKGGKGLGKGGAKR 2+ 761.9382 1521.8627 -0.0009 2 Acetyl & Propionyl (K5, K8, K12, K16) 49 
H4 GKGGKGLGKGGAKR 2+ 775.9536 1549.894 -0.0013 4 Propionyl (K5, K8, K12, K16) 72 
H4 DNIQGITKPAIR 2+ 719.4055 1436.7987 -0.0023 Propionyl (K31) 68 
H4 ISGLIYEETR 2+ 618.8275 1235.6397 0.0007  50 
H4 DAVTYTEHAKR 2+ 701.8502 1401.6888 -0.0030 Propionyl (K76) 35 
H4 KTVTAMDVVYALKR 2+ 889.9891 1777.9648 -0.0011 2 Propionyl (K81, K93), Oxidation (M86) 49 
H2A.1 GKQGGKAR 2+ 457.2641 912.5141 -0.0005 2 Propionyl (K5, K9) 32 
H2A.1 GKQGGKAR 2+ 478.2695 954.5247 -0.0002 Propionyl (K5), Acetyl (K9) 39 
H2A.1 AKAKTR 2+ 421.7587 841.5021 0.0007 2 Propionyl (K13, K15) 23 
H2A.1 AKAKTR 2+ 414.7514 827.4865 0.0018 Acetyl (K13), Propionyl (K15) 23 
H2A.1 KGNYAER 2+ 503.2535 1004.4927 -0.0002 2 Propionyl (K36, Y39) 23 
H2A.1 AGLQFPVGR 2+ 500.7822 999.5502 -0.0003  49 
H2A.1 DNKKTR 2+ 465.2553 928.4978 -0.0017 2 Propionyl (K74, K75) 38 
H2A.1 HLQLAIR 2+ 453.7792 905.5447 -0.0008  37 
H2A.1C AKAKSR   813.4908  Trimethyl (K13), Propionyl (K15)  
H2A.1C AKAKSR 2+ 414.7514 827.4865 0.0018 2 Propionyl (K13, K15) 34 
H2A.1C AKAKSR 
2+ 407.7423 813.4708 -0.0008 
Propionyl (K13), Acetyl (K15) 
20 
H2A.1C AKAKSR Propionyl (K15), Acetyl (K13)  
H2A.1C NDEELNKLLGR 2+ 706.8730 1411.7307 0.0008 Propionyl (K95) 22 
H2A.3 KGNYSER 2+ 511.2512 1020.4876 0.0003 2 Propionyl (K36, Y39) 21 
H2A.2B HLQLAVR 2+ 446.7717 891.5290 -0.0002  37 
H2A.X GKTGGKAR   927.5138  Propionyl (K9), Acetyl (K5)  
H2A.X GKTGGKAR 2+ 471.7707 941.5294 -0.0026 2 Propionyl (K5, K9) 32 
H2A.X KGHYAER 2+ 514.7607 1027.5087 -0.0018 2 Propionyl (K36, Y39) 26 
H2A.V HLKTR 2+ 383.7330 765.4497 0.0017 Propionyl (K37) 19 
H2A.V TTSHGR 2+ 385.6937 769.3719 0.0010 Propionyl (S42) 22 
H2A.Z HLKSR   751.4341  Propionyl (K37)  
H2B.1B LAHYNKR 2+ 535.2922 1068.5716 -0.0017 2 Propionyl (K66, Y64) 28 
H2B.1B LAHYNKR   1054.5923  Trimethyl (K66), Propionyl (Y64)  
H2B.1B IAGEAGR 2+ 380.2030 758.3922 -0.0008  36 
H2B.1B STITSREIQTAVR 2+ 759.4176 1516.8209 -0.0003  30 
H2B.1B EIQTAVR 2+ 464.7582 927.5025 -0.0007 Propionyl (T96) 41 
H2B.FS LPHYNKR 2+ 548.3008 1094.5873 -0.0002 2 Propionyl (K66, Y64) 25 
H2B.3B IASEASR 2+ 395.2083 788.4028 -0.0008  41 
H2B.3B EVQTAVR 2+ 429.7377 857.4607 0.0002  34 
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Suppl. Table 5.4.3. List of tryptic peptides of histones H3, H4, H2A, H2B and histone variants (HV) identified by LC-MS/MS in MDA-MB231. Listed are detected tryptic 
peptides of core histones H3 by LC-MS/MS. H3 was propionylated before and after enzymatic digestion, therefore each listed peptide is propionylated at the N-termini as well. 
Besides, charges of detected tryptic peptides, observed and predicted masses, and delta (in ppm) or mass difference between observed and predicted masses are listed. In 
addition, detected modifications of K and mascot scores for MS/MS fragmentation spectra can be found in the following table. The Table shows information of all detected 
peptides in proliferating and confluent cells. 
Protein 
Peptide sequence  
(N-propionylated) 
Charge 
Observed  
m/z 
Predicted  
m/z 
Delta (Da) Modification 
Mascot 
score 
H3 TKQTAR 2+, 1+ 
408.7337,  
815.4528 
815.4501 0.0027 Propionyl (K4) 31 
H3 TKQTAR 2+, 1+ 
415.7397,  
829.4648 
829.4658 -0.0009 Propionyl-methyl (K4) 30 
H3 TKQTAR 2+ 394.7345 787.4552 -0.0007 Dimethyl (K4) 16 
H3 TKQTAR 2+ 401.7428 801.4708 0.0002 Trimethyl (K4) 19 
H3 KSTGGKAPR 2+ 535.3040 1068.5927 0.0007 2 Propionyl (K9 & K14) 42 
H3 KSTGGKAPR  521.3056 1040,5978 -0.0012 Dimethyl (K9), Propionyl (K14) 31 
H3 KSTGGKAPR 2+ 521.3059 1040,5978 -0.0006 Trimethyl (K9), Acetyl (K14) 28 
H3 KSTGGKAPR 2+ 528.2945 1054.5771 -0.0026 Propionyl (K9), Acetyl (K14) 35 
H3 KSTGGKAPR 2+ 542.3123 1082.6084 0.0016 Propionyl-methyl (K9), Propionyl (K14) 36 
H3 KSTGGKAPR 2+ 535.3032 1068.5927 -0.0009 Propionyl-methyl (K9), Acetyl (K14) 25 
H3 KSTGGKAPR   1040.5614  2 Acetyl (K9, K14)  
H3 KSTGGKAPR 2+ 514.2983 1026.5822 -0.0001 Dimethyl (K9), Acetyl (K14) 25 
H3 KQLATKAAR 2+ 577.8483 1153.6819 0.0002 2 Propionyl (K18, K23) 43 
H3 KQLATKAAR 2+ 570.8403 1139.6662 -0.0002 Propionyl (K18), Acetyl (K23) 61 
H3 KQLATKAAR 2+ 563.8306 1125.6506 -0.0039 2 Acetyl (K18, K23) 47 
H3 KSAPATGGVKKPHR 3+ 534.6538 1600.9413 -0.0017 2 Dimethyl (K27 & K36), Propionyl (K37)  20 
H3 KSAPATGGVKKPHR 3+ 543.9857 1628.9362 -0.0009 Dimethyl (K27), 2 Propionyl (K36 & K37) 37 
H3 KSAPATGGVKKPHR 4+ 408.2422 1628.9362 0.0035 Dimethyl (K36), 2 Propionyl (K27, K37) 37 
H3 KSAPATGGVKKPHR 3+ 548.6597 1642.9519 0.0054 Propionyl-methyl (K27), Dimethyl (K36), Propionyl (K37) 27 
H3 KSAPATGGVKKPHR 3+ 548.6583 1642.9519 0.0012 Propionyl-methyl (K36), Dimethyl (K27), Propionyl (K37) 18 
H3 KSAPATGGVKKPHR 3+ 548.6566 1642.9519 -0.0039 Trimethyl (K27), 2 Propionyl (K36, K37) 29 
H3 KSAPATGGVKKPHR 2+ 829.4730 1656.9311 0.0003 3 Propionyl (K27, K36 & K37) 34 
H3 KSAPATGGVKKPHR 3+ 557.9901 1670.9468 0.0017 Propionyl-methyl (K36), 2 Propionyl (K27, K37) 16 
H3 KSAPATGGVKKPHR 2+ 836.4800 1670.9468 -0.0013 Propionyl-methyl (K27), 2 Propionyl (K36, K37) 49 
H3 YRPGTVALR 2+ 544.8139 1087.6138 -0.0006  28 
H3 YQKSTELLIR 2+ 681.8842 1361.7554 -0.0016 Propionyl (K56) 24 
H3 KLPFQR   899.5229  Propionyl (K64)  
H3 EIAQDFKTDLR 2+ 710.3755 1418.7405 -0.0041 Dimethyl (K79) 22 
H3 EIAQDFKTDLR 2+ 724.3746 1446.7354 -0.0008 Propionyl (K79) 64 
H3 EIAQDFKTDLR   1460.7511  Propionyl-methyl (K79)  
H3 VTIMPKDIQLAR 2+ 756.9268 1511.8381 0.0009 Propionyl (K122), Oxidation (M120) 32 
H3.3 KSAPSTGGVKKPHR 3+ 549.3168 1644.9311 -0.0026 Dimethyl (K27), 2 Propionyl (K36, K37) 30 
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Red color: histone PTM fragmentation spectra identified manually. No identified by mascot database.  
Table continuation 
H4 GKGGKGLGKGGAKR 2+ 768.9498 1535.8784 0.0067 Acetyl & 3 Propionyl (K5, K8, K12, K16)  71 
H4 GKGGKGLGKGGAKR 2+ 747.9221 1493.8314 -0.0017 4 Acetyl (K5, K8, K12, K16) 56 
H4 GKGGKGLGKGGAKR 2+ 754.9288 1507.8470 -0.0040 3 Acetyl & Propionyl (K5, K8, K12, K16) 42 
H4 GKGGKGLGKGGAKR 2+ 761.9379 1521.8627 -0.0015 2 Acetyl & Propionyl (K5, K8, K12, K16) 55 
H4 GKGGKGLGKGGAKR 2+ 775.9536 1549.894 -0.0014 4 Propionyl (K5, K8, K12, K16) 69 
H4 DNIQGITKPAIR 2+ 719.4061 1436.7987 -0.0011 Propionyl (K31) 55 
H4 ISGLIYEETR 2+ 618.8271 1235.6397 -0.0001  27 
H4 DAVTYTEHAKR 2+ 701.8497 1401.6888 -0.0040 Propionyl (K76) 48 
H4 KTVTAMDVVYALKR 2+ 889.9888 1777.9648 -0.0018 2 Propionyl (K81, K93), Oxidation (M86) 40 
H2A.1 GKQGGKAR 2+ 457.2641 912.5141 -0.0005 2 Propionyl (K5, K9) 29 
H2A.1 GKQGGKAR 2+ 478.2697 954.5247 0.0002 Propionyl (K5), Acetyl (K9) 40 
H2A.1 AKAKTR 2+ 421.7589 841.5021 0.0011 2 Propionyl (K13, K15) 25 
H2A.1 AKAKTR 2+ 414.7512 827.4865 0.0014 Acetyl (K13), Propionyl (K15) 20 
H2A.1 KGNYAER 2+ 503.2535 1004.4927 -0.0002 2 Propionyl (K36, Y39) 22 
H2A.1 AGLQFPVGR 2+ 500.7820 999.5502 -0.0007  48 
H2A.1 DNKKTR 2+ 465.2561 928.4978 -0.0001 2 Propionyl (K74, K75) 32 
H2A.1 HLQLAIR 2+ 453.7795 905.5447 -0.0002  29 
H2A.1C AKAKSR 2+ 414.7505 827.4865 0.0000 2 Propionyl (K13, K15) 31 
H2A.1C AKAKSR 
  813.4708  
Propionyl (K13), Acetyl (K15) 
 
H2A.1C AKAKSR Propionyl (K15), Acetyl (K13)  
H2A.1C NDEELNKLLGR 2+ 706.8729 1411.7307 0.0006 Propionyl (K95) 19 
H2A.3 KGNYSER   1020.4876  2 Propionyl (K36, Y39)  
H2A.2B HLQLAVR 2+ 446.7716 891.5290 -0.0004  30 
H2A.X GKTGGKAR 2+ 464.7645 927.5138 0.0007 Propionyl (K9), Acetyl (K5) 28 
H2A.X GKTGGKAR 2+ 471.7712 941.5294 -0.0016 2 Propionyl (K5, K9) 29 
H2A.X KGHYAER 2+ 514.7614 1027.5087 -0.0004 2 Propionyl (K36, Y39) 33 
H2A.V HLKTR 2+ 383.7321 765.4497 -0.0001 Propionyl (K37) 16 
H2A.V TTSHGR 2+ 385.6937 769.3719 0.0010 Propionyl (S42) 26 
H2A.Z HLKSR 2+ 376.7244 751.4341 0.0002 Propionyl (K37) 19 
H2B.1B LAHYNKR 2+ 535.2922 1068.5716 -0.0017 2 Propionyl (K66, Y64) 30 
H2B.1B LAHYNKR   1054.5923  Trimethyl (K66), Propionyl (Y64)  
H2B.1B IAGEAGR 2+ 380.2032 758.3922 -0.0004  36 
H2B.1B STITSREIQTAVR   1516.8209    
H2B.1B EIQTAVR 2+ 464.7581 927.5025 -0.0009 Propionyl (T96) 37 
H2B.FS LPHYNKR 2+ 548.3004 1094.5873 -0.0010 2 Propionyl (K66, Y64) 21 
H2B.3B IASEASR 2+ 395.2080 788.4028 -0.0014  40 
H2B.3B EVQTAVR   857.4607    
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Suppl. Table 5.4.4. List of tryptic peptides of histones H3, H4, H2A, H2B and histone variants (HV) identified by LC-MS/MS in MCF-7. Listed are detected tryptic peptides 
of core histones by LC-MS/MS. H3 was propionylated before and after enzymatic digestion, therefore each listed peptide is propionylated at the N-termini as well. Besides, 
charges of detected tryptic peptides, observed and predicted masses, and delta (in ppm) or mass difference between observed and predicted masses are listed. In addition, 
detected modifications of K and mascot scores for MS/MS fragmentation spectra can be found in the following table. The Table shows information of all detected peptides in 
proliferating and confluent cells. 
Protein 
Peptide sequence  
(N-propionylated) 
Charge 
Observed  
m/z 
Predicted  
m/z 
Delta (Da) Modification 
Mascot 
score 
H3 TKQTAR 2+, 1+ 408.7338, 815.4530 815.4501 0.0029 Propionyl (K4) 40 
H3 TKQTAR 2+, 1+ 415.7398, 829.4650 829.4658 -0.0007 Propionyl-methyl (K4) 31 
H3 TKQTAR 2+ 394.7348 787.4552 -0.0001 Dimethyl (K4) 19 
H3 TKQTAR 2+ 401.7427 801.4708 0.0000 Trimethyl (K4) 18 
H3 KSTGGKAPR 2+ 535.3036 1068.5927 -0.0001 2 Propionyl (K9 & K14) 36 
H3 KSTGGKAPR  521.3056 1040,5978 -0.0012 Dimethyl (K9), Propionyl (K14) 29 
H3 KSTGGKAPR 2+ 521.3057 1040,5978 -0.0010 Trimethyl (K9), Acetyl (K14) 30 
H3 KSTGGKAPR 2+ 528.2968 1054.5771 0.0020 Propionyl (K9), Acetyl (K14) 49 
H3 KSTGGKAPR 2+ 542.3116 1082.6084 0.0003 Propionyl-methyl (K9), Propionyl (K14) 48 
H3 KSTGGKAPR 2+ 535.3025 1068.5927 -0.0023 Propionyl-methyl (K9), Acetyl (K14) 26 
H3 KSTGGKAPR   1040.5614  2 Acetyl (K9, K14)  
H3 KSTGGKAPR 2+ 514.2985 1026.5822 0.0003 Dimethyl (K9), Acetyl (K14) 19 
H3 KQLATKAAR 2+ 577.8476 1153.6819 -0.0012 2 Propionyl (K18, K23) 44 
H3 KQLATKAAR 2+ 570.8403 1139.6662 -0.0002 Propionyl (K18), Acetyl (K23) 58 
H3 KQLATKAAR 2+ 563.8324 1125.6506 -0.0003 2 Acetyl (K18, K23) 51 
H3 KSAPATGGVKKPHR   1600.9413  2 Dimethyl (K27 & K36), Propionyl (K37)   
H3 KSAPATGGVKKPHR 3+ 543.9861 1628.9362 0.0003 Dimethyl (K27), 2 Propionyl (K36 & K37) 29 
H3 KSAPATGGVKKPHR 4+ 408.2415 1628.9362 0.0007 Dimethyl (K36), 2 Propionyl (K27, K37) 48 
H3 KSAPATGGVKKPHR 4+ 411.7448 1642.9519 -0.0018 Propionyl-methyl (K27), Dimethyl (K36), Propionyl (K37) 20 
H3 KSAPATGGVKKPHR 4+ 411.7442 1642.9519 -0.0041 Propionyl-methyl (K36), Dimethyl (K27), Propionyl (K37) 24 
H3 KSAPATGGVKKPHR 3+ 548.6563 1642.9519 -0.0048 Trimethyl (K27), 2 Propionyl (K36, K37) 30 
H3 KSAPATGGVKKPHR 2+ 829.4711 1656.9311 -0.0035 3 Propionyl (K27, K36 & K37) 63 
H3 KSAPATGGVKKPHR   1670.9468  Propionyl-methyl (K36), 2 Propionyl (K27, K37)  
H3 KSAPATGGVKKPHR 2+ 836.4803 1670.9468 -0.0007 Propionyl-methyl (K27), 2 Propionyl (K36, K37) 38 
H3 KSAPATGGVKKPHR 2+ 843.4885 1684.9624 0.0000 2 Propionyl-methyl (K27, K36), Propionyl (K37) 36 
H3 YRPGTVALR 2+ 544.8145 1087.6138 0.0006  17 
H3 YQKSTELLIR 2+ 681.8845 1361.7554 -0.0010 Propionyl (K56) 50 
H3 KLPFQR   899.5229  Propionyl (K64)  
H3 EIAQDFKTDLR 2+ 710.3777 1418.7405 0.0003 Dimethyl (K79) 29 
H3 EIAQDFKTDLR 2+ 724.3749 1446.7354 -0.0002 Propionyl (K79) 66 
H3 EIAQDFKTDLR   1460.7511  Propionyl-methyl (K79)  
H3 VTIMPKDIQLAR 2+ 756.9263 1511.8381 -0.0001 Propionyl (K122), Oxidation (M120) 33 
H3.3 KSAPSTGGVKKPHR 3+ 549.3175 1644.9311 -0.0004 Dimethyl (K27), 2 Propionyl (K36, K37) 30 
H3.3 KSAPSTGGVKKPHR 3+ 553.9917 1658.9468 0.0065 Propionyl-methyl (K36), Dimethyl (K27), Propionyl (K37) 31 
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Red color: histone PTM fragmentation spectra identified manually. No identified by mascot database.  
Table continuation 
H4 GKGGKGLGKGGAKR 2+ 768.9498 1535.8784 0.0067 Acetyl & 3 Propionyl (K5, K8, K12, K16)  57 
H4 GKGGKGLGKGGAKR 2+ 747.9424 1493.8314 0.0024 4 Acetyl (K5, K8, K12, K16) 27 
H4 GKGGKGLGKGGAKR 2+ 754.9300 1507.8470 -0.0016 3 Acetyl & Propionyl (K5, K8, K12, K16) 42 
H4 GKGGKGLGKGGAKR 2+ 761.9388 1521.8627 0.0003 2 Acetyl & Propionyl (K5, K8, K12, K16) 43 
H4 GKGGKGLGKGGAKR 2+ 775.9537 1549.894 -0.0012 4 Propionyl (K5, K8, K12, K16) 71 
H4 DNIQGITKPAIR 2+ 719.4061 1436.7987 -0.0011 Propionyl (K31) 55 
H4 ISGLIYEETR 2+ 618.8275 1235.6397 0.0007  46 
H4 DAVTYTEHAKR 2+ 701.8501 1401.6888 -0.0032 Propionyl (K76) 30 
H4 KTVTAMDVVYALKR 2+ 889.9890 1777.9648 -0.0014 2 Propionyl (K81, K93), Oxidation (M86) 29 
H2A.1 GKQGGKAR 2+ 457.2642 912.5141 -0.0003 2 Propionyl (K5, K9) 28 
H2A.1 GKQGGKAR 2+ 478.2693 954.5247 -0.0006 Propionyl (K5), Acetyl (K9) 41 
H2A.1 AKAKTR 2+ 421.7585 841.5021 0.0003 2 Propionyl (K13, K15) 24 
H2A.1 AKAKTR 2+ 414.7507 827.4865 0.0004 Acetyl (K13), Propionyl (K15) 25 
H2A.1 KGNYAER 2+ 503.2534 1004.4927 -0.0004 2 Propionyl (K36, Y39) 23 
H2A.1 AGLQFPVGR 2+ 500.7825 999.5502 0.0003  44 
H2A.1 DNKKTR 2+ 465.2561 928.4978 -0.0001 2 Propionyl (K74, K75) 36 
H2A.1 HLQLAIR 2+ 453.7794 905.5447 -0.0004  33 
H2A.1C AKAKSR 2+ 414.7507 827.4865 0.0004 2 Propionyl (K13, K15) 38 
H2A.1C AKAKSR 
  813.4708  
Propionyl (K13), Acetyl (K15) 
 
H2A.1C AKAKSR Propionyl (K15), Acetyl (K13)  
H2A.1C NDEELNKLLGR 2+ 706.8727 1411.7307 0.0002 Propionyl (K95) 36 
H2A.3 KGNYSER  511.2511 1020.4876 0.0001 2 Propionyl (K36, Y39) 22 
H2A.2B HLQLAVR 2+ 446.7716 891.5290 -0.0004  34 
H2A.X GKTGGKAR 2+ 464.7657 927.5138 0.0031 Propionyl (K9), Acetyl (K5) 27 
H2A.X GKTGGKAR 2+ 471.7723 941.5294 0.0006 2 Propionyl (K5, K9) 28 
H2A.X KGHYAER 2+ 514.7610 1027.5087 -0.0012 2 Propionyl (K36, Y39) 33 
H2A.V HLKTR   765.4497  Propionyl (K37)  
H2A.V TTSHGR 2+ 385.6931 769.3719 -0.0002 Propionyl (S42) 25 
H2A.Z HLKSR   751.4341  Propionyl (K37)  
H2A.Z HLKSR   765.4497  Propionyl-methyl (K37)  
H2B.1B LAHYNKR 2+ 535.2927 1068.5716 -0.0007 2 Propionyl (K66, Y64) 22 
H2B.1B LAHYNKR   1054.5923  Trimethyl (K66), Propionyl (Y64)  
H2B.1B IAGEAGR 2+ 380.2032 758.3922 -0.0004  33 
H2B.1B STITSREIQTAVR 2+ 706.8719 1516.8209 -0.0014  35 
H2B.1B EIQTAVR 2+ 464.7584 927.5025 -0.0003 Propionyl (T96) 46 
H2B.FS LPHYNKR 2+ 548.3009 1094.5873 0.0000 2 Propionyl (K66, Y64) 17 
H2B.3B IASEASR 2+ 395.2078 788.4028 -0.0018  41 
H2B.3B EVQTAVR 2+ 429.7377 857.4607 0.0002  34 
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Suppl. Table 5.4.5. Relative quantification of histone H4 PTMs identified in MCF-7, HeLa, HeK-293T and MDA-MB231 by LC-MS/MS. Listed are the abundances of histone 
H4 PTMs detected by LC-MS/MS in MCF-7, HeLa, HeK-293T and MDA-MB231. Standard deviation represents error between 3 biological replicates. ND: no detected. 
Abbreviations: pr, propionyl, ac, acetyl, O, oxidation. 
 
   HeK-293T HeLa MDA-MB238 MCF-7 
H4 peptide sequence Histone PTM m/z 2+ Prolif. Cells Confl. Cells Prolif. Cells Confl. Cells Prolif. Cells Confl. Cells Prolif. Cells Confl. Cells 
DNIQGITKPAIR K31ac 712.3967 0% 0% 0% 0% 0% 0% 0% 0% 
DNIQGITKPAIR K31pr 719.4033 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 
ISGLIYEETR 
 
618.8246 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 
DAVTYTEHAKR K76pr-Y71pr 729.8612 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 
KTVTAMDVVYALKR K81pr-K93pr-M86O 889.9877 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 100 ± 0% 
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